WO2013025958A1 - Amino quinazolines as kinase inhibitors - Google Patents

Amino quinazolines as kinase inhibitors Download PDF

Info

Publication number
WO2013025958A1
WO2013025958A1 PCT/US2012/051247 US2012051247W WO2013025958A1 WO 2013025958 A1 WO2013025958 A1 WO 2013025958A1 US 2012051247 W US2012051247 W US 2012051247W WO 2013025958 A1 WO2013025958 A1 WO 2013025958A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
phenyl
hydroxy
group
Prior art date
Application number
PCT/US2012/051247
Other languages
French (fr)
Inventor
Michael Jonathan Bury
Linda N. Casillas
Adam Kenneth Charnley
Michael P. Demartino
Xiaoyang Dong
Patrick M. EIDAM
Pamela A. Haile
Robert W. Marquis, Jr.
Joshi M. Ramanjulu
Joseph J. Romano
Robert R. Singhaus, Jr.
Ami Lakdawala SHAH
Gren WANG
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013025958(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA201490474A priority Critical patent/EA025436B1/en
Priority to US14/239,193 priority patent/US9604938B2/en
Priority to ES12824263.3T priority patent/ES2615749T3/en
Priority to CA2845630A priority patent/CA2845630C/en
Priority to SG2014009526A priority patent/SG2014009526A/en
Priority to CN201280050811.1A priority patent/CN103874495B/en
Priority to BR112014003693A priority patent/BR112014003693A2/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to EP12824263.3A priority patent/EP2744501B1/en
Priority to AU2012296411A priority patent/AU2012296411B2/en
Priority to NZ621314A priority patent/NZ621314B2/en
Priority to KR1020147006731A priority patent/KR20140054246A/en
Priority to JP2014526237A priority patent/JP6090801B2/en
Priority to MX2014001879A priority patent/MX2014001879A/en
Publication of WO2013025958A1 publication Critical patent/WO2013025958A1/en
Priority to IL230902A priority patent/IL230902A0/en
Priority to MA36820A priority patent/MA35434B1/en
Priority to US15/431,942 priority patent/US9994529B2/en
Priority to US15/978,377 priority patent/US20180258056A1/en
Priority to US16/286,920 priority patent/US10717711B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to quinazolyl amines that inhibit RIP2 kinase and methods of making and using the same. Specifically, the present invention relates to substituted quinazolyl amines as RIP2 kinase inhibitors.
  • Receptor interacting protein-2 (RIP2) kinase which is also referred to as CARD3,
  • RICK is a TKL family serine/threonine protein kinase involved in innate immune signaling.
  • RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region ((1998) J. Biol. Chem. 273, 12296-12300; (1998) Current Biology 8, 885-889; and (1998) J. Biol. Chem. 273, 16968-16975).
  • CARD domain of RIP2 kinase mediates interaction with other CARD -containing proteins, such as NODI and NOD2 ((2000) J. Biol. Chem.
  • NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide (MDP), respectively ((2007) J Immunol 178, 2380-2386).
  • DAP diaminopimelic acid
  • MDP muramyl dipeptide
  • RIP2 kinase associates with NODI or NOD2 and appears to function principally as a molecular scaffold to bring together other kinases (TAK1, ⁇ / ⁇ / ⁇ ) involved in NF- ⁇ and mitogen-activated protein kinase activation ((2006) Nature Reviews Immunology 6, 9-20). RIP2 kinase undergoes a K63-linked
  • a potent, selective, small molecule inhibitor of RIP2 kinase activity would block RIP2-dependent pro-inflammatory signaling and thereby provide a therapeutic benefit in autoinflammatory diseases characterized by increased and/or dysregulated RIP2 kinase activity.
  • the invention is directed to quinazolyl amine compounds according to Formula (I):
  • R 1 is H, -S0 2 (Ci-C 4 )alkyl, -CO(Ci-C 4 )alkyl, or (Ci-C 4 )alkyl;
  • R 2 is - SR a , -SOR a , -S0 2 R a , -S0 2 NH 2 , or -S0 2 NR b R c ,
  • R a is (Ci-C 6 )alkyl, halo(Ci-C 6 )alkyl, (C 3 -C 7 )cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:
  • said (Ci-C 6 )alkyl is optionally substituted by one or two groups each independently selected from the group consisting of cyano, hydroxyl, (Ci-C 6 )alkoxy,
  • (C 3 -C 7 )cycloalkyl, phenyl, (phenyl)(Ci-C 4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF 3 , hydroxyl, amino, ((Ci-C 4 )alkyl)amino-, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino-, (Ci-C 4 )alkyl, phenyl(Ci-C 4 )alkyl-, hydroxy(Ci-C 4 )alkyl and (Ci-C 4 )alkoxy,
  • said (C 3 -C 7 )cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF 3 , hydroxyl, amino, ((Ci-C 4 )alkyl)amino-, ((Ci-C 4 )alkyl)((Ci-C 4 )alkyl)amino-, (Ci-C 4 )alkyl, phenyl(Ci-C 4 )alkyl-, hydroxy(Ci-C 4 )alkyl-, oxo and (Ci-C 4 )alkoxy, and
  • said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF 3 , hydroxyl, amino,
  • R b is (Ci-C6)alkyl or 4-7 membered heterocycloalkyl, wherein:
  • said (Ci-C 6 )alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C 6 )alkoxy,
  • said 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxycarbonyl-, hydroxy(Ci-C 4 )alkyl-, oxo and (Ci-C 4 )alkoxy, and
  • R c is H, (Ci-C 4 )alkoxy or (Ci-C 6 )alkyl
  • R b and R c taken together with the nitrogen atom to which they are attached form a 3-7 membered heterocycloalkyl group, optionally containing one or two additional ring heteroatoms each independently selected from nitrogen and oxygen, wherein said 3-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of (Ci-C 4 )alkyl, hydroxy, -C0 2 H and -CO(Ci-C 4 )alkyl;
  • R 3 is H, halogen, hydroxy, (Ci-C 4 )alkyl-,(C 2 -C 4 )alkenyl-, halo(Ci-C 4 )alkyl-, hydroxy(C 2 -C 4 )alkenyl-, (Ci-C 4 )alkoxy-, (C 2 -C 4 )alkenyloxy-, halo(Ci-C 4 )alkoxy-,
  • halo(Ci-C 4 )alkoxy(Ci-Ce)alkyl-, or halo(Ci-C 4 )alkoxy(C 2 -C 6 )alkoxy- groups contain 2 or 3 halo atoms,
  • the (C 3 -C 6 )cycloalkyl moiety of the (C 3 -C 6 )cycloalkyl(Ci-C 4 )alkoxy- or (C 3 -Ce)cycloalkoxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (Ci-Ce)alkoxy and (Ci-C 4 )alkoxy(C 2 -C 6 )alkoxy, and wherein the 4-6 membered heterocycloalkyl moiety of the 4-6 membered heterocycloalkyl(Ci-C 4 )alkoxy-, or 4-6 membered-heterocycloalkyl-oxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (Ci-C 6 )alkoxy and (Ci-C 4 )alkoxy(C 2 -C 6 )alkoxy;
  • Z is phenyl or aryl(Ci-C 4 )alkyl-, wherein in the phenyl group or the aryl moiety of the aryl(Ci-C 4 )alkyl- group is substituted by R 4 , R 5 , R 6 and R 7 , wherein:
  • R 4 is H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; and
  • each of R 5 , R 6 and R 7 is independently selected from the group consisting of H, hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; or
  • Z is phenyl or pyridyl, substituted by R 8 , R 9 and R 10 , wherein:
  • R 8 and R 9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5 -membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5 -membered ring is substituted by R 11 ; wherein one of R 10 or R 11 is H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4
  • R 10 or R 11 is H, hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, -C 4 )alkyl or (Ci-C 4 )alkoxy; or
  • Z is pyrazolyl, having the formula: wherein:
  • R is H, methyl or hydroxymethyl
  • R 13 is methyl, trifluoromethyl or hydroxymethyl
  • R 14 is H, OH, or (Ci-C 3 )alkyl; or R and R , taken together with the atoms to which they are attached, form a 6-membered ring substituted by R 15 and R 16 , wherein the 6-membered ring optionally contains 1 nitrogen atom;
  • R 15 and R 16 are each independently selected from the group consisting of H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy,
  • phenyl(Ci-C 4 )alkoxy hydroxyl, hydroxy(Ci-C 4 )alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy;
  • the compounds of Formula (I) do not include:
  • the compounds according to Formula (I), or salts, particularly pharmaceutically acceptable salts, thereof, are inhibitors of RIP2 kinase.
  • the present invention is also directed to a method of inhibiting RIP2 kinase which method comprises contacting a cell with a compound according to
  • the invention is further directed to a method of treating a RIP2 kinase-mediated disease or disorder which comprises administering a therapeutically effective amount of a compound according to Formula (I), or a salt, particularly a pharmaceutically acceptable salt thereof, to a patient (a human or other mammal, particularly, a human) in need thereof.
  • a RIP2 kinase-mediated diseases or disorders include uveitis, Crohn's disease, ulcerative colitis, early-onset and extra-intestinal inflammatory bowel disease and granulomateous disorders, such as sarcoidosis, Blau syndrome, early-onset sarcoidosis and Wegner's Granulomatosis.
  • the present invention is further directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable excipient.
  • this invention is directed to a pharmaceutical composition for the treatment of a RIP2 kinase-mediated disease or disorder, where the composition comprises a compound according to Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable excipient.
  • Figure 1 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 4 or prednisolone, followed by dosing with LI 8-MDP.
  • Figure 2 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 6 or prednisolone, followed by dosing with LI 8-MDP.
  • Figure 3 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 16 or prednisolone, followed by dosing with LI 8-MDP.
  • Figure 4 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 21 or prednisolone, followed by dosing with L18-MDP.
  • R When R is H, the compounds of this invention may exist as tautomers. However, when R 14 is (Ci-C3)alkyl, the compounds of this invention, may exist as either one of the regioisomers represented by Formula (I- A) or Formula (I-B), or as a mixture thereof.
  • alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl and pentyl.
  • C 1 -C 4 alkyl refers to an alkyl group or moiety containing from 1 to 4 carbon atoms.
  • alkyl When the term “alkyl” is used in combination with other substituent groups, such as “haloalkyl” or “hydroxyalkyl” or “arylalkyl”, the term “alkyl” is intended to encompass a divalent straight or branched-chain hydrocarbon radical.
  • arylalkyl is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH 2 -phenyl);
  • halo(Ci-C 4 )alkyl or "(Ci-C 4 )haloalkyl” is intended to mean a radical having one or more halogen atoms, which may be the same or different, at one or more carbon atoms of an alkyl moiety containing from 1 to 4 carbon atoms, which a is straight or branched-chain carbon radical, and is represented by a trifluoromethyl group (-CF 3 ).
  • cycloalkyl refers to a non-aromatic, saturated, cyclic hydrocarbon ring.
  • (C 3 -Cv)cycloalkyl refers to a non-aromatic cyclic hydrocarbon ring having from three to eight ring carbon atoms.
  • (C 3 -C8)cycloalkyl groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • Alkoxy refers to a group containing an alkyl radical attached through an oxygen linking atom.
  • (Ci-C 4 )alkoxy refers to a straight- or branched-chain
  • hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom.
  • exemplary "(Ci-C4)alkoxy” groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, isobutoxy, and t-butoxy.
  • Aryl represents a group or moiety comprising an aromatic, monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms, which may be fused one or more cycloalkyl rings.
  • aryl is phenyl.
  • a heterocyclic group or moiety is a cyclic group or moiety having as ring members atoms of at least two different elements (carbon and one or more of nitrogen, oxygen and/or sulfur), which cyclic group or moiety may be saturated or partially unsaturated (non-aromatic; e.g., a heterocycloalkyl group or moiety) or fully unsaturated (aromatic; e.g., a heteroaryl group or moiety).
  • Heterocycloalkyl represents a group or moiety comprising a non-aromatic, monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, unless otherwise specified, which includes 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.
  • heterocycloalkyls include, but are not limited to, azetidinyl, oxetanyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-l,4-thiazinyl, tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1 ,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3-dithianyl, azabicylo[3.2.1 ]octyl, azabicylo[3.3.1 ]non
  • heterocycloalkyl groups include 4-membered heterocycloalkyl groups containing one heteroatom, such as oxetanyl, thietanyl and azetidinyl.
  • heterocycloalkyl groups include 5-membered heterocycloalkyl groups containing one heteroatom selected from nitrogen, oxygen and sulfur and optionally containing one or two an additional nitrogen atoms, or optionally containing one additional oxygen or sulfur atom, such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuryl (or tetrahydrofuranyl), tetrahydrothienyl, dihydrofuryl, oxazolinyl, thiazolinyl, imidazolinyl, pyrazolinyl, 1,3-dioxolanyl, and l,3-oxathiolan-2-on-yl.
  • heterocycloalkyl groups include 5-membered heterocycloalkyl groups containing one heteroatom selected from nitrogen, oxygen and sulfur and optionally containing one or two an additional nitrogen atoms, or optionally containing one additional oxygen or sulfur atom, such as pyrrolidyl (or pyrrol
  • heterocycloalkyl groups are 6-membered heterocycloalkyl groups containing one heteroatom selected from nitrogen, oxygen and sulfur and optionally containing one or two an additional nitrogen atoms or one additional oxygen or sulfur atom, such as piperidyl (or piperidinyl), piperazinyl, morpholinyl, thiomorpholinyl, l,ldioxoido-thiomorpholin-4-yl, tetrahydropyranyl, dihydropyranyl, tetrahydro-2H-l,4-thiazinyl, 1 ,4-dioxanyl, 1,3-oxathianyl, and 1,3-dithianyl.
  • piperidyl or piperidinyl
  • piperazinyl morpholinyl
  • thiomorpholinyl thioxoido-thiomorpholin-4-yl
  • tetrahydropyranyl dihydropyranyl, tetrahydro-2H
  • Heteroaryl refers to a group or moiety comprising an aromatic monocyclic or bicyclic radical, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur. This term also encompasses bicyclic heterocyclic-aryl compounds containing an aryl ring moiety fused to a heterocycloalkyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur.
  • heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (or furanyl), isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridyl (or pyridinyl), pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[£]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl,
  • heteroaryl groups present in the compounds of this invention are 5-membered and/or 6-membered monocyclic heteroaryl groups. Selected
  • 5- membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1, 2 or 3 additional nitrogen ring atoms.
  • Selected 6-membered heteroaryl groups contain 1, 2, 3 or 4 nitrogen ring heteroatoms.
  • 6- membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (furanyl), isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl.
  • the heteroaryl groups present in the compounds of this invention are 9-membered or 10-membered monocyclic heteroaryl groups.
  • Selected 9-10 membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1, 2, 3 or 4 additional nitrogen ring atoms.
  • heteroaryl groups include a
  • 9- membered heteroaryl group which includes benzothienyl, benzofuranyl, indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, indolizinyl, isobenzofuryl,
  • heteroaryl groups include a
  • 10- membered heteroaryl group which includes chromenyl, chromanyl, quinolyl, isoquinolyl, phthalazinyl, naphthridinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, tetrahydroquinolinyl, cinnolinyl, and pteridinyl.
  • heterocyclic, heteroaryl, and heterocycloalkyl are intended to encompass stable heterocyclic groups where a ring nitrogen heteroatom is optionally oxidized (e.g., heterocyclic groups containing an N-oxide, such as pyridine-N-oxide) or where a ring sulfur heteroatom is optionally oxidized (e.g., heterocyclic groups containing sulfones or sulfoxide moieties, such as
  • tetrahydrothienyl-1 -oxide a tetrahydrothienyl sulfoxide
  • tetrahydrothienyl- 1,1 -dioxide a tetrahydrothienyl sulfone
  • Hydroxo or hydroxyl is intended to mean the radical -OH.
  • the terms "compound(s) of the invention” or “compound(s) of this invention” mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
  • any salt or non-salt form e.g., as a free acid or base form, or as a salt, particularly a pharmaceutically acceptable salt thereof
  • any physical form thereof e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., a
  • the term "optionally substituted” indicates that a group (such as an alkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, or heteroaryl group) or ring or moiety (such as a carbocyclic or heterocyclic ring or moiety) may be unsubstituted, or the group, ring or moiety may be substituted with one or more substituent(s) as defined.
  • groups may be selected from a number of alternative groups, the selected groups may be the same or different.
  • R 1 is H, -S0 2 (Ci-C 4 )alkyl, -CO(Ci-C 4 )alkyl, or (Ci-C 4 )alkyl;
  • R 2 is - SR a , -SOR a , or -S0 2 R a , wherein R a is (Ci-C 6 )alkyl, halo(Ci-C 6 )alkyl, (C 3 -Cy)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:
  • said (Ci-C 6 )alkyl is optionally substituted by one or two groups each independently selected from cyano, hydroxyl, (Ci-C 6 )alkoxy, (Ci-C6)alkoxy(C2-C 6 )alkoxy, -C0 2 H, -C0 2 (Ci-C 4 )alkyl, -S0 2 (Ci-C 4 )alkyl, (C 3 -Cy)cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and
  • phenyl)(Ci-C 4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF 3 , hydroxyl, amino, ((Ci-C 4 )alkyl)amino-,
  • said (C 3 -C 7 )cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF 3 , hydroxyl, amino,
  • said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from halogen, -CF 3 , hydroxyl, amino, ((Ci-C 4 )alkyl)amino-,
  • R 3 is H, halogen, hydroxy, (Ci-C 4 )alkyl-,(C 2 -C 4 )alkenyl-, halo(Ci-C 4 )alkyl-, (Ci-C 4 )alkoxy-, halo(Ci-C 4 )alkoxy-, (Ci-C 4 )alkoxy(Ci-Ce)alkyl-,
  • halo(Ci-C 4 )alkoxy(Ci-Ce)alkyl-, or halo(Ci-C 4 )alkoxy(C 2 -Ce)alkoxy- groups contain 2 or 3 halo atoms; and wherein the (C 3 -C 6 )cycloalkyl moiety of the (C3-C 6 )cycloalkyl(Ci-C 4 )alkoxy- or (C3-C 6 )cycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (Ci-C 6 )alkoxy and (Ci-C 4 )alkoxy(C 2 -Ce)alkoxy;
  • 4-6 membered-heterocycloalkyl moiety of the 4-6 membered- heterocycloalkyl(Ci-C 4 )alkoxy-, or 4-6 membered-heterocycloalkoxy- is optionally substituted by a group selected from cyano, halo, hydroxyl, (Ci-C 6 )alkoxy and
  • Z is phenyl or aryl(Ci-C 4 )alkyl-, substituted by R 4 , R 5 , R 6 and R 7 , wherein:
  • R 4 is H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy- is optionally substituted by 1-3 substituents each independently selected from halogen, -CF 3 , (Ci-C 4 )alkyl and
  • each of R 5 , R 6 and R 7 is independently selected from H, hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; or
  • Z is phenyl or pyridyl substituted by R 8 , R 9 and R 10 , wherein:
  • R 8 and R 9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered heterocyclic group containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered heterocyclic group is substituted by R 11 ;
  • R 10 or R 11 is H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; and
  • R 10 or R 11 is H, hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl or (Ci-C 4 )alkoxy; or
  • Z is pyrazolyl, having the formula:
  • R 12 is H, methyl or hydroxymethyl; R is methyl, trifluoromethyl or hydroxymethyl;
  • R 14 is H, OH, or (Ci-C 3 )alkyl
  • R 12 and R 13 taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R 15 and R 16 , wherein the heterocyclic ring contains 1 nitrogen atom;
  • R 15 and R 16 are each independently selected from H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy.
  • the compounds of Formula (I) do not include ethyl 5- ⁇ [4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio ⁇ pentanoate; ethyl 4- ⁇ [4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio ⁇ butanoate; ethyl 4- ⁇ [4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6- quinazolinyl]thio ⁇ heptanoate; 7-(methoxy)-N-[l-(phenylmethyl)-lH-indazol-5-yl]-6- [(trifluoromethyl)sulfonyl]-4-quinazolinamine; or ethyl 4- ⁇ [4-
  • R 1 is ⁇ . In other embodiments, R 1 is (Ci-C 3 )alkyl; specifically, -CH 3 or -CH 2 CH 3 . Generally, in the compounds of this invention, R 1 is H.
  • R 2 is -SR a or -S0 2 R a . In a further embodiment, R 2 is -SOR a . In a still further embodiment, R 2 is -S0 2 R a .
  • R a is an optionally substituted (Ci-C 6 )alkyl, (C 3 -C 6 )cycloalkyl, 4-6-membered heterocycloalkyl,
  • (Ci-C 6 )alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C 4 )alkoxy,
  • R a is an unsubstituted (Ci-C 6 )alkyl or a (Ci-C 6 )alkyl substituted by one or two groups each independently selected from the group consisting of hydroxyl,
  • R a is an optionally substituted (C 3 -C 6 )cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl group, wherein the
  • (C 3 -C 6 )cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF 3 , hydroxyl, amino, (Ci-C 4 )alkyl, phenyl(Ci-C 4 )alkyl-,
  • R a is a heterocycloalkyl or heteroaryl group
  • the heterocycloalkyl or heteroaryl group is bonded to the sulfur atom of the -SR a , -SOR a or -S0 2 R a moiety by a ring carbon atom.
  • R a is an optionally substituted (Ci-C 6 )alkyl
  • said (Ci-C 6 )alkyl is optionally substituted by a group selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, (Ci-C 2 )alkoxy(C 2 -C 3 )alkoxy-, -S0 2 (Ci-C 2 )alkyl, and a group selected from the group consisting of (C 3 -C 6 )cycloalkyl (optionally substituted by (Ci-C 4 )alkyl or hydroxy(Ci-C 4 )alkyl), 4-6-membered heterocycloalkyl (optionally substituted by (Ci-C 4 )alkyl or halogen), 5-6-membered heteroaryl (optionally substituted by (Ci-C 4 )alkyl or hydroxy(Ci-C 4 )alkyl), phenyl, and 9-10-membered heteroaryl, and said (C 3 -Ce)cycloalkyl or 4-6-member
  • any of said 5-6 membered heterocycloalkyl groups contains 1 heteroatom selected from N, O and S.
  • R a is an optionally substituted (Ci-C 6 )alkyl
  • said (Ci-C 6 )alkyl is optionally substituted by a group selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, and (Ci-C 2 )alkoxy(C 2 -C 3 )alkoxy-.
  • R a is an optionally substituted (Ci-C 6 )alkyl or 5-6-membered heterocycloalkyl group, wherein:
  • said (Ci-C 6 )alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, (Ci-C 2 )alkoxy(C 2 -C 3 )alkoxy-, amino,
  • said 5-6 membered heterocycloalkyl is optionally substituted by 1 or 2 groups each independently selected from the group consisting of halogen, (Ci-C 4 )alkyl, and
  • any of said 5-6 membered heterocycloalkyl contains 1 heteroatom selected from N, O and S.
  • R a is halo(Ci-C 4 )alkyl containing 1-9 halogen atoms.
  • R a is halo(Ci-C 2 )alkyl, specifically a halo(Ci-C 2 )alkyl containing 1-5 halogen atoms, and more specifically a halo(Ci-C 2 )alkyl containing 3 halogen atoms.
  • R a is (Ci-C 6 )alkyl, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, and
  • R a is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C 4 )alkyl groups.
  • R a is an unsubstituted (Ci-Cs)alkyl. In a further embodiment of the compounds of this invention, R a is an unsubstituted (Ci-C 4 )alkyl group. In another embodiment, R a is a (Ci-C 5 )alkyl group substituted by a hydroxyl,
  • R a is a (Ci-C 5 )alkyl substituted by one hydroxyl group. In yet another specific embodiment, R a is a tetrahydropyranyl group.
  • R a is -CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 .
  • R a is -CH 2 CH 2 OH or -C(CH 3 ) 2 CH 2 CH 2 OH.
  • R a is tetrahydro-2H-pyran-4-yl.
  • R b is (Ci-C 6 )alkyl or 4-7 membered heterocycloalkyl, wherein: said (Ci-C 6 )alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C 6 )alkoxy,
  • heterocycloalkyl wherein said 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, (Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkyl and (Ci-C 4 )alkoxy,
  • said 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (Ci-C 4 )alkyl, hydroxy(Ci-C 4 )alkyl-, oxo and (Ci-C 4 )alkoxy, and
  • R c is H or (Ci-C 4 )alkyl
  • R b and R c taken together with the nitrogen atom to which they are attached form a 5-7 membered heterocycloalkyl group, optionally containing one additional ring heteroatom selected from nitrogen and oxygen, wherein said 5-7 membered
  • heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of (Ci-C 4 )alkyl, hydroxy, -C0 2 H and -CO(Ci-C 4 )alkyl.
  • R b is (Ci-C 6 )alkyl and said (Ci-C 6 )alkyl is optionally substituted by lor 2 substituents each independently selected from the group consisting of hydroxyl, (Ci-C 4 )alkoxy, (Ci-C 4 )alkoxy(C 2 -C 4 )alkoxy-, (Ci-C 4 alkyl)amino-,
  • R b is unsubstituted (Ci-C 6 )alkyl, particularly, R b is unsubstituted (Ci-C 4 )alkyl.
  • R b is a (Ci-C 6 )alkyl substituted by lor 2 substituents each independently selected from the group consisting of hydroxyl,
  • R b is a (Ci-C 4 )alkyl substituted by hydroxyl, (Ci-C 2 )alkoxy,
  • R b is -CH 3 or -CH(CH 3 ) 2 . In another embodiment, R b is
  • R b is -oxetan-3-yl, tetrahydro-2H-pyran-4-yl, -CH 2 -tetrahydro- 2H-pyran-4-yl, or -CH 2 CH 2 -lH-tetrazol-5-yl.
  • R c is ⁇ or (Ci-C 4 )alkyl. In some specific embodiments, R c is -CH 3 . In other specific embodiments, R c is H.
  • R b and R c taken together with the nitrogen atom to which they are attached form a 5-7 membered heterocycloalkyl group, optionally containing one additional ring heteroatom selected from nitrogen and oxygen, which 5-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of ((Ci-C 4 )alkyl, hydroxy, -CO 2 H and -CO(Ci-C 4 )alkyl.
  • R b and R c taken together with the nitrogen atom to which they are attached form a 5-6-membered heterocycloalkyl, optionally containing 1 additional heteroatom selected from N and O, and optionally substituted by a hydroxyl, (Ci-C 4 )alkyl, carboxy or (Ci-C 4 )alkylcarbonyl- group.
  • R b and R c taken together with the nitrogen atom to which they are attached form a morpholin-4-yl, 4-methylcarbonyl-piperazin-l-yl (that is, 4-acetyl-piperazin-l-yl), pyrrolidin-l-yl, 3-hydroxy-pyrrolidin-l-yl, or
  • R 3 is H.
  • R 3 is halogen, hydroxy, (Ci-C 3 )alkyl-,
  • R 3 is halogen, hydroxy, (Ci-C 3 )alkyl-, (C 2 -C 3 )alkenyl-, halo(Ci-C 2 )alkyl-, hydroxy(C 2 -C 3 )alkenyl-, (Ci-C 4 )alkoxy-,
  • R 3 is H or R 3 is halogen, hydroxy, (Ci-C 4 )alkyl-, (C 2 -C 4 )alkenyl-, halo(Ci-C 4 )alkyl-, (Ci-C 4 )alkoxy-, halo(Ci-C 4 )alkoxy-,
  • R 3 is H, halogen, hydroxy, (Ci-C 3 )alkyl-, (C 2 -C 3 )alkenyl-, halo(Ci-C 2 )alkyl-, (Ci-C 4 )alkoxy-, halo(Ci-C 3 )alkoxy-, (C 5 -C 6 )cycloalkyl(Ci-C 3 )alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-, (Ci-C 3 )alkoxy(Ci-C 4 )alkyl-,
  • Z is phenyl substituted by R 4 , R 5 , R 6 and R 7 wherein:
  • R 4 is ⁇ , halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl, or hydroxy(Ci-C4)alkyl-;
  • each of R 5 , R 6 and R 7 is independently selected from the group consisting of ⁇ , hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl, halo(Ci-C4)alkyl and
  • Z is phenyl, substituted by 1 , 2 or 3 (more specifically, 1 or 2) substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy.
  • Z is
  • Z is 2-methyl-5-hydroxy-phenyl.
  • Z is phenyl or pyridyl substituted by R 8 , R 9 and R 10 , wherein:
  • R 8 and R 9 are located on adjacent atoms (carbon atoms) and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by
  • R 11 wherein one of R 10 or R 11 is ⁇ , halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl,
  • R 10 or R 11 is ⁇ , hydroxyl, halogen, -CF 3 , hydroxy(Ci-C4)alkyl,
  • pyrazolyl having the formula: wherein: R is H, methyl or hydroxymethyl;
  • R 13 is methyl, trifluoromethyl or hydroxymethyl
  • R 14 is H, OH, or (Ci-C 3 )alkyl
  • R 12 and R 13 taken together with the atoms to which they are attached, form a 6-membered ring substituted by R 15 and R 16 , wherein the 6-membered ring contains 1 nitrogen atom;
  • R 15 and R 16 are each independently selected from the group consisting of H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy,
  • phenyl(Ci-C 4 )alkoxy hydroxyl, hydroxy(Ci-C 4 )alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (C C 4 )alkoxy.
  • the 5-membered ring formed from R 8 and R 9 and the atoms to which they are attached may be non-aromatic (partially unsaturated) or aromatic (fully unsaturated). It will be further understood by one skilled in the art that the 6-membered ring formed from R 12 and R 13 and the atoms to which they are attached may be non-aromatic (partially unsaturated) or aromatic (fully unsaturated).
  • Z is not phenyl or aryl(Ci-C 4 )alkyl-, wherein in the phenyl group or the aryl moiety of the aryl(Ci-C 4 )alkyl- group is substituted by R 4 , R 5 , R 6 and R 7 , wherein R 4 is H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl,
  • hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; and each of R 5 , R 6 and R 7 is independently selected from the group consisting of H, hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy.
  • Z is phenyl substituted by R 8 , R 9 and R 10 , wherein R 8 and R 9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by R 11 ; wherein R 10 and R 11 are each H or one of R 10 or R 11 is H, halogen, cyano, (Ci-C 4 )alkyl, -CF 3 , (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3
  • Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C 4 )alkyl,
  • Z is unsubstituted benzothiazolyl.
  • Z is benzothiazolyl substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C 4 )alkyl,
  • Z is benzo[ ⁇ i]thiazol-5-yl optionally substituted by chloro, fluoro, -CF 3 , methyl, or methoxy.
  • Z is benzo[ ⁇ i]thiazol-5-yl.
  • Z is pyridyl substituted by R 8 , R 9 and R 10 , wherein R 8 and R 9 are located on adjacent atoms (carbon atoms) and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by R 11 ; wherein one of R 10 or R 11 is H, halogen, cyano, (Ci-C 4 )alkyl, -CF 3 , (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3
  • Z is pyrazolyl and R 12 is H or hydroxymethyl, R 13 is methyl or trifluoromethyl, and R 14 is H or methyl; or R 12 is H or methyl, R 13 is hydroxymethyl, and R 14 is H or methyl.
  • Z is pyrazolyl, R 12 is H or methyl, R 13 is methyl or trifluoromethyl, and R 14 is OH.
  • Z is pyrazolyl, R 12 is H or methyl, R is methyl or trifluoromethyl, and R is H or methyl.
  • Z is pyrazolyl, R 12 and R 13 are both methyl, and R 14 is H.
  • Z is 5-(trifluoromethyl)-lH-pyrazol-3-yl, l,3,4-trimethyl-lH-pyrazol-5-yl, or 4,5-dimethyl-lH-pyrazol-3-yl.
  • Z is pyrazolyl, substituted by R 12 and R 13 wherein:
  • R 12 and R 13 are located on adjacent carbon atoms and taken together with the atoms to which they are attached form a 6 membered carbocyclic ring or heterocyclic ring substituted by R 15 and R 16 ;
  • R 15 is ⁇ , halogen, cyano, (Ci-C 4 )alkyl, -CF 3 , (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; and
  • R 16 is ⁇ , hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl or
  • the invention is directed to a compound according to Formula (I), wherein Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NR 1 ) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-3 ⁇ 4]pyridinyl group, or a salt, particularly a pharmaceutically acceptable salt, thereof.
  • Z is a 9-membered bi-cyclic hetero
  • Z is an optionally substituted indazolyl or
  • pyrazolo[3,4-3 ⁇ 4]pyridinyl wherein the indazolyl or pyrazolo[3,4-3 ⁇ 4]pyridinyl is optionally substituted by hydroxyl, chloro, fluoro, -CF 3 , cyano, hydroxymethyl-, methyl, methoxy or aminocarbonyl.
  • Z is 5 -fluoro- lH-indazol-3-yl, lH-indazol-6-yl or 3-methyl-lH-indazol-6-yl.
  • Z is 5-fluoro-lH-indazol-3-yl.
  • the invention is directed to a compound according to Formula (II):
  • R 1 , R 2 , R 3 , R 12 and R 13 are as defined herein.
  • the invention is directed to method of inhibiting RIP2 kinase comprising contacting a cell with a compound according to Formula (III):
  • R 1 , R 2 and R 3 are as defined herein, and
  • R Z1 is H, halogen, -CF 3 , (Ci-C 4 )alkyl or (Ci-C 4 )alkoxy; particularly, R Z1 is H or methyl;
  • R Z2 is H, halogen, -CF 3 , (Ci-C 4 )alkyl or (Ci-C 4 )alkoxy;
  • R Z3 is H, halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; and R is hydroxyl, hydroxy(Ci-C 4 )alkyl or (Ci-C 4 )alkoxy;
  • the invention is directed to a compound of Formula (I), wherein:
  • R 1 is H or (Ci-C 4 )alkyl
  • R 2 is -SR a or -S0 2 R a
  • R a is an optionally substituted (Ci-C 6 )alkyl
  • said (Ci-C 6 )alkyl is optionally substituted by a groups selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, (Ci-C 2 )alkoxy(C 2 -C3)alkoxy-, -S0 2 (Ci-C 2 )alkyl, and a group selected from the group consisting of (C 3 -C 6 )cycloalkyl (optionally substituted by (Ci-C 4 )alkyl or hydroxy(Ci-C 4 )alkyl), 4-6-membered heterocycloalkyl (optionally substituted by (Ci-C 4 )alkyl or halogen), 5-6-membered heteroaryl (optionally substituted by (Ci-C 4 )alkyl or hydroxy(Ci-C 4 )alkyl), phenyl, and 9-10-membered heteroaryl, and said (C 3 -C 6 )cycloalkyl or 4-6-membere
  • any of said 5-6 membered heterocycloalkyl groups contains 1 heteroatom selected from N, O and S;
  • R 3 is H, halogen, hydroxy, (Ci-C 4 )alkyl-, (C 2 -C 4 )alkenyl-, halo(Ci-C 4 )alkyl-, (Ci-C 4 )alkoxy-, halo(Ci-C 4 )alkoxy-, (C3-C 6 )cycloalkyl(Ci-C 4 )alkoxy-, 5-6-memebered- heterocycloalkyl-oxy-, (Ci-C 4 )alkoxy(Ci-C 6 )alkyl-, (Ci-C 4 )alkoxy(C 2 -C 6 )alkoxy-, carboxy-(Ci-Ce)alkoxy-, (Ci-C 4 )alkoxycarbonyl(Ci-C 6 )alkoxy-, hydroxy(Ci-Ce)alkyl-, or hydroxy(C 2 -C 6 )alkoxy-;
  • Z is phenyl, substituted by 1 , 2 or 3 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and
  • R 8 and R 9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5 -membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5 -membered ring is substituted by R 11 ; wherein R 10 and R 11 are each H or one of R 10 or R 11 is H, halogen, cyano,
  • R 12 is H or methyl
  • R 13 is methyl or trifluoromethyl
  • R 14 is H or methyl
  • R 12 and R 13 are located on adjacent carbon atoms and taken together with the atoms to which they are attached form a 6-membered carbocyclic ring or heterocyclic ring substituted by R 15 and R 16 ;
  • R 15 is H, halogen, cyano, (Ci-C 4 )alkyl, -CF 3 , (Ci-C 4 )alkoxy, phenoxy, phenyl(Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C 4 )alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF 3 , (Ci-C 4 )alkyl and (Ci-C 4 )alkoxy; and
  • R 16 is H, hydroxyl, halogen, -CF 3 , hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl or
  • R 2 is -S0 2 R a and/or R 3 is halogen, hydroxy, (Ci-C 4 )alkyl-,
  • the invention is directed to a compound of Formula (I), wherein:
  • R 1 is H;
  • R 2 is -SR a , -SOR a or -S0 2 R a , wherein R a is a (Ci-C 6 )alkyl group, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, and (Ci-C 2 )alkoxy(C 2 -C 3 )alkoxy-,
  • R a is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C 4 )alkyl groups;
  • R 3 is halogen, hydroxy, (Ci-C 3 )alkyl-, (C 2 -C 3 )alkenyl-, halo(Ci-C 2 )alkyl-, hydroxy(C 2 -C 3 )alkenyl-, (Ci-C 4 )alkoxy-, (C 2 -C 3 )alkenyl-oxy-, halo(Ci-C 3 )alkoxy-, (C5-C 6 )cycloalkyl(Ci-C 3 )alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
  • Z is phenyl, substituted by 1 or 2 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and
  • Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl and
  • R 12 is H or methyl
  • R 13 is methyl or trifluoromethyl
  • R 14 is H or methyl
  • Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NR 1 ) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group,
  • the invention is directed to a compound of Formula (I), wherein:
  • R 1 is H;
  • R 2 is -SR a , -SOR a or -S0 2 R a , wherein R a is a (Ci-C 6 )alkyl group, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, and (Ci-C 2 )alkoxy(C 2 -C3)alkoxy-;
  • R 3 is halogen, hydroxy, (Ci-C 3 )alkyl-, (C2-C 3 )alkenyl-, halo(Ci-C 2 )alkyl-, hydroxy(C 2 -C 3 )alkenyl-, (Ci-C4)alkoxy-, (C 2 -C 3 )alkenyl-oxy-, halo(Ci-C 3 )alkoxy-, (C5-C6)cycloalkyl(Ci-C 3 )alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
  • Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl and
  • R 12 is H or methyl
  • R 13 is methyl or trifluoromethyl
  • R 14 is H or methyl
  • Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NR 1 ) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group;
  • the invention is directed to a compound of Formula (I), wherein:
  • R 1 is H or -CH 2 CH 3 ; particularly, R 1 is H;
  • R 2 is -SR a or -S0 2 R a , wherein:
  • R a is a (Ci-C 6 )alkyl group, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C 2 )alkoxy, and (Ci-C 2 )alkoxy(C 2 -C 3 )alkoxy-,
  • R a is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C 4 )alkyl groups;
  • R 3 is H, halogen, hydroxy, (Ci-C3)alkyl-, (C 2 -C 3 )alkenyl-, halo(Ci-C 2 )alkyl-, (Ci-C 4 )alkoxy-, halo(Ci-C 3 )alkoxy-, (C5-C6)cycloalkyl(Ci-C 3 )alkoxy-, 5-6-memebered heterocycloalkyl-oxy-, (Ci-C 3 )alkoxy(Ci-C 4 )alkyl-, (Ci-C 3 )alkoxy(C 2 -C 4 )alkoxy-, carboxy-(Ci-C 4 )alkoxy-, (Ci-C 3 )alkoxycarbonyl(Ci-C 4
  • Z is phenyl, substituted by 1 or 2 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C 4 )alkyl, (Ci-C 4 )alkyl and
  • Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl or
  • R 12 is H or methyl
  • R 13 is methyl or trifluoromethyl
  • R 14 is H or methyl
  • Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxyl, hydroxy(Ci-C 4 )alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NH) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group,
  • the invention is directed to a compound of Formula (I), wherein:
  • R 1 is H
  • R 2 is -S0 2 R a ,wherein R a is an unsubstituted (Ci-C 5 )alkyl group or R a is a
  • Z is benzothiazolyl, optionally substituted by a halogen, (Ci-C 4 )alkyl,
  • R 12 is H or methyl
  • R 13 is methyl or trifluoromethyl
  • R 14 is H or methyl
  • Z is a 9-membered bi-cyclic heteroaryl, optionally substituted on either ring by a halogen, cyano, (Ci-C 4 )alkyl, halo(Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, hydroxyl,
  • the 9-membered bi-cyclic heteroaryl is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the ammo (NR ⁇ /NH) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group;
  • R 1 is H or -CH 2 CH 3 ; particularly, R 1 is H;
  • R 2 is -SR a or -S0 2 R a
  • R a is -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH 2 OH,
  • Z is 2-methyl-4-hydroxy-phenyl, benzo[ ⁇ i]thiazol-5-yl or 5-fluoro-lH-indazol-3-yl, or Z is pyrazolyl, wherein R 12 is ⁇ or methyl, R 13 is methyl or trifluoromethyl, and R 14 is ⁇ or methyl,
  • the invention is directed to a compound according to Formula (I) wherein:
  • R 1 is ⁇
  • R 2 is -S0 2 R a , and R a is -CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3;
  • Z is benzo[ ⁇ i]thiazol-5-yl or 5-fluoro-lH-indazol-3-yl,
  • R 12 is ⁇ or methyl, R 13 is methyl or trifluoromethyl, and R 14 is ⁇ or methyl;
  • R 1 is ⁇ ;
  • R 2 is -SR a or -S0 2 R a , and R a is -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH 2 OH, -C(CH 3 ) 2 CH 2 CH 2 OH, or tetrahydro-2H-pyran-4-yl;
  • -OCH CH-C0 2 H
  • -OCH CH-C0 2 CH 3
  • -OCH CH-CONH 2 , -OH, -OCH 3 , -OCF 2 H, -OCH(CH 3 ) 2 , -OCH 2 CH 3 , -OCH 2 CF 3 , -OCH 2 CH 2 CH 3 , -0CH 2 CH 2 C1, -OCH 2 CH 2 Br, -OCH 2 CH 2 SCH 3 , -OCH 2 CH 2 S0 2 CH 3 , -OCH 2 CH 2 S0 2 CH(CH 3 ) 2 , -OCH 2 CH 2 OH,
  • Z is 2-methyl-5 -hydroxy-phenyl, 2-fluoro-4-chloro-phenyl,
  • the invention is further directed to a compound according to Formula (I) wherein:
  • R 1 is ⁇
  • R 2 is -S0 2 R a .
  • R a is -CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , or
  • R a is -CH 2 CH 2 OH or -C(CH 3 ) 2 CH 2 CH 2 OH;
  • -OCH CH-C0 2 H
  • -OCH CH-C0 2 CH 3
  • -OCH CH-CONH 2 , -OH, -OCH 3 , -OCF 2 H, -OCH(CH 3 ) 2 , -OCH 2 CH 3 , -OCH 2 CF 3 , -OCH 2 CH 2 CH 3 , -0CH 2 CH 2 C1, -OCH 2 CH 2 Br, -OCH 2 CH 2 SCH 3 , -OCH 2 CH 2 S0 2 CH 3 , -OCH 2 CH 2 S0 2 CH(CH 3 ) 2 , -OCH 2 CH 2 OH,
  • Z is benzo[ ⁇ i]thiazol-5-yl, 5-(trifluoromethyl)-lH-pyrazol-3-yl, 1,3,4-trimethyl-lH- pyrazol-5-yl, 4,5-dimethyl-lH-pyrazol-3-yl, 5-fluoro-lH-indazol-3-yl, lH-indazol-6-yl or 3-methyl-lH-indazol-6-yl,
  • Representative compounds of this invention include the compounds of Examples 1-80, specifically: 4-methy 1-3 - ⁇ [6-(methylthio)-4-quinazolinyl] amino ⁇ phenol,
  • N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-7-ethyl-4-quinazolinamine N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-7-ethyl-4-quinazolinamine
  • this invention is directed to N-l,3-benzothiazol-5-yl-6-[(l,l- dimethylethyl)sulfonyl]-4-quinazolinamine or a salt, particularly a pharmaceutically acceptable salt, thereof.
  • This invention is also directed to N-l,3-benzothiazol-5-yl-6-[(l- methylethyl)sulfonyl]-4-quinazolinamine, or a salt, particularly a pharmaceutically acceptable salt, thereof.
  • This invention is further directed to N-(6-(tert-butylsulfonyl)-7-methoxyquinazolin- 4-yl)benzo[ ⁇ i]thiazol-5 -amine or a salt, particularly a pharmaceutically acceptable salt, thereof.
  • this invention is directed to 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)ethanol or a salt, particularly a pharmaceutically acceptable salt, thereof.
  • a compound of the invention includes a compound of Formula (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • a compound of the invention includes a compound of Formula (I), particularly the specific compounds described herein, or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
  • the invention is directed to a method of inhibiting RIP2 kinase comprising contacting a cell with a compound of the invention.
  • the invention is directed to a method of treating a RIP2 kinase-mediated disease or disorder comprising administering a therapeutically effective amount of a compound of the invention to a human in need thereof.
  • the invention is still further directed to the use of a compound of the invention or a pharmaceutical composition comprising a compound of the invention to inhibit RIP2 kinase and/or treat a RIP2 kinase- mediated disease or disorder.
  • the compounds according to Formula (I) may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof.
  • Chiral centers such as a chiral carbon, or particularly, a chiral -SO- moiety, may also be present in the compounds of this invention.
  • the stereochemistry of a chiral center present in a compound of this invention e.g., compound name
  • the compound, compound name, or structure is intended to encompass all individual stereoisomers and all mixtures thereof.
  • compounds according to Formula (I) containing one or more chiral center may be present as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
  • each of (i?)-N-(6-(tert-butylsulfinyl)-7-methoxyquinazolin-4- yl)benzo [d]thiazol-5 -amine and (5)-N-(6-(tert-butylsulfinyl)-7-methoxyquinazolin-4- yl)benzo[ ⁇ i]thiazol-5 -amine are encompassed by the chemical name N-(6-(tert- butylsulfinyl)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine.
  • Individual stereoisomers of a compound according to Formula (I) which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • a solid form of a compound of the invention may exist in crystalline forms, non-crystalline forms or a mixture thereof. Such crystalline forms may also exhibit polymorphism (i.e. the capacity to occur in different crystalline forms). These different crystalline forms are typically known as "polymorphs.” Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
  • Formula (I) are preferably pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse J.Pharm.Sci (1977) 66, pp 1-19. Salts encompassed within the term “pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
  • a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as /
  • Suitable addition salts include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxynaphthoate, isethionate,
  • methylsulfate monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmate, palmitate, pantothenate,
  • phosphate/diphosphate pyruvate, polygalacturonate, propionate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate.
  • exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-l,4-dioate, hexyne-l,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, ⁇ -hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene- 1 -sulfonate and naphthalene-2-sulfonate.
  • an inventive basic compound is isolated as a salt
  • the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pK a than the free base form of the compound.
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
  • an inorganic or organic base such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as glycine and arginine
  • ammonia such as glycine and arginine
  • primary, secondary, and tertiary amines such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine
  • Certain of the compounds of the invention may form salts with one or more equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety).
  • the present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
  • Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
  • This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention into another pharmaceutically acceptable salt of a compound of this invention.
  • pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization.
  • Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and EtOAc, or they may involve water as the solvent that is incorporated into the crystalline lattice.
  • Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates.” Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates, particularly hydrates. It is to be understood that the term "a salt, particularly a pharmaceutically acceptable salt, thereof, or hydrate thereof encompasses a salt of a compound of Formula (I), a pharmaceutically acceptable salt of a compound of Formula (I), a hydrate of a compound of Formula (I), a hydrate of a salt of a compound of Formula (I), and a hydrate of a pharmaceutically acceptable salt of a compound of Formula (I).
  • the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
  • the compounds of Formula (I) may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist.
  • the syntheses provided in these Schemes are applicable for producing compounds of the invention having a variety of different substituent groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula (I), they are illustrative of processes that may be used to make the compounds of the invention.
  • 4-Chloroquinazoline intermediates may be from the appropriately functionalized nitrobenzoic acid via reduction of the nitro group to an aniline followed by condensation with formamide or formimamide and cyclization to the 4-quinazolinone. Conversion to the chloroquinazoline could be accomplished with POCI3 or SOCl 2 at elevated temperatures.
  • 6-alkylthioquinazo lines which could be final products, or further subjected to oxidation with Oxone to afford the corresponding sulfone final products.
  • Sulfoxides may also be obtained by this route through carefully monitoring the reaction. Additionally, any sulfides at R 3 may be oxidized to sulfones in this manner.
  • Substitution at C6 could also be installed prior to installation of the "A" moiety.
  • a palladium catalyzed coupling of a thiol with the 6-iodoquinazolinone can provide a sulfide which can subsequently be oxidized to the sulfone.
  • Chlorination with POCI 3 or SOCl 2 may provide the 4-chloroquinazoline.
  • the sulfide at C6 could be installed while dealkylating C7 methoxyquinazoline with the appropriate sodium alkylthiolate.
  • Final product may be obtained following alkylation of the resultant C7 hydroxyl and oxidation to the sulfone.
  • the 7-ethylquinazoline could synthesized via a Stille coupling with the C7 triflate to provide the ethylenebenezene followed by hydrogeno lysis.
  • the triflate can undergo a palladium catalyzed reaction to install the allylic alcohol.
  • 5-Fluoro-lH-pyrazolo[3,4-3 ⁇ 4]pyridin-3-amine may be synthesized from 2-chloro-5- fluoro-3-pyridinecarboxylic acid. Formation of the acylchloride followed by the addition of ammonia can provide the amide which may be subsequently converted to the nitrile. Treatment with hydrazine may provide the azaindazole. Scheme 12
  • 3,4-Dimethyl-lH-pyrazol-5-amine may be synthesized by alkylation of 3-amino-2- methylacrylonitrile followed by a cyclization with hydrazine.
  • the pyrazolamine can be further methylated by reaction with formic acid followed by reduction with borohy dride .
  • a groups may be installed via a C4 sulfide intermediate. Treatment of the 4-chloro-7-methoxyquinazo lines with sodium ethanethiolate provides the 4-ethylsulfide-7- hydroxyquinoazolines. These 4-alkythio-quinazoline intermediates may be directly treated with an excess of amine (A-NH 2 ) under acidic microwave conditions to provide final products. Alternatively, the intermediates could be alkylated at R 3 to afford the hydroxy ethyl ethers before undergoing reaction with amine (A-NH 2 ).
  • Sulfonamides may be obtained through the sulfonyl chloride. Formation of the benzylthioether via a palladium catalyzed reaction at the 6-iodoquinazoline followed by treatment with NCS under acidic conditions provided the sulfonyl chloride. Treatment with an amine or ammonia affords the sulfonamide.
  • the compounds of this invention may be particularly useful for treatment of RIP2 kinase-mediated diseases or disorders, particularly, uveitis, interleukin-1 converting enzyme (ICE, also known as Caspase-1) associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis (specifically rheumatoid arthritis), inflammatory bowel disorders (such as ulcerative colitis and Crohn's disease), early-onset and extraintestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organs (specifically kidney) in response ischemia induced by cardiac surgery, organ transplant, sepsis and other insults, liver diseases (non-alcohol steatohepatitis, alcohol steatohepatitis, and autoimmune hepatitis), allergic diseases (such as asthma), transplant reactions (such as graft versus host disease), autoimmune diseases (such as systemic lupus erythematosus, and multiple sclerosis), and granulomateous disorders (
  • the compounds of this invention may be particularly useful in the treatment of uveitis, ICE fever, Blau Syndrome, early-onset sarcoidosis, ulcerative colitis, Crohn's disease, Wegener's granulamatosis and sarcoidosis.
  • Treatment of RIP2 kinase-mediated diseases or disorders may be achieved using a compound of this invention as a monotherapy, or in dual or multiple combination therapy, particularly for the treatment of refractory cases, such as in combination with other anti-inflammatory and/or anti-TNF agents, which may be administered in
  • the compounds of this invention may be administered in combination with corticosteroids and/or anti-TNF agents to treat Blau syndrome, early-onset sarcoidosis; or in combination with anti-TNF biologies or other anti-inflammatory biologies to treat Crohn's Disease; or in combination with 5 -ASA (mesalamine) or sulfasalazine to treat ulcerative colitis; or in combination with low-dose corticosteroids and/or methotrexate to treat Wegener's granulamatosis or sarcoidosis or interstitial pulmonary disease; or in combination with a biologic (e.g.
  • anti-TNF anti-IL-6, etc.
  • suitable anti-inflammatory agents include corticosteroids, particularly low-dose corticosteroids (such as Deltasone ® (prednisone)) and anti-inflammatory biologies (such as Acterma ® (anti-IL6R mAb) and Rituximab ® (anti-CD20
  • anti-TNF agents include anti-TNF biologies (such as Enbrel® (etanecerpt)), Humira ® (adalimumab), Remicade ® (infliximab) and Simponi ® (golimumab)).
  • Enbrel® etanecerpt
  • Humira ® adalimumab
  • Remicade ® infliximab
  • Simponi ® golimumab
  • This invention also provides a compound of Formula (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof, for use in therapy.
  • This invention specifically provides for the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as an active therapeutic substance in the treatment of a RIP2 kinase-mediated disease or disorder, for example the diseases and disorders recited herein; more specifically, for use in the treatment of a disease mediated by inhibition of RIP2 kinase.
  • the invention also provides for the use of a compound of Formula (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a RIP2 kinase-mediated disease or disorder, for example the diseases and disorders recited herein.
  • a therapeutically "effective amount” is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
  • a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to modulate or inhibit the activity of RIP2 kinase such that a disease condition which is mediated by that activity is reduced, alleviated or prevented.
  • the amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pIC 5 o), efficacy (EC 50 ), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • the particular compound e.g., the potency (pIC 5 o), efficacy (EC 50 ), and the biological half-life of the particular compound
  • disease condition and its severity e.g., the identity of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or disorder and its severity and the specific composition and method being used, but can nevertheless be determined by one of skill in the art.
  • Treating is intended to mean at least the mitigation of a disease or disorder in a patient.
  • the methods of treatment for mitigation of a disease or disorder include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a mediated disease or disorder. Specific diseases and disorders that may be particularly susceptible to treatment using a compound of this invention are described herein.
  • the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
  • Parenteral administration refers to routes of administration other than enteral, transdermal, or by inhalation, and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • Topical administration includes application to the skin.
  • the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of the invention depend on the disease or disorder being treated, the severity of the disease or disorder being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • the compounds of the invention will be normally, but not necessarily, formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, the invention also is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable excipient.
  • compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection.
  • the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form.
  • a dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof).
  • the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
  • compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
  • pharmaceutically acceptable excipient means a material, composition or vehicle involved in giving form or consistency to the composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
  • each excipient must of course be of sufficiently high purity to render it pharmaceutically acceptable.
  • the compounds of the invention and the pharmaceutically acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration.
  • Conventional dosage forms include those adapted for (1) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients may serve more than one function and may serve alternative functions depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation.
  • Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically acceptable excipients in appropriate amounts for use in the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically acceptable excipients and may be useful in selecting suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
  • the invention also includes various deuterated forms of the compounds of
  • Each available hydrogen atom attached to a carbon atom may be any available hydrogen atom attached to a carbon atom.
  • deuterated pyrazole alkyl groups or deuterated alkyl-thioquinazolines or alkyl- sulfonylquinazo lines may be prepared by conventional techniques (see for example:
  • ⁇ may be named as a tert-butylsulfonyl or as a (l,l-dimethylethyl)sulfonyl group/moiety.
  • this program will name a structurally depicted compound as a tautomer of that compound. It is to be understood that any reference to a named compound or a structurally depicted compound is intended to encompass all tautomers of such compounds and any mixtures of tautomers thereof.
  • Step 1 4-chloro-6-iodoquinazoline: 6-iodo-4(lH)-quinazolinone (10 g, 37 mmol) was weighed into a 250 mL flask. Thionyl chloride (100 mL, 1.4 mmol) and DMF (0.5 mL, 6.5 mmol) were added to give a grey suspension. The mixture was heated to reflux. Heating was continued for 6 h and then the mixture was cooled on ice bath for 1 h. A yellow solid precipitated and was collected by filtration to afford 8.6 g (77%) of the title compound.
  • N-l,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine To a solution of 4- chloro-6-iodoquinazoline (2.60 g, 8.95 mmol) in isopropanol (60 mL) was added 1,3- benzothiazol-5 -amine (1.479 g, 9.85 mmol). The mixture was then placed in oil bath preheated to 90°C. The reaction was complete in 30 min., and the solution was allowed to cool to room temperature. A yellow solid precipitated and was filtered and dried to provide 3.6 g (91%) of the title compound.
  • Step 1 6-[(l-methylethyl)thio]-4(lH)-quinazolinone: To a solution of 6-iodo- 4(lH)-quinazolinone (3.0 g, 11.0 mmol), 2-propanethiol (1.1 mL, 12.1 mmol) and Et 3 N (4.6 mL, 33.1 mmol) in DMF (40 mL) was added Pd(Ph 3 P) 4 (1.27 g, 1.10 mmol) under nitrogen. The solution was stirred at 90 °C for 1 h. The reaction mixture was allowed to cool to rt and DMF was removed in vacuo.
  • Step 3 4-chloro-6-[(l-methylethyl)sulfonyl]quinazoline: 6-[(l-Methylethyl)thio]- 4(lH)-quinazolinone (0.20 g, 0.91 mmol), DMF (0.1 mL) and thionyl chloride (5 mL) were place in a sealed tube and heated at 85°C for 5 h. LCMS showed 85% of starting material was converted to product. The solvent was removed in vacuo to provide the title compound (0.20 g crude material). MS (m/z): 271 ( ⁇ + ⁇ ).
  • Step 1 7-chloro-6-iodo-4(lH)-quinazolinone: A solution of methyl 2-amino-4- chloro-5-iodobenzoate (3.4 g, 10.9 mmol) and imidoformamide (3.4 g, 32.7 mmol) in 2- methoxyethanol (15 mL) was stirred at 125°C for 7 h. The reaction mixture was allowed to cool to rt and the residue suspended in water. The solid was collected by filtration, washed with water and dried under vacuum (50 °C) to give 3.2 g of the title compound (96%). MS: m/z: 307 [M+H] + .
  • Step 2 7-chloro-6-[(l,l-dimethylethyl)thio]-4(lH)-quinazolinone: To a solution of 6,7-3 ⁇ 4z5[(l,l-dimethylethyl)thio]-4(lH)-quinazolinone (500 mg, 1.6 mmol), 2-methyl-2- propanethiol (162 mg, 1.8 mmol), Et 3 N (0.68 mL, 4.9 mmol) in DMF (5 mL) was added Pd(Ph 3 P) 4 (189 mg, 0.16 mmol). The reaction mixture was stirred at 90°C for 1 h. Solvent was removed in vacuo. The crude material was purified by column chromatography (0 to 5% MeOH/CH 2 Cl 2 ) to provide 0.37 g of the title compound (84%). MS: m/z: 269 [M+H] + .
  • Step 1 6-[(l,l-dimethylethyl)thio]-7-(methyloxy)-4(lH)-quinazolinone: To a solution of 6-iodo-7-(methyloxy)-4(lH)-quinazolinone(1.0 g, 3.3 mmol), 2-methyl-2- propanethiol (0.36 g, 4.0 mmol), Et 3 N (1.4 mL, 9.9 mmol) in DMF (5 mL) was added Pd(Ph 3 P)4 (0.38 g, 0.33 mmol). The reaction mixture was stirred at 90°C for 1 h. Solvent was removed in vacuo. The crude material was purified by column chromatography (0 to 5% MeOH/CH 2 Cl 2 ) to provide 0.90 g of the title compound (93%). MS:m/z: 265 [M+H] + .
  • Step 3 4-chloro-6-[(l , 1 -dimethylethyl)sulfonyl]-7-(methyloxy)quinazoline:
  • Stepl. 3-amino-2-methyl-2-butenenitrile To a suspension of NaH (11.7 g, 292 mmol) in toluene (100 mL) at 30°C was added a solution of (2Z)-3-amino-2-butenenitrile (20 g, 244 mmol) in toluene (400 mL) and the reaction mixture was stirred for 10 min. lodomethane (15.23 mL, 244 mmol) was added and the reaction was cooled with cold water to maintain a temperature of 40 °C. The reaction was then cooled to 30°C and stirred overnight. An orange solid formed and was collected via filtration washing with toluene.
  • Step 2 3,4-dimethyl-lH-pyrazol-5-amine: To a solution of 3-amino-2-methyl-2- butenenitrile (1.0 g, 10.4 mmol) in ethanol (10.4 mL) was added hydrazine (0.60 mL, 10.4 mmol). The resulting mixture was heated to 75°C for 16 h open to atmosphere. The reaction was concentrated onto silica gel and purified via flash chromatography eluting with 0-10% MeOH in CH 2 C1 2 to give the title compound as a yellow oil (710 mg, 61%).
  • Step 1 (4,5-dimethyl-lH-pyrazol-3-yl)formamide.
  • a mixture of 4, 5 -dimethyl- 1H- pyrazol-3 -amine (1.92 g, 17.3 mmol) in formic acid (10 mL) was stirred under nitrogen at reflux for 2 h.
  • the reaction mixture was cooled to rt and concentrated to yield the title compound as a solid.
  • Step 2 N,4,5-trimethyl-lH-pyrazol-3-amine.
  • a mixture of (4,5-dimethyl-lH- pyrazol-3-yl)formamide (2.47 g, 17.7 mmol) and BH 3 » THF (53.1 mL of a 1.0 M solution in THF, 53.1 mmol) was stirred under nitrogen at rt for 3 h. The mixture was then cooled to 0°C and quenched with MeOH (dropwise addition). The crude product was purified via column chromatography using 0-7% MeOH:CH 2 Cl 2 gradient, 80 g column to yield 0.70 g of the title compound as a colorless viscous oil.
  • this reaction can be run in solvents other than 1 ,4-dioxane, including DMF, and at temperatures other than 60°C as appropriate for each substrate.
  • N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)thio]-4-quinazolinamine (150 mg, 0.327 mmol) was dissolved in MeOH (10 mL) in a 20 mL scintillation vial. To this deep red solution was added oxone (300 mg, 0.488 mmol) and the reaction was stirred at rt. After 1 hr the reaction was treated with 5 mL of (5: 1 Na 2 S 2 0 3 /NaHC0 3 ) for 5 min then poured into 50mL sat. aq. bicarbonate solution.
  • Step 1 3- ⁇ [4-(l,3-benzothiazol-5-ylamino)-6-quinazolinyl]thio ⁇ -3-methyl-l- butanol: To a solution of N-l,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine (202 mg, 0.500 mmol), 3-mercapto-3-methyl-l-butanol (60 mg, 0.50 mmol), potassium tert-butoxide (168 mg, 1.50 mmol) and (oxydi-2,l-phenylene)bis(diphenyl phosphine) (27 mg, 0.05 mmol) in dioxane (4 mL) was added Pd 2 dba 3 (46 mg, 0.05 mmol) and the mixture was sparged with N 2 for 10 min.
  • Cesium carbonate may also be used as the base in these coupling reactions.
  • An equivalent of triethamine may also be added when the starting quinazoline is an HCl salt.
  • EtOH and water (1 : 1) may also be used as the solvent mixture.
  • the following example was prepared in a similar manner:
  • Methyl 2-amino-5-iodo-4-methoxybenzoate Methyl 2-amino-4- (methyloxy) benzoate (3.78 g, 20.86 mmol) was dissolved in 25 mL of water, 15 mL of ethanol and 2.2 mL of concentrated HCl. A solution of ICl (1.1 mL, 21.9 mmol) in 3.8 mL concentrated HCl and 14 mL of water at 5 °C was added to the aniline solution. The reaction was stirred overnight and was then filtered to obtain 6.9 g of a light brown solid. MS: m/z: 308 [M+H] +
  • Step 4 4-chloro-6-iodo-7-(methyloxy)quinazoline: 6-Iodo-7-(methyloxy)-4(lH)- quinazolinone (2.0 g, 6.6 mmol), POCl 3 (3.1 mL, 33.1 mmol) and DIPEA (6.9 mL, 40 mmol) were combined in DCE (50 mL) a round bottom flask. The reaction mixture was heated at 80°C for 5 h, followed by heating at 70°C for 10 h. The reaction mixture was allowed to cool to rt. A yellow solid was precipitated out. The solid was filtered. The solution was concentrated and neutralized with satd. NaHC0 3 , extracted with CH 2 CI 2 and dried over Na 2 S0 4 . The mixture was filtered, and the solvent was removed in vacuo.
  • N-l,3-benzothiazol-5-yl-6-iodo-7-(methyloxy)-4-quinazolinamine To a solution of 4-chloro-6-iodo-7-(methyloxy)quinazoline (2.0 g, 5.4 mmol) in isopropanol (30 mL) was added l,3-benzothiazol-5-amine (1.2 g, 8.1 mmol). The suspension was heated in oil bath at 90°C (preheated). The reaction mixture stirred at this temperature for 30 min. A yellow solid precipitated out as the reaction mixture was allowed to cool to rt. The solid was filtered to provide 2.1 g of the title compound (77%, 93% pure). MS: m/z: All
  • N-(6-(tert-butylthio)-7-methoxyquinazolin-4-yl)benzo [d]thiazol-5 -amine To a solution of N-l,3-benzothiazol-5-yl-6-iodo-7-(methyloxy)-4-quinazolinamine (2.1 g, 4.5 mmol), 2-methyl-2-propanethiol (483 mg, 5.35 mmol), Et 3 N (1.9 mL, 13.4 mmol) in DMF (5 mL) was added Pd(Ph 3 P) 4 (516 mg, 0.45 mmol). The reaction mixture was stirred at 90°C for 1 h. Most of DMF was removed in vacuo. The crude material was triturated with MeOH. The red solid was filtered and washed with Et 2 0 to provide 1.7 g of the title compound as an off white solid (96%). MS: m/z: 397 [M+H] + .
  • Step 1 4-(benzo[ ⁇ i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl trifluoromethanesulfonate: To an ice cooled solution of 4-(benzo[d]thiazol-5-ylamino)-6- (tert-butylsulfonyl)quinazolin-7-ol (346 mg, 0.83 mmol) in pyridine (6 mL) was slowly added triflic anhydride (421 ⁇ , 2.50 mmol). The reaction was warmed to rt over 5 min. The reaction mixture was triturated from CH 2 CI 2 .
  • Step 2 N-(6-(tert-butylsulfonyl)-7-vinylquinazolin-4-yl)benzo [ ]thiazol-5 -amine : To a solution of 4-(benzo[ ⁇ i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl trifluoromethanesulfonate (60.0 mg, 0.091 mmol) and vinyltri-n-butyltin (37.1 ⁇ , 0.126 mmol) in DMF (1.01 mL) was added PdCl 2 (dppf)-CH 2 Ci 2 adduct (18 mg, 0.02 mmol).
  • reaction mixture was filtered through glass filter paper and concentrated in vacuo.
  • the residue was purified via reverse phase chromatography (6% to 75% 0.1% TFA in MeCN in 0.1% TFA in water; 5um 30x150 mm Waters Sunfire column, 15 min gradient).
  • the pure fraction was partitioned between EtOAc and satd. NaHCCh, the organic layer was washed with brine, then dried over MgS0 4 and concentrated in vacuo to obtain N-(6-(tert- butylsulfonyl)-7-ethylquinazolin-4-yl)benzo [ ]thiazol-5 -amine (7.5 mg, 19% yield).
  • Step 1 2-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)thio)ethanol: To a flask was added N-(6-iodo-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5 -amine (1 g, 2.30 mmol), Pd 2 dba 3 (0.21 g, 0.23 mmol), and Xantphos (0.13 g, 0.23 mmol) which was then evacuated and backfilled with nitrogen three times before DMF (15 ml), TEA (0.96 ml, 6.91 mmol), and mercaptoethanol (0.17 ml, 2.42 mmol) were added.
  • 6-(tert-Butylsulfonyl)-4-(ethylthio)quinazolin-7-ol 144 mg, 0.44 mmol
  • 4-chloro-2- fluoroaniline 0.49 mL, 4.4 mmol
  • MeOH MeOH
  • MP carbonate resin 400 mg, 3 eq. @ 3.28 mmol/gram loading
  • Step 1 Methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin- 7-yl)oxy)acetate: A suspension of 4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-ol (350 mg, 0.84 mmol) and potassium carbonate (350 mg, 2.5 mmol) in DMF (4.4 mL) was stirred 2 minutes before adding methyl 2-bromoacetate (108 ⁇ , 1.14 mmol). The reaction was heated at 25°C for 6 h.
  • Tablets are prepared using conventional methods and are formulated as follows:
  • Lactose lOOmg Sodium starch glycollate 30mg
  • Capsules are prepared using conventional methods and are formulated as follows: Ingredient Amount per tablet
  • a fluorescent polarization based binding assay was developed to quantitate interaction of novel test compounds at the ATP binding pocket of RIPK2, by competition with a fluorescently labeled ATP competitive ligand.
  • Full length FLAG His tagged RIPK2 was purified from a Baculovirus expression system and was used at a final assay concentration of twice the KDapparent.
  • a fluorescent labeled ligand (5-( ⁇ [2-( ⁇ [3-( ⁇ 4-[(5- hydroxy-2-methylphenyl)amino]-2-pyrimidinyl ⁇ amino)phenyl]carbonyl ⁇ amino)ethyl] amino ⁇ carbonyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, prepared as described in WO2011/120025) was used at a final assay concentration of 5nM. Both the enzyme and ligand were prepared in solutions in 50mM HEPES pH7.5, 150mM NaCl, lOmM MgCl 2 , ImM DTT, and lmM CHAPS.
  • Test compounds were prepared in 100% DMSO and lOOnL was dispensed to individual wells of a multiwell plate. Next, 5ul RIPK2 was added to the test compounds at twice the final assay concentration, and incubated at rt for 10 min. Following the incubation, 5ul of the fluorescent labeled ligand solution, was added to each reaction, at twice the final assay concentration, and incubated at rt for at least 10 min. Finally, samples were read on an instrument capable of measuring fluorescent polarization. Test compound inhibition was expressed as percent (%) inhibition of internal assay controls. For concentration/dose response experiments, normalized data were fit and pICsoS determined using conventional techniques. The pICsoS are averaged to determine a mean value, for a minimum of 2 experiments.
  • the compounds of Examples 1-80 exhibited a pIC 5 o between approximately 5.0 and 9.0.
  • the compounds of Examples 4 and 16 inhibited RIP2 kinase in the above method with a mean pIC 5 o of approximately 7.5 and 8.5, respectively.
  • the compounds of Examples 4, 6, 16, 21 , and 23 inhibited RIP2 kinase in the above method with a mean pICso in the range of
  • RIPK2 receptor-interacting serine -threonine kinase 2
  • cDNA was purchased from Invitrogen (Carlsbad, California, USA, Clone ID:IOH6368, RIPK2- pENTR 221).
  • Gateway® LR cloning was used to site-specifically recombine RIPK2 downstream to an N-terminal FLAG-6His contained within the destination vector pDEST8- FLAG-His6 according to the protocol described by Invitrogen.
  • Spodoptera frugiperda(Sf9) insect cells was performed using Cellfectin® (Invitrogen), according to the manufacturer's protocol.
  • the lysate was decanted from the insoluble pellet and loaded at a linear flow rate of 16 cm/h onto a 55 mL FLAG-M2 affinity column (2.6 x 10.4 cm) that had been pre- equilibrated with 10 column volumes buffer A (50mM Tris (pH 8.0), 150mM NaCl,
  • the purification process yielded 11.3 mg of total protein, with the RIPK2 present at 40% purity by gel densitometry scanning, and identity confirmed by peptide mass fingerprinting.
  • the main contaminating proteins in the preparation were identified as lower molecular weight degraded species of RIPK2.
  • lOOg cells (10 liter scale fermentation) were frozen, thawed, and re-suspended in 1L lysis buffer (50mM Tris HCL pH7.5, 250 mM NaCl, O. lmM TCEP, 3ml Protease inhibitor cocktail) and lysed by high pressure homogenization at 10,000 psi once (Avestin). The suspension was then clarified by centrifugation at 35,000g for 45 minutes at 4°C. The supernatant was collected by centrifugation and incubated with 5 ml anti-FLAG-M2 resin which was pre-equilibrated with buffer A (50mM Tris HCL pH7.5, 250 mM NaCl, O. lmM TCEP).
  • buffer A 50mM Tris HCL pH7.5, 250 mM NaCl, O. lmM TCEP
  • the resin was packed into two 25ml disposable columns. Each column was washed with 25ml buffer A and eluted with 10ml (buffer A + 200ug/ml Flag peptide). The elution pool was concentrated to 1ml and applied to a superdex 200 (16/60) sizing column.
  • the efficacy of RIP2 inhibitors may also be evaluated in vivo in rodents.
  • Intraperitoneal (i.p.) or intravenous (z ' .v.) administration of L18-MDP in mice has been shown to induce an inflammatory response through activation of the NOD2 signaling pathway (Rosenweig, H. L., et al. 2008. Journal of Leukocyte Biology 84:529-536).
  • the level of the inflammatory response in the L18-MDP treated mice/rats is monitored using conventional techniques by measuring increases in cytokine levels (IL8, TNFa, IL6 and IL- ⁇ ) in serum and/or peritoneal lavage fluid and by measuring neutrophil influx into the peritoneal space (when L18-MDP is dosed i.p.).
  • Inhibition of the L18-MDP induced inflammatory response in treated rodents may be shown by orally pre-dosing with selected compounds of this invention, then measuring and comparing cytokine levels (IL8, TNFa, IL6 and IL-1 ⁇ ) in serum and/or peritoneal lavage fluid and neutrophil influx into the peritoneal space (when L18-MDP is dosed i.p.) using conventional techniques.
  • cytokine levels IL8, TNFa, IL6 and IL-1 ⁇
  • rats were orally pre-dosed with a compound of Example 4, 6, 16, or 21, at a dose of 2 mg/kg or 10 mg/kg (8 rats) and with prednisolone (8 rats, used as a positive control), followed by dosing with L18-MDP (50 ⁇ g/rat) 0.25 h/min after pre- dosing.
  • Combined cytokine levels IL8, TNFa, IL6 and IL- ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are compounds having the formula (Formula (I)): wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.

Description

AMINO QUINAZOLINES AS KINASE INHIBITORS
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to quinazolyl amines that inhibit RIP2 kinase and methods of making and using the same. Specifically, the present invention relates to substituted quinazolyl amines as RIP2 kinase inhibitors.
Background of the Invention
Receptor interacting protein-2 (RIP2) kinase, which is also referred to as CARD3,
RICK, CARDIAK, or RIPK2, is a TKL family serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM) region ((1998) J. Biol. Chem. 273, 12296-12300; (1998) Current Biology 8, 885-889; and (1998) J. Biol. Chem. 273, 16968-16975). The CARD domain of RIP2 kinase mediates interaction with other CARD -containing proteins, such as NODI and NOD2 ((2000) J. Biol. Chem. 275, 27823-27831 and (2001) EMBO reports 2, 736-742). NODI and NOD2 are cytoplasmic receptors which play a key role in innate immune surveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated by specific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) and muramyl dipeptide (MDP), respectively ((2007) J Immunol 178, 2380-2386).
Following activation, RIP2 kinase associates with NODI or NOD2 and appears to function principally as a molecular scaffold to bring together other kinases (TAK1, ΙΚΚα/β/γ) involved in NF-κΒ and mitogen-activated protein kinase activation ((2006) Nature Reviews Immunology 6, 9-20). RIP2 kinase undergoes a K63-linked
polyubiquitination on lysine-209 which facilitates TAK1 recruitment ((2008) EMBO Journal 27, 373-383). This post-translational modification is required for signaling as mutation of this residue prevents NOD 1/2 mediated NF-kB activation. RIP2 kinase also undergoes autophosphorylation on serine- 176, and possibly other residues ((2006) Cellular Signalling 18, 2223-2229). Studies using kinase dead mutants (K47A) and non-selective small molecule inhibitors have demonstrated that RIP2 kinase activity is important for regulating the stability of RIP2 kinase expression and signaling ((2007) Biochem J 404, 179-190 and (2009) J. Biol. Chem. 284, 19183-19188).
Dysregulation of RIP2-dependent signaling has been linked to autoinflammatory diseases. Gain-of- function mutations in the NACHT-domain of NOD2 cause Blau
Syndrome, early-onset sarcoidosis, a pediatric granulomateous disease characterized by uveitis, dermatitis, and arthritis ((2001) Nature Genetics 29, 19-20; (2005) Journal of Rheumatology 32, 373-375; (2005) Current Rheumatology Reports 7, 427-433; (2005) Blood 105, 1195-1197; (2005) European Journal of Human Genetics 13, 742-747; (2006) American Journal of Ophthalmology 142, 1089-1092; (2006) Arthritis & Rheumatism 54, 3337-3344; (2009) Arthritis & Rheumatism 60, 1797-1803; and (2010) Rheumatology 49, 194-196). Mutations in the LRR-domain of NOD2 have been strongly linked to susceptibility to Crohn's Disease ((2002) Am. J. Hum. Genet. 70, 845-857; (2004) European Journal of Human Genetics 12, 206-212; (2008) Mucosal Immunology (2008) I (Suppl 1), S5-S9. 1, S5-S9; (2008) Inflammatory Bowel Diseases 14, 295-302; (2008) Experimental Dermatology 17 ', 1057-1058; (2008) British Medical Bulletin 87 17-30; (2009) Inflammatory Bowel Diseases 15, 1145 - 1154 and (2009) Microbes and Infection 11, 912-918). Mutations in NODI have been associated with asthma ((2005) Hum. Mol. Genet. 14, 935-941) and early-onset and extra-intestinal inflammatory bowel disease ((2005) Hum. Mol. Genet. 14, 1245-1250). Genetic and functional studies have also suggested a role for RIP2-dependent signaling in a variety of other granulomateous disorders, such as sarcoidosis ((2009) Journal of Clinical Immunology 29, 78-89 and (2006) Sarcoidosis Vasculitis and Diffuse Lung Diseases 23, 23-29) and Wegner's Granulomatosis ((2009) Diagnostic Pathology 4, 23).
A potent, selective, small molecule inhibitor of RIP2 kinase activity would block RIP2-dependent pro-inflammatory signaling and thereby provide a therapeutic benefit in autoinflammatory diseases characterized by increased and/or dysregulated RIP2 kinase activity.
SUMMARY OF THE INVENTION
The invention is directed to quinazolyl amine compounds according to Formula (I):
Figure imgf000005_0001
wherein:
R1 is H, -S02(Ci-C4)alkyl, -CO(Ci-C4)alkyl, or (Ci-C4)alkyl;
R2 is - SRa, -SORa, -S02Ra, -S02NH2, or -S02NRbRc,
wherein Ra is (Ci-C6)alkyl, halo(Ci-C6)alkyl, (C3-C7)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:
said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of cyano, hydroxyl, (Ci-C6)alkoxy,
(Ci-C6)alkoxy(C2-C6)alkoxy, -C02H, -C02(C C4)alkyl, -S02(Ci-C4)alkyl,
(C3-C7)cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and (phenyl)(Ci-C4 alkyl)amino-, wherein said
(C3-C7)cycloalkyl, phenyl, (phenyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said (C3-C7)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino,
((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl,
phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy;
Rb is (Ci-C6)alkyl or 4-7 membered heterocycloalkyl, wherein:
said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C6)alkoxy,
(Ci-C6)alkoxy(C2-C6)alkoxy, -C02H, -C02(Ci-C4)alkyl, (Ci-C4 alkyl)amino-,
(Ci-C4 alkyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein said 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, (Ci-C4)alkyl, hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (Ci-C4)alkyl, (Ci-C4)alkoxycarbonyl-, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
Rc is H, (Ci-C4)alkoxy or (Ci-C6)alkyl;
or Rb and Rc taken together with the nitrogen atom to which they are attached form a 3-7 membered heterocycloalkyl group, optionally containing one or two additional ring heteroatoms each independently selected from nitrogen and oxygen, wherein said 3-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of (Ci-C4)alkyl, hydroxy, -C02H and -CO(Ci-C4)alkyl;
R3 is H, halogen, hydroxy, (Ci-C4)alkyl-,(C2-C4)alkenyl-, halo(Ci-C4)alkyl-, hydroxy(C2-C4)alkenyl-, (Ci-C4)alkoxy-, (C2-C4)alkenyloxy-, halo(Ci-C4)alkoxy-,
(Ci-C4)alkoxy(Ci-C6)alkyl-, halo(Ci-C4)alkoxy(Ci-C6)alkyl-,
(C i -C4)alkoxy(C2-C6)alkoxy-, halo(C i -C4)alkoxy(C2-C6)alkoxy-, hydroxy(C i -C6)alkyl-, hydroxy(C2-C6)alkoxy-, hydroxy(C3-C4)alkenyl-, cyano(C i-C4)alkyl-,
cyano(C2-C6)alkoxy-, (Ci-C4)alkyl-thio-(C2-C4)alkoxy, (Ci-C4)alkyl- sulfonyl-(C2-C4)alkoxy-, carboxy-(Ci-Ce)alkoxy-, carboxy-(C2-C4)alkenyl-oxy-,
(Ci-C4)alkoxycarbonyl(Ci-C6)alkoxy-, (Ci-C4)alkoxycarbonyl(C2-C4)alkenyl-oxy-, carboxy(C2-C4)alkenyl-, (Ci-C4)alkoxycarbonyl(C2-C4)alkenyl-,
aminocarbonyl(Ci-C6)alkoxy-, aminocarbonyl(C2-C4)alkenyl-oxy-,
(C3-C6)cycloalkyl(Ci-C4)alkoxy-, (C3-Ce)cycloalkoxy-, 4-6 membered- heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered-heterocycloalkyl-oxy- (that is, 4-6 membered-heterocycloalkoxy-),
wherein the halo(Ci-C4)alkyl-, halo(Ci-C4)alkoxy-,
halo(Ci-C4)alkoxy(Ci-Ce)alkyl-, or halo(Ci-C4)alkoxy(C2-C6)alkoxy- groups contain 2 or 3 halo atoms,
wherein the (C3-C6)cycloalkyl moiety of the (C3-C6)cycloalkyl(Ci-C4)alkoxy- or (C3-Ce)cycloalkoxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (Ci-Ce)alkoxy and (Ci-C4)alkoxy(C2-C6)alkoxy, and wherein the 4-6 membered heterocycloalkyl moiety of the 4-6 membered heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered-heterocycloalkyl-oxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (Ci-C6)alkoxy and (Ci-C4)alkoxy(C2-C6)alkoxy;
Z is phenyl or aryl(Ci-C4)alkyl-, wherein in the phenyl group or the aryl moiety of the aryl(Ci-C4)alkyl- group is substituted by R4, R5, R6 and R7, wherein:
R4 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
each of R5, R6 and R7is independently selected from the group consisting of H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and (Ci-C4)alkoxy; or
Z is phenyl or pyridyl, substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5 -membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5 -membered ring is substituted by R11; wherein one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, -C4)alkyl or (Ci-C4)alkoxy; or
Figure imgf000007_0001
Z is pyrazolyl, having the formula: wherein:
R is H, methyl or hydroxymethyl;
R13 is methyl, trifluoromethyl or hydroxymethyl;
R14 is H, OH, or (Ci-C3)alkyl; or R and R , taken together with the atoms to which they are attached, form a 6-membered ring substituted by R15 and R16, wherein the 6-membered ring optionally contains 1 nitrogen atom;
wherein R15 and R16 are each independently selected from the group consisting of H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy,
phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy;
or a salt, particularly a pharmaceutically acceptable salt, thereof.
In selected embodiments of this invention, the compounds of Formula (I) do not include:
ethyl 5-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl] thio}pentanoate,
ethyl 4-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio} butanoate,
ethyl 7-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio} heptanoate,
N-(3 -chloro-4-fluorophenyl)-7-methoxy-6- [(trifluoromethyl)sulfonyl] -4- quinazolinamine,
ethyl 7-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl] sulfonyl} heptanoate,
N-[(3,4-difluorophenyl)methyl]-6-[(methyl)sulfonyl]-4-quinazolinamine,
3 -methoxy-5 - [[6- [(methylthio)] -4-quinazolinyl]amino]-phenol,
3 -methoxy-5 - [[6- [(methylsulfinyl)]-4-quinazolinyl] amino]-phenol,
N- [(3 ,4-dichlorophenyl)methyl] -6-(methylthio)-4-quinazolinamine,
N-[(3-fluoro-4-methoxyphenyl)methyl]-6-(methylthio)-4-quinazolinamine,
6-(methylthio)-N-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,
6-(methylsulfonyl)-N-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,
6-(methylsulfinyl)-N-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,
6-(methylthio)-N-(4-(phenoxyphenyl)-4-quinazolinamine,
N-(3-(methylphenyl)-6-(methylthio)-4-quinazolinamine, or a salt thereof.
The compounds according to Formula (I), or salts, particularly pharmaceutically acceptable salts, thereof, are inhibitors of RIP2 kinase.
Accordingly, the present invention is also directed to a method of inhibiting RIP2 kinase which method comprises contacting a cell with a compound according to
Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof.
The invention is further directed to a method of treating a RIP2 kinase-mediated disease or disorder which comprises administering a therapeutically effective amount of a compound according to Formula (I), or a salt, particularly a pharmaceutically acceptable salt thereof, to a patient (a human or other mammal, particularly, a human) in need thereof. Examples of RIP2 kinase-mediated diseases or disorders include uveitis, Crohn's disease, ulcerative colitis, early-onset and extra-intestinal inflammatory bowel disease and granulomateous disorders, such as sarcoidosis, Blau syndrome, early-onset sarcoidosis and Wegner's Granulomatosis.
The present invention is further directed to a pharmaceutical composition comprising a compound according to Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable excipient. Particularly, this invention is directed to a pharmaceutical composition for the treatment of a RIP2 kinase-mediated disease or disorder, where the composition comprises a compound according to Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable excipient.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 4 or prednisolone, followed by dosing with LI 8-MDP.
Figure 2 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 6 or prednisolone, followed by dosing with LI 8-MDP.
Figure 3 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 16 or prednisolone, followed by dosing with LI 8-MDP. Figure 4 shows the combined cytokine response in rat whole blood samples obtained after pre-dosing rats with the compound of Example 21 or prednisolone, followed by dosing with L18-MDP.
DETAILED DESCRIPTION OF THE INVENTION
The alternative definitions for the various groups and substituent groups of Formula (I) provided throughout the specification are intended to particularly describe each compound species disclosed herein, individually, as well as groups of one or more compound species. The scope of this invention includes any combination of these group and substituent group definitions. The compounds of the invention are only those which are contemplated to be "chemically stable" as will be appreciated by those skilled in the art.
It will also be appreciated by those skilled in the art that when Z is pyrazolyl, the compounds of this invention may exist as pyrazole isomers represented by Formula (I- A) and Formula (I-B):
Figure imgf000010_0001
When R is H, the compounds of this invention may exist as tautomers. However, when R14 is (Ci-C3)alkyl, the compounds of this invention, may exist as either one of the regioisomers represented by Formula (I- A) or Formula (I-B), or as a mixture thereof.
In addition, it will be appreciated by those skilled in the art that the compounds of this invention, depending on further substitution, may exist in other tautomeric forms. All tautomeric forms of the compounds described herein are intended to be encompassed within the scope of the present invention. It is to be understood that any reference to a named compound of this invention is intended to encompass all tautomers of the named compound and any mixtures of tautomers of the named compound. As used herein, the term "alkyl" represents a saturated, straight or branched hydrocarbon moiety. Exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl and pentyl. The term "C1-C4 alkyl" refers to an alkyl group or moiety containing from 1 to 4 carbon atoms.
When the term "alkyl" is used in combination with other substituent groups, such as "haloalkyl" or "hydroxyalkyl" or "arylalkyl", the term "alkyl" is intended to encompass a divalent straight or branched-chain hydrocarbon radical. For example, "arylalkyl" is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH2-phenyl); "halo(Ci-C4)alkyl" or "(Ci-C4)haloalkyl" is intended to mean a radical having one or more halogen atoms, which may be the same or different, at one or more carbon atoms of an alkyl moiety containing from 1 to 4 carbon atoms, which a is straight or branched-chain carbon radical, and is represented by a trifluoromethyl group (-CF3).
As used herein, the term "cycloalkyl" refers to a non-aromatic, saturated, cyclic hydrocarbon ring. The term "(C3-Cv)cycloalkyl" refers to a non-aromatic cyclic hydrocarbon ring having from three to eight ring carbon atoms. Exemplary
"(C3-C8)cycloalkyl" groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
"Alkoxy" refers to a group containing an alkyl radical attached through an oxygen linking atom. The term "(Ci-C4)alkoxy" refers to a straight- or branched-chain
hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom. Exemplary "(Ci-C4)alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, isobutoxy, and t-butoxy.
"Aryl" represents a group or moiety comprising an aromatic, monocyclic or bicyclic hydrocarbon radical containing from 6 to 10 carbon ring atoms, which may be fused one or more cycloalkyl rings. Generally, in the compounds of this invention, aryl is phenyl.
A heterocyclic group or moiety is a cyclic group or moiety having as ring members atoms of at least two different elements (carbon and one or more of nitrogen, oxygen and/or sulfur), which cyclic group or moiety may be saturated or partially unsaturated (non-aromatic; e.g., a heterocycloalkyl group or moiety) or fully unsaturated (aromatic; e.g., a heteroaryl group or moiety).
"Heterocycloalkyl" represents a group or moiety comprising a non-aromatic, monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, unless otherwise specified, which includes 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur. Illustrative examples of heterocycloalkyls include, but are not limited to, azetidinyl, oxetanyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-l,4-thiazinyl, tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1 ,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3-dithianyl, azabicylo[3.2.1 ]octyl, azabicylo[3.3.1 ]nonyl, azabicylo[4.3.0]nonyl,
oxabicylo[2.2.1]heptyl and 1,5,9-triazacyclododecyl.
In some of the compounds of this invention, heterocycloalkyl groups include 4-membered heterocycloalkyl groups containing one heteroatom, such as oxetanyl, thietanyl and azetidinyl.
In other compounds of this invention, heterocycloalkyl groups include 5-membered heterocycloalkyl groups containing one heteroatom selected from nitrogen, oxygen and sulfur and optionally containing one or two an additional nitrogen atoms, or optionally containing one additional oxygen or sulfur atom, such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuryl (or tetrahydrofuranyl), tetrahydrothienyl, dihydrofuryl, oxazolinyl, thiazolinyl, imidazolinyl, pyrazolinyl, 1,3-dioxolanyl, and l,3-oxathiolan-2-on-yl.
In other compounds of this invention, heterocycloalkyl groups are 6-membered heterocycloalkyl groups containing one heteroatom selected from nitrogen, oxygen and sulfur and optionally containing one or two an additional nitrogen atoms or one additional oxygen or sulfur atom, such as piperidyl (or piperidinyl), piperazinyl, morpholinyl, thiomorpholinyl, l,ldioxoido-thiomorpholin-4-yl, tetrahydropyranyl, dihydropyranyl, tetrahydro-2H-l,4-thiazinyl, 1 ,4-dioxanyl, 1,3-oxathianyl, and 1,3-dithianyl.
"Heteroaryl" refers to a group or moiety comprising an aromatic monocyclic or bicyclic radical, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur. This term also encompasses bicyclic heterocyclic-aryl compounds containing an aryl ring moiety fused to a heterocycloalkyl ring moiety, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur. Illustrative examples of heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (or furanyl), isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridyl (or pyridinyl), pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[£]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl, benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl, and isothiazolyl.
In some embodiments, the heteroaryl groups present in the compounds of this invention are 5-membered and/or 6-membered monocyclic heteroaryl groups. Selected
5- membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1, 2 or 3 additional nitrogen ring atoms. Selected 6-membered heteroaryl groups contain 1, 2, 3 or 4 nitrogen ring heteroatoms. Selected 5- or
6- membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (furanyl), isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl.
In other embodiments, the heteroaryl groups present in the compounds of this invention are 9-membered or 10-membered monocyclic heteroaryl groups. Selected 9-10 membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1, 2, 3 or 4 additional nitrogen ring atoms.
In some of the compounds of this invention, heteroaryl groups include a
9- membered heteroaryl group, which includes benzothienyl, benzofuranyl, indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, indolizinyl, isobenzofuryl,
2,3-dihydrobenzofuryl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benzoxadiazolyl, benzthiadiazolyl, benzotriazolyl, l,3-benzoxathiol-2-on-yl (2-oxo-l,3-benzoxathiolyl), purinyl and imidazopyridinyl.
In some of the compounds of this invention, heteroaryl groups include a
10- membered heteroaryl group, which includes chromenyl, chromanyl, quinolyl, isoquinolyl, phthalazinyl, naphthridinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, tetrahydroquinolinyl, cinnolinyl, and pteridinyl.
It is to be understood that the terms heterocyclic, heteroaryl, and heterocycloalkyl are intended to encompass stable heterocyclic groups where a ring nitrogen heteroatom is optionally oxidized (e.g., heterocyclic groups containing an N-oxide, such as pyridine-N-oxide) or where a ring sulfur heteroatom is optionally oxidized (e.g., heterocyclic groups containing sulfones or sulfoxide moieties, such as
tetrahydrothienyl-1 -oxide (a tetrahydrothienyl sulfoxide) or tetrahydrothienyl- 1,1 -dioxide (a tetrahydrothienyl sulfone)).
"Oxo" represents a double-bonded oxygen moiety; for example, if attached directly to a carbon atom forms a carbonyl moiety (C = O). The terms "halogen" and "halo" represent chloro, fluoro, bromo or iodo substituents. "Hydroxy" or "hydroxyl" is intended to mean the radical -OH.
As used herein, the terms "compound(s) of the invention" or "compound(s) of this invention" mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
As used herein, the term "optionally substituted" indicates that a group (such as an alkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, or heteroaryl group) or ring or moiety (such as a carbocyclic or heterocyclic ring or moiety) may be unsubstituted, or the group, ring or moiety may be substituted with one or more substituent(s) as defined. In the case where groups may be selected from a number of alternative groups, the selected groups may be the same or different.
The term "independently" means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.
In addition, it will be appreciated by those skilled in the art that the compounds of this invention, depending on further substitution, may exist in other tautomeric forms. All tautomeric forms of the compounds described herein are intended to be encompassed within the scope of the present invention. It is to be understood that any reference to a named compound of this invention is intended to encompass all tautomers of the named compound and any mixtures of tautomers of the named compound.
In one embodiment of the compounds of Formula (I) of this invention,
R1 is H, -S02(Ci-C4)alkyl, -CO(Ci-C4)alkyl, or (Ci-C4)alkyl; R2 is - SRa, -SORa, or -S02Ra, wherein Ra is (Ci-C6)alkyl, halo(Ci-C6)alkyl, (C3-Cy)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:
said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from cyano, hydroxyl, (Ci-C6)alkoxy, (Ci-C6)alkoxy(C2-C6)alkoxy, -C02H, -C02(Ci-C4)alkyl, -S02(Ci-C4)alkyl, (C3-Cy)cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and
(phenyl)(Ci-C4 alkyl)amino-, wherein said (C3-Cy)cycloalkyl, phenyl,
(phenyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-,
hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said (C3-C7)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF3, hydroxyl, amino,
((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl,
phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-,
hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy;
R3 is H, halogen, hydroxy, (Ci-C4)alkyl-,(C2-C4)alkenyl-, halo(Ci-C4)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C4)alkoxy-, (Ci-C4)alkoxy(Ci-Ce)alkyl-,
halo(Ci-C4)alkoxy(Ci-C6)alkyl-, (Ci-C4)alkoxy(C2-C6)alkoxy-,
halo(Ci-C4)alkoxy(C2-Ce)alkoxy-, hydroxy(Ci-Ce)alkyl-, hydroxy(C2-Ce)alkoxy-, cyano(Ci-C4)alkyl-, cyano(C2-C6)alkoxy-, carboxy-(Ci-C6)alkoxy-,
(C i -C4)alkoxycarbonyl(C i -C6)alkoxy-, (C3-C6)cycloalkyl(C i -C4)alkoxy-,
(C3-Ce)cycloalkoxy-, 4-6 membered-heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered- heterocycloalkoxy-,
wherein the halo(Ci-C4)alkyl-, halo(Ci-C4)alkoxy-,
halo(Ci-C4)alkoxy(Ci-Ce)alkyl-, or halo(Ci-C4)alkoxy(C2-Ce)alkoxy- groups contain 2 or 3 halo atoms; and wherein the (C3-C6)cycloalkyl moiety of the (C3-C6)cycloalkyl(Ci-C4)alkoxy- or (C3-C6)cycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (Ci-C6)alkoxy and (Ci-C4)alkoxy(C2-Ce)alkoxy;
wherein the 4-6 membered-heterocycloalkyl moiety of the 4-6 membered- heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered-heterocycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (Ci-C6)alkoxy and
(C i -C4)alkoxy(C2-Ce)alkoxy ;
Z is phenyl or aryl(Ci-C4)alkyl-, substituted by R4, R5, R6 and R7, wherein:
R4 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from halogen, -CF3, (Ci-C4)alkyl and
(Ci-C4)alkoxy; and
each of R5, R6 and R7is independently selected from H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and (Ci-C4)alkoxy; or
Z is phenyl or pyridyl substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered heterocyclic group containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered heterocyclic group is substituted by R11;
wherein one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or (Ci-C4)alkoxy; or
Figure imgf000016_0001
Z is pyrazolyl, having the formula:
R12 is H, methyl or hydroxymethyl; R is methyl, trifluoromethyl or hydroxymethyl;
R14 is H, OH, or (Ci-C3)alkyl; or
R12 and R13, taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R15 and R16, wherein the heterocyclic ring contains 1 nitrogen atom;
wherein R15 and R16 are each independently selected from H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy.
In selected embodiments, the compounds of Formula (I) do not include ethyl 5- {[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio}pentanoate; ethyl 4- {[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio}butanoate; ethyl 4- {[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6- quinazolinyl]thio}heptanoate; 7-(methoxy)-N-[l-(phenylmethyl)-lH-indazol-5-yl]-6- [(trifluoromethyl)sulfonyl]-4-quinazolinamine; or ethyl 4- {[4-[(3-chloro-4- fluorophenyl)amino]-7-(methyloxy)-6-quinazolinyl]sulfonyl}heptanoate.
In another embodiment of this invention, R1 is Η. In other embodiments, R1 is (Ci-C3)alkyl; specifically, -CH3 or -CH2CH3. Generally, in the compounds of this invention, R1 is H.
In one embodiment, R2 is -SRa or -S02Ra. In a further embodiment, R2 is -SORa. In a still further embodiment, R2 is -S02Ra.
In one embodiment of the compounds of this invention, Ra is an optionally substituted (Ci-C6)alkyl, (C3-C6)cycloalkyl, 4-6-membered heterocycloalkyl,
5-6-membered heteroaryl or phenyl group;
wherein said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C4)alkoxy,
-C02(Ci-C4)alkyl, -S02(Ci-C4)alkyl, and a (C3-C6)cycloalkyl, phenyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl, or 9-10-membered heteroaryl, where said (C3-C6)cycloalkyl, phenyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl, or 9-10-membered heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy; and
wherein said (C3-C6)cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, (Ci-C4)alkyl,
phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy.
Suitably, Ra is an unsubstituted (Ci-C6)alkyl or a (Ci-C6)alkyl substituted by one or two groups each independently selected from the group consisting of hydroxyl,
(Ci-C4)alkoxy, -C02(Ci-C4)alkyl, -S02(Ci-C4)alkyl, and a cyclic substituent which is a (C3-C6)cycloalkyl, phenyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl, or 9-10-membered heteroaryl, where the (C3-C6)cycloalkyl, phenyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl, or 9-10-membered heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy.
Suitably, Ra is an optionally substituted (C3-C6)cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl group, wherein the
(C3-C6)cycloalkyl, 4-6-membered heterocycloalkyl, 5-6-membered heteroaryl or phenyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-,
hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy.
When Ra is a heterocycloalkyl or heteroaryl group, it is to be understood that the heterocycloalkyl or heteroaryl group is bonded to the sulfur atom of the -SRa, -SORa or -S02Ra moiety by a ring carbon atom.
In a still further embodiment, Ra is an optionally substituted (Ci-C6)alkyl,
(C3-C6)cycloalkyl, or 4-6-membered heterocycloalkyl group, wherein
said (Ci-C6)alkyl is optionally substituted by a group selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, (Ci-C2)alkoxy(C2-C3)alkoxy-, -S02(Ci-C2)alkyl, and a group selected from the group consisting of (C3-C6)cycloalkyl (optionally substituted by (Ci-C4)alkyl or hydroxy(Ci-C4)alkyl), 4-6-membered heterocycloalkyl (optionally substituted by (Ci-C4)alkyl or halogen), 5-6-membered heteroaryl (optionally substituted by (Ci-C4)alkyl or hydroxy(Ci-C4)alkyl), phenyl, and 9-10-membered heteroaryl, and said (C3-Ce)cycloalkyl or 4-6-membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen,
(Ci-C4)alkyl, and hydroxy(Ci-C4)alkyl-,
wherein any of said 5-6 membered heterocycloalkyl groups contains 1 heteroatom selected from N, O and S. Particularly, in this embodiment, when Ra is an optionally substituted (Ci-C6)alkyl, said (Ci-C6)alkyl is optionally substituted by a group selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, and (Ci-C2)alkoxy(C2-C3)alkoxy-.
In a still further embodiment, Ra is an optionally substituted (Ci-C6)alkyl or 5-6-membered heterocycloalkyl group, wherein:
said (Ci-C6)alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, (Ci-C2)alkoxy(C2-C3)alkoxy-, amino,
(C1-C3 alkyl)amino-, (C1-C3 alkyl)(Ci-C2 alkyl)amino-, 5-6-membered heterocycloalkyl (optionally substituted by (Ci-C4)alkyl), and C3-C6cycloalkyl (optionally substituted by (Ci-C4)alkyl or hydroxy(Ci-C4)alkyl), and
said 5-6 membered heterocycloalkyl is optionally substituted by 1 or 2 groups each independently selected from the group consisting of halogen, (Ci-C4)alkyl, and
hydroxy(C 1 -C4)alkyl-;
wherein any of said 5-6 membered heterocycloalkyl contains 1 heteroatom selected from N, O and S.
In another embodiment, Ra is halo(Ci-C4)alkyl containing 1-9 halogen atoms. In specific embodiments, Ra is halo(Ci-C2)alkyl, specifically a halo(Ci-C2)alkyl containing 1-5 halogen atoms, and more specifically a halo(Ci-C2)alkyl containing 3 halogen atoms.
In another embodiment, Ra is (Ci-C6)alkyl, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, and
(Ci-C2)alkoxy(C2-C3)alkoxy-. In yet another embodiment, Ra is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C4)alkyl groups.
In a specific embodiment, Ra is an unsubstituted (Ci-Cs)alkyl. In a further embodiment of the compounds of this invention, Ra is an unsubstituted (Ci-C4)alkyl group. In another embodiment, Ra is a (Ci-C5)alkyl group substituted by a hydroxyl,
(Ci-C2)alkoxy, or (Ci-C2)alkoxy(C2-C3)alkoxy- group. In another specific embodiment, Ra is a (Ci-C5)alkyl substituted by one hydroxyl group. In yet another specific embodiment, Ra is a tetrahydropyranyl group.
In a specific embodiment, Ra is -CH3, -CH(CH3)2, or -C(CH3)3. In another specific embodiment, Ra is -CH2CH2OH or -C(CH3)2CH2CH2OH. In yet another specific embodiment, Ra is tetrahydro-2H-pyran-4-yl.
In one embodiment, Rb is (Ci-C6)alkyl or 4-7 membered heterocycloalkyl, wherein: said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C6)alkoxy,
(Ci-C6)alkoxy(C2-C6)alkoxy, -C02H, -C02(Ci-C4)alkyl, (Ci-C4 alkyl)amino-,
(Ci-C4 alkyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, and 4-7 membered
heterocycloalkyl, wherein said 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, (Ci-C4)alkyl, hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (Ci-C4)alkyl, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
Rc is H or (Ci-C4)alkyl;
or Rb and Rc taken together with the nitrogen atom to which they are attached form a 5-7 membered heterocycloalkyl group, optionally containing one additional ring heteroatom selected from nitrogen and oxygen, wherein said 5-7 membered
heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of (Ci-C4)alkyl, hydroxy, -C02H and -CO(Ci-C4)alkyl.
In another embodiment, Rb is (Ci-C6)alkyl and said (Ci-C6)alkyl is optionally substituted by lor 2 substituents each independently selected from the group consisting of hydroxyl, (Ci-C4)alkoxy, (Ci-C4)alkoxy(C2-C4)alkoxy-, (Ci-C4 alkyl)amino-,
(Ci-C4 alkyl)(Ci-C4 alkyl)amino-, -C02(Ci-C4)alkyl, and a 4-6-membered heterocycloalkyl or 5-6-membered heteroaryl, where said 4-6-membered heterocycloalkyl or 5-6-membered heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (Ci-C4)alkyl, hydroxy(Ci-C4)alkyl- and
(Ci-C4)alkoxy.
In a further embodiment, Rb is unsubstituted (Ci-C6)alkyl, particularly, Rb is unsubstituted (Ci-C4)alkyl. In another embodiment, Rb is a (Ci-C6)alkyl substituted by lor 2 substituents each independently selected from the group consisting of hydroxyl,
(Ci-C2)alkoxy, (Ci-C2)alkoxy(C2-C3)alkoxy-, (C1-C3 alkyl)amino-,
(C1-C3 alkyl)(Ci-C2 alkyl)amino-, -C02(Ci-C2)alkyl, and a 4-6-membered heterocycloalkyl optionally substituted by (Ci-C4)alkyl, or a 5-6-membered heteroaryl optionally substituted by (Ci-C4)alkyl.
Particularly, Rb is a (Ci-C4)alkyl substituted by hydroxyl, (Ci-C2)alkoxy,
(C1-C3 alkyl)amino-, (C1-C3 alkyl)(Ci-C2 alkyl)amino-, a 4-6-membered heterocycloalkyl, optionally substituted by (Ci-C4)alkyl, or a 5-6-membered heteroaryl, optionally substituted by (Ci-C4)alkyl.
In one embodiment, Rb is -CH3 or -CH(CH3)2. In another embodiment, Rb is
-CH2CH2OH, -CH2CH2OCH3, -CH2C(CH3)2OH, -CH2CH(CH3)OH, or -CH2CH2N(CH3)2. In a further embodiment, Rb is -oxetan-3-yl, tetrahydro-2H-pyran-4-yl, -CH2-tetrahydro- 2H-pyran-4-yl, or -CH2CH2-lH-tetrazol-5-yl.
In one embodiment of this invention, Rc is Η or (Ci-C4)alkyl. In some specific embodiments, Rc is -CH3. In other specific embodiments, Rc is H.
In a further embodiment, Rb and Rc taken together with the nitrogen atom to which they are attached form a 5-7 membered heterocycloalkyl group, optionally containing one additional ring heteroatom selected from nitrogen and oxygen, which 5-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of ((Ci-C4)alkyl, hydroxy, -CO2H and -CO(Ci-C4)alkyl.
In a still further embodiment, Rb and Rc taken together with the nitrogen atom to which they are attached form a 5-6-membered heterocycloalkyl, optionally containing 1 additional heteroatom selected from N and O, and optionally substituted by a hydroxyl, (Ci-C4)alkyl, carboxy or (Ci-C4)alkylcarbonyl- group.
In yet another embodiment, Rb and Rc taken together with the nitrogen atom to which they are attached form a morpholin-4-yl, 4-methylcarbonyl-piperazin-l-yl (that is, 4-acetyl-piperazin-l-yl), pyrrolidin-l-yl, 3-hydroxy-pyrrolidin-l-yl, or
2-(carboxy)- 1 -pyrrolidin- 1 -yl group .
In one embodiment of this invention, R3 is H.
In another embodiment of this invention, R3 is halogen, hydroxy, (Ci-C3)alkyl-,
(C2-C3)alkenyl-, halo(Ci-C2)alkyl-, hydroxy(C2-C3)alkenyl-, (Ci-C4)alkoxy-,
(C2-C3)alkenyl-oxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-, (Ci-C3)alkoxy(Ci-C4)alkyl-,
(Ci-C3)alkoxy(C2-C4)alkoxy-, (Ci-C3)alkyl-thio-(C2-C4)alkoxy-,
(Ci-C3)alkyl-sulfonyl-(C2-C4)alkoxy-, carboxy-(Ci-C4)alkoxy-,
carboxy-(C2-C4)alkenyl-oxy-, (Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-,
(Ci-C3)alkoxycarbonyl(C2-C4)alkenyl-oxy-, aminocarbonyl(Ci-C4)alkoxy-,
aminocarbonyl(C2-C4)alkenyl-oxy-, or hydroxy(C2-C4)alkoxy-.
In another embodiment of this invention, R3 is halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-, hydroxy(C2-C3)alkenyl-, (Ci-C4)alkoxy-,
(C2-C3)alkenyl-oxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-,
5-6-memebered-heterocycloalkyl-oxy-, (Ci-C3)alkoxy(Ci-C4)alkyl-,
(Ci-C3)alkoxy(C2-C3)alkoxy-, (Ci-C3)alkyl-thio-(C2-C3)alkoxy-,
(Ci-C3)alkyl-sulfonyl-(C2-C3)alkoxy-, carboxy-(Ci-C4)alkoxy-,
carboxy-(C2-C4)alkenyl-oxy-, (Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-,
(Ci-C3)alkoxycarbonyl(C2-C4)alkenyl-oxy-, aminocarbonyl(Ci-C3)alkoxy-,
aminocarbonyl(C2-C3)alkenyl-oxy-, or hydroxy(C2-C4)alkoxy-.
In yet another embodiment, R3 is H or R3 is halogen, hydroxy, (Ci-C4)alkyl-, (C2-C4)alkenyl-, halo(Ci-C4)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C4)alkoxy-,
(C3-C6)cycloalkyl(Ci-C4)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
(C i -C4)alkoxy(C i -C6)alkyl-, (C i-C4)alkoxy(C2-C6)alkoxy-, carboxy-(C i -C6)alkoxy-, (Ci-C4)alkoxycarbonyl(Ci-C6)alkoxy-, hydroxy(Ci-Ce)alkyl-, or hydroxy(C2-Ce)alkoxy-.
In a further embodiment, R3 is H, halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-, (Ci-C3)alkoxy(Ci-C4)alkyl-,
(Ci-C3)alkoxy(C2-C4)alkoxy-, carboxy-(Ci-C4)alkoxy-,
(Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-, or hydroxy(C2-C4)alkoxy-.
In a specific embodiment, R3 is chloro, -CH2CH3, -CH=CH2, -CH=CHCH2OH, -OCH=CH2, -OCH=CH-C02H, -OCH=CH-C02CH3, -OCH=CH-CONH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2, -OCH2CH3, -OCH2CF3, -OCH2CH2CH3, -0CH2CH2C1,
-OCH2CH2Br, -OCH2CH2SCH3, -OCH2CH2S02CH3, -OCH2CH2S02CH(CH3)2,
-OCH2CH2OH, -OCH2CH2CH2OH, -OCH2CH2OCH3, -OC(CH3)2CH2OH,
-OCH(CH3)CH2OH, -OCH(CH3)C02CH3, -OCH2CH(CH3)OH, -OC(CH3)2C02CH2CH3, -OCH2C02H, -OCH2CONH2, -OCH2-cyclohexyl, or -0-tetrahydro-2H-pyran-4-yl. In a more specific embodiment, R3 is H, chloro,-CH2CH3, -CH=CH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2, -OCH2CH3, -OCH2CF3, -0CH2CH2C1, -OCH2CH2OH,
-OCH2CH2CH2OH, -OCH2CH2OCH3, -OC(CH3)2CH2OH, -OCH(CH3)CH2OH,
-OC(CH3)2C02CH2CH3, cyclohexylmethyloxy-, or tetrahydro-2H-pyran-4-yloxy-.
In another embodiment, Z is phenyl substituted by R4, R5, R6 and R7 wherein:
R4 is Η, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl, or hydroxy(Ci-C4)alkyl-; and
each of R5, R6 and R7 is independently selected from the group consisting of Η, hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl, halo(Ci-C4)alkyl and
(Ci-C4)alkoxy.
Specifically, Z is phenyl, substituted by 1 , 2 or 3 (more specifically, 1 or 2) substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and (Ci-C4)alkoxy. In specific embodiments, Z is
2- methyl-5 -hydroxy-phenyl, 2-fluoro-4-chloro-phenyl, 3-methoxy-4-chloro-phenyl, or
3- hydroxy-4-chloro-phenyl. In selected embodiments, Z is 2-methyl-5-hydroxy-phenyl.
In a further embodiment of the compounds of Formula (I) of this invention, Z is phenyl or pyridyl substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent atoms (carbon atoms) and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by
R 11 wherein one of R10 or R11 is Η, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl,
(Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
the other of R10 or R11 is Η, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl,
(Ci-C4)alkyl or (Ci-C4)alkoxy;
Figure imgf000023_0001
pyrazolyl, having the formula: wherein: R is H, methyl or hydroxymethyl;
R13 is methyl, trifluoromethyl or hydroxymethyl;
R14 is H, OH, or (Ci-C3)alkyl;
or R12 and R13, taken together with the atoms to which they are attached, form a 6-membered ring substituted by R15 and R16, wherein the 6-membered ring contains 1 nitrogen atom;
wherein R15 and R16 are each independently selected from the group consisting of H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy,
phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (C C4)alkoxy.
It will be understood by one skilled in the art that the 5-membered ring formed from R8 and R9 and the atoms to which they are attached may be non-aromatic (partially unsaturated) or aromatic (fully unsaturated). It will be further understood by one skilled in the art that the 6-membered ring formed from R12 and R13 and the atoms to which they are attached may be non-aromatic (partially unsaturated) or aromatic (fully unsaturated).
In another embodiment of the compounds of this invention, Z is not phenyl or aryl(Ci-C4)alkyl-, wherein in the phenyl group or the aryl moiety of the aryl(Ci-C4)alkyl- group is substituted by R4, R5, R6 and R7, wherein R4 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl,
hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and each of R5, R6 and R7is independently selected from the group consisting of H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and (Ci-C4)alkoxy.
In yet another embodiment, Z is phenyl substituted by R8, R9 and R10, wherein R8 and R9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by R11; wherein R10 and R11 are each H or one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, -CF3, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy, and the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or (Ci-C4)alkoxy. In this embodiment, Z is a
9-membered bicyclic heteroaryl group bonded to the amino (NR1) moiety of Formula (I) via a substitutable carbon ring atom of the 6-membered, phenyl moiety of the 9-membered bicyclic heteroaryl group.
Specifically, Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C4)alkyl,
halo(Ci-C4)alkyl and (Ci-C4)alkoxy. Accordingly, in one embodiment, Z is unsubstituted benzothiazolyl. In another embodiment, Z is benzothiazolyl substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C4)alkyl,
halo(Ci-C4)alkyl and (Ci-C4)alkoxy. More specifically, Z is benzo[<i]thiazol-5-yl optionally substituted by chloro, fluoro, -CF3, methyl, or methoxy. In a specific embodiment, Z is benzo[<i]thiazol-5-yl.
In yet another embodiment, Z is pyridyl substituted by R8, R9 and R10, wherein R8 and R9 are located on adjacent atoms (carbon atoms) and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by R11; wherein one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, -CF3, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy and the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or (Ci-C4)alkoxy. In this embodiment, Z is a
9-membered bicyclic heteroaryl group bonded to the amino (NR1) moiety of Formula (I) via a substitutable carbon ring atom of the 6-membered, pyridyl moiety of the 9-membered bicyclic heteroaryl group.
In one embodiment, Z is pyrazolyl and R12 is H or hydroxymethyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl; or R12 is H or methyl, R13 is hydroxymethyl, and R14 is H or methyl. In another embodiment, Z is pyrazolyl, R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is OH. In still another embodiment, Z is pyrazolyl, R12 is H or methyl, R is methyl or trifluoromethyl, and R is H or methyl. In a further embodiment, Z is pyrazolyl, R12 and R13 are both methyl, and R14 is H. In specific embodiments, Z is 5-(trifluoromethyl)-lH-pyrazol-3-yl, l,3,4-trimethyl-lH-pyrazol-5-yl, or 4,5-dimethyl-lH-pyrazol-3-yl.
In a still further embodiment, Z is pyrazolyl, substituted by R12 and R13 wherein:
R12 and R13 are located on adjacent carbon atoms and taken together with the atoms to which they are attached form a 6 membered carbocyclic ring or heterocyclic ring substituted by R15 and R16;
wherein R15 is Η, halogen, cyano, (Ci-C4)alkyl, -CF3, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
R16 is Η, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or
(Ci-C4)alkoxy.
In another embodiment, the invention is directed to a compound according to Formula (I), wherein Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NR1) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-¾]pyridinyl group, or a salt, particularly a pharmaceutically acceptable salt, thereof.
In a further embodiment, Z is an optionally substituted indazolyl or
pyrazolo[3,4-¾]pyridinyl, wherein the indazolyl or pyrazolo[3,4-¾]pyridinyl is optionally substituted by hydroxyl, chloro, fluoro, -CF3, cyano, hydroxymethyl-, methyl, methoxy or aminocarbonyl. In specific embodiments, Z is 5 -fluoro- lH-indazol-3-yl, lH-indazol-6-yl or 3-methyl-lH-indazol-6-yl. In selected embodiments, Z is 5-fluoro-lH-indazol-3-yl. In another embodiment, the invention is directed to a compound according to Formula (II):
Figure imgf000027_0001
or a salt, particularly a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R12 and R13 are as defined herein.
In another embodiment, the invention is directed to method of inhibiting RIP2 kinase comprising contacting a cell with a compound according to Formula (III):
Figure imgf000027_0002
or a salt, particularly a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined herein, and
RZ1 is H, halogen, -CF3, (Ci-C4)alkyl or (Ci-C4)alkoxy; particularly, RZ1 is H or methyl;
RZ2 is H, halogen, -CF3, (Ci-C4)alkyl or (Ci-C4)alkoxy;
RZ3 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and R is hydroxyl, hydroxy(Ci-C4)alkyl or (Ci-C4)alkoxy;
or a salt, particularly a pharmaceutically acceptable salt, thereof.
In one embodiment, the invention is directed to a compound of Formula (I), wherein:
R1 is H or (Ci-C4)alkyl;
R2 is -SRa or -S02Ra, and Ra is an optionally substituted (Ci-C6)alkyl,
(C3-C6)cycloalkyl, or 4-6-membered heterocycloalkyl group, wherein
said (Ci-C6)alkyl is optionally substituted by a groups selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, (Ci-C2)alkoxy(C2-C3)alkoxy-, -S02(Ci-C2)alkyl, and a group selected from the group consisting of (C3-C6)cycloalkyl (optionally substituted by (Ci-C4)alkyl or hydroxy(Ci-C4)alkyl), 4-6-membered heterocycloalkyl (optionally substituted by (Ci-C4)alkyl or halogen), 5-6-membered heteroaryl (optionally substituted by (Ci-C4)alkyl or hydroxy(Ci-C4)alkyl), phenyl, and 9-10-membered heteroaryl, and said (C3-C6)cycloalkyl or 4-6-membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen,
(Ci-C4)alkyl, and hydroxy(Ci-C4)alkyl-,
wherein any of said 5-6 membered heterocycloalkyl groups contains 1 heteroatom selected from N, O and S;
R3 is H, halogen, hydroxy, (Ci-C4)alkyl-, (C2-C4)alkenyl-, halo(Ci-C4)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C4)alkoxy-, (C3-C6)cycloalkyl(Ci-C4)alkoxy-, 5-6-memebered- heterocycloalkyl-oxy-, (Ci-C4)alkoxy(Ci-C6)alkyl-, (Ci-C4)alkoxy(C2-C6)alkoxy-, carboxy-(Ci-Ce)alkoxy-, (Ci-C4)alkoxycarbonyl(Ci-C6)alkoxy-, hydroxy(Ci-Ce)alkyl-, or hydroxy(C2-C6)alkoxy-;
Z is phenyl, substituted by 1 , 2 or 3 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and
(Ci-C4)alkoxy,
or Z is phenyl substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5 -membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5 -membered ring is substituted by R11; wherein R10 and R11 are each H or one of R10 or R11 is H, halogen, cyano,
(Ci-C4)alkyl, -CF3, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy, and the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or (Ci-C4)alkoxy,
or Z is pyrazolyl, wherein R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl,
or Z is pyrazolyl, substituted by R12 and R13 wherein:
R12 and R13 are located on adjacent carbon atoms and taken together with the atoms to which they are attached form a 6-membered carbocyclic ring or heterocyclic ring substituted by R15 and R16;
wherein R15 is H, halogen, cyano, (Ci-C4)alkyl, -CF3, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
R16 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or
(Ci-C4)alkoxy;
or a salt, particularly a pharmaceutically acceptable salt, thereof. Particularly, in this embodiment, R2 is -S02Ra and/or R3 is halogen, hydroxy, (Ci-C4)alkyl-,
(C2-C4)alkenyl-, halo(Ci-C4)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C4)alkoxy-,
(C3-C6)cycloalkyl(Ci-C4)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
(C i -C4)alkoxy(C i -C6)alkyl-, (C i-C4)alkoxy(C2-Ce)alkoxy-, carboxy-(C i -C6)alkoxy-, (Ci-C4)alkoxycarbonyl(Ci-C6)alkoxy-, hydroxy(Ci-Ce)alkyl-, or hydroxy(C2-Ce)alkoxy- and/or Z is other than phenyl, substituted by 1, 2 or 3 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C4)alkyl,
(Ci-C4)alkyl and (Ci-C4)alkoxy.
In another embodiment, the invention is directed to a compound of Formula (I), wherein:
R1 is H; R2 is -SRa , -SORa or -S02Ra, wherein Ra is a (Ci-C6)alkyl group, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, and (Ci-C2)alkoxy(C2-C3)alkoxy-,
or Ra is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C4)alkyl groups;
R3 is halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-, hydroxy(C2-C3)alkenyl-, (Ci-C4)alkoxy-, (C2-C3)alkenyl-oxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
(Ci-C3)alkoxy(Ci-C4)alkyl-, (Ci-C3)alkoxy(C2-C3)alkoxy-,
(Ci-C3)alkyl-thio-(C2-C3)alkoxy-, (Ci-C3)alkyl-sulfonyl-(C2-C3)alkoxy-,
carboxy-(Ci-C4)alkoxy-, carboxy-(C2-C4)alkenyl-oxy-,
(Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-, (Ci-C3)alkoxycarbonyl(C2-C4)alkenyl-oxy-, aminocarbonyl(Ci-C3)alkoxy-, aminocarbonyl(C2-C3)alkenyl-oxy-, or
hydroxy(C2-C4)alkoxy-;
Z is phenyl, substituted by 1 or 2 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and
(Ci-C4)alkoxy,
or Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C4)alkyl, halo(Ci-C4)alkyl and
(Ci-C4)alkoxy,
or Z is pyrazolyl, wherein R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl,
or Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NR1) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group,
or a salt, particularly a pharmaceutically acceptable salt, thereof.
In another embodiment, the invention is directed to a compound of Formula (I), wherein:
R1 is H; R2 is -SRa , -SORa or -S02Ra, wherein Ra is a (Ci-C6)alkyl group, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, and (Ci-C2)alkoxy(C2-C3)alkoxy-;
R3 is halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-, hydroxy(C2-C3)alkenyl-, (Ci-C4)alkoxy-, (C2-C3)alkenyl-oxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
(Ci-C3)alkoxy(Ci-C4)alkyl-, (Ci-C3)alkoxy(C2-C3)alkoxy-,
(Ci-C3)alkyl-thio-(C2-C3)alkoxy-, (Ci-C3)alkyl-sulfonyl-(C2-C3)alkoxy-,
carboxy-(Ci-C4)alkoxy-, carboxy-(C2-C4)alkenyl-oxy-,
(Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-, (Ci-C3)alkoxycarbonyl(C2-C4)alkenyl-oxy-, aminocarbonyl(Ci-C3)alkoxy-, aminocarbonyl(C2-C3)alkenyl-oxy-, or
hydroxy(C2-C4)alkoxy-;
Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C4)alkyl, halo(Ci-C4)alkyl and
(Ci-C4)alkoxy,
or Z is pyrazolyl, wherein R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl,
or Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NR1) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group;
or a salt, particularly a pharmaceutically acceptable salt, thereof.
In another embodiment, the invention is directed to a compound of Formula (I), wherein:
R1 is H or -CH2CH3; particularly, R1 is H;
R2 is -SRa or -S02Ra, wherein:
Ra is a (Ci-C6)alkyl group, optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, and (Ci-C2)alkoxy(C2-C3)alkoxy-,
or Ra is a 5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C4)alkyl groups; R3 is H, halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered heterocycloalkyl-oxy-, (Ci-C3)alkoxy(Ci-C4)alkyl-, (Ci-C3)alkoxy(C2-C4)alkoxy-, carboxy-(Ci-C4)alkoxy-, (Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-, or hydroxy(C2-C4)alkoxy-;
Z is phenyl, substituted by 1 or 2 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and
(Ci-C4)alkoxy,
or Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C4)alkyl, halo(Ci-C4)alkyl or
(Ci-C4)alkoxy,
or Z is pyrazolyl, wherein R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl,
or Z is a 9-membered bi-cyclic heteroaryl group, optionally substituted on either ring by halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl- or aminocarbonyl, wherein the 9-membered bi-cyclic heteroaryl group is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the amino (NH) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group,
or a salt, particularly a pharmaceutically acceptable salt, thereof.
In another embodiment, the invention is directed to a compound of Formula (I), wherein:
R1 is H;
R2 is -S02Ra,wherein Ra is an unsubstituted (Ci-C5)alkyl group or Ra is a
(Ci-C5)alkyl group substituted by a hydroxyl, (Ci-C2)alkoxy, or
(Ci-C2)alkoxy(C2-C3)alkoxy- group;
Z is benzothiazolyl, optionally substituted by a halogen, (Ci-C4)alkyl,
halo(Ci-C4)alkyl or (Ci-C4)alkoxy,
or Z is pyrazolyl, wherein R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl,
or Z is a 9-membered bi-cyclic heteroaryl, optionally substituted on either ring by a halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, hydroxyl,
hydroxy(Ci-C4)alkyl- or aminocarbonyl group, wherein the 9-membered bi-cyclic heteroaryl is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, bonded to the ammo (NR^/NH) moiety via a substitutable carbon ring atom of the 5-membered pyrazolyl ring moiety of the indazolyl or pyrazolo[3,4-£]pyridinyl group;
or a salt, particularly a pharmaceutically acceptable salt, thereof.
Specifically, the invention is directed to a compound according to Formula (I) wherein:
R1 is H or -CH2CH3; particularly, R1 is H;
R2 is -SRa or -S02Ra, and Ra is -CH3, -CH(CH3)2, -C(CH3)3, -CH2CH2OH,
-C(CH3)2CH2CH2OH, or tetrahydro-2H-pyran-4-yl;
R3 is Η, chloro,-CH2CH3, -CH=CH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2, -OCH2CH3, -OCH2CF3, -0CH2CH2C1, -OCH2CH2OH, -OCH2CH2CH2OH,
-OCH2CH2OCH3, -OC(CH3)2CH2OH, -OCH(CH3)CH2OH, -OC(CH3)2C02CH2CH3, cyclohexylmethyloxy-, or tetrahydro-2H-pyran-4-yloxy-; and
Z is 2-methyl-4-hydroxy-phenyl, benzo[<i]thiazol-5-yl or 5-fluoro-lH-indazol-3-yl, or Z is pyrazolyl, wherein R12 is Η or methyl, R13 is methyl or trifluoromethyl, and R14 is Η or methyl,
or a salt, specifically a pharmaceutically acceptable salt, thereof.
In another embodiment, the invention is directed to a compound according to Formula (I) wherein:
R1 is Η;
R2 is -S02Ra, and Ra is -CH3, -CH(CH3)2, or -C(CH3)3;
R3 is H, chloro,-CH2CH3, -CH=CH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2, -OCH2CH3, -OCH2CF3, -0CH2CH2C1, -OCH2CH2OH, -OCH2CH2CH2OH,
-OCH2CH2OCH3, -OC(CH3)2CH2OH, -OCH(CH3)CH2OH, -OC(CH3)2C02CH2CH3, cyclohexylmethyloxy-, or tetrahydro-2H-pyran-4-yloxy-; and
Z is benzo[<i]thiazol-5-yl or 5-fluoro-lH-indazol-3-yl,
or Z is pyrazolyl, wherein R12 is Η or methyl, R13 is methyl or trifluoromethyl, and R14 is Η or methyl;
or a salt, specifically a pharmaceutically acceptable salt, thereof.
More specifically, the invention is directed to a compound according to Formula (I) wherein:
R1 is Η; R2 is -SRa or -S02Ra, and Ra is -CH3, -CH(CH3)2, -C(CH3)3, -CH2CH2OH, -C(CH3)2CH2CH2OH, or tetrahydro-2H-pyran-4-yl;
R3 is chloro, -CH2CH3, -CH=CH2, -CH=CHCH2OH, -OCH=CH2,
-OCH=CH-C02H, -OCH=CH-C02CH3, -OCH=CH-CONH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2, -OCH2CH3, -OCH2CF3, -OCH2CH2CH3, -0CH2CH2C1, -OCH2CH2Br, -OCH2CH2SCH3, -OCH2CH2S02CH3, -OCH2CH2S02CH(CH3)2, -OCH2CH2OH,
-OCH2CH2CH2OH, -OCH2CH2OCH3, -OC(CH3)2CH2OH, -OCH(CH3)CH2OH,
-OCH(CH3)C02CH3, -OCH2CH(CH3)OH, -OC(CH3)2C02CH2CH3, -OCH2C02H, -OCH2CONH2, -OCH2-cyclohexyl, or -0-tetrahydro-2H-pyran-4-yl; and
Z is 2-methyl-5 -hydroxy-phenyl, 2-fluoro-4-chloro-phenyl,
3-methoxy-4-chloro-phenyl, 3-hydroxy-4-chloro-phenyl, benzo[<i]thiazol-5-yl, 5- (trifluoromethyl)-lH-pyrazol-3-yl, l,3,4-trimethyl-lH-pyrazol-5-yl, 4,5-dimethyl-lH- pyrazol-3-yl, 5-fluoro-lH-indazol-3-yl, lH-indazol-6-yl or 3-methyl-lH-indazol-6-yl, or a salt, specifically a pharmaceutically acceptable salt, thereof.
The invention is further directed to a compound according to Formula (I) wherein:
R1 is Η;
R2 is -S02Ra, and
Ra is -CH3, -CH(CH3)2, or -C(CH3)3, or
Ra is -CH2CH2OH or -C(CH3)2CH2CH2OH;
R3 is chloro, -CH2CH3, -CH=CH2, -CH=CHCH2OH, -OCH=CH2,
-OCH=CH-C02H, -OCH=CH-C02CH3, -OCH=CH-CONH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2, -OCH2CH3, -OCH2CF3, -OCH2CH2CH3, -0CH2CH2C1, -OCH2CH2Br, -OCH2CH2SCH3, -OCH2CH2S02CH3, -OCH2CH2S02CH(CH3)2, -OCH2CH2OH,
-OCH2CH2CH2OH, -OCH2CH2OCH3, -OC(CH3)2CH2OH, -OCH(CH3)CH2OH,
-OCH(CH3)C02CH3, -OCH2CH(CH3)OH, -OC(CH3)2C02CH2CH3, -OCH2C02H, -OCH2CONH2, -OCH2-cyclohexyl, or -0-tetrahydro-2H-pyran-4-yl; and
Z is benzo[<i]thiazol-5-yl, 5-(trifluoromethyl)-lH-pyrazol-3-yl, 1,3,4-trimethyl-lH- pyrazol-5-yl, 4,5-dimethyl-lH-pyrazol-3-yl, 5-fluoro-lH-indazol-3-yl, lH-indazol-6-yl or 3-methyl-lH-indazol-6-yl,
or a salt, specifically a pharmaceutically acceptable salt, thereof.
Representative compounds of this invention include the compounds of Examples 1-80, specifically: 4-methy 1-3 - { [6-(methylthio)-4-quinazolinyl] amino } phenol,
4-methyl-3 - { [6-(methylsulfonyl)-4-quinazolinyl] amino } phenol,
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)thio]-4-quinazolinamine,
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-4-quinazolinamine,
6-(tert-butylsulfonyl)-N-(5-fluoro-lH-indazol-3-yl)quinazolin-4-amine,
N-l ,3-benzothiazol-5-yl-6-[(l-methylethyl)sulfonyl]-4-quinazolinamine,
2- {[4-(l ,3-benzothiazol-5-ylamino)-6-quinazolinyl]sulfonyl}ethanol,
N- 1 ,3 -benzothiazol-5 -yl-6-(tetrahydro-2H-pyran-4-ylsulfonyl)-4-quinazolinamine,
N- 1 ,3 -benzothiazol-5 -yl-6-(tetrahydro-2H-pyran-4-ylsulfonyl)-4-quinazolinamine,
2-((4-((4,5-dimethyl- lH-pyrazol-3-yl)amino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol, N-(5-fluoro-lH-indazol-3-yl)-6-[(l-methylethyl)sulfonyl]-4-quinazolinamine,
N-(4,5-dimethyl-lH-pyrazol-3-yl)-6-[(l-methylethyl)sulfonyl]-4-quinazolinamine,
6-(tert-butylsulfonyl)-N-(5-(trifluoromethyl)-lH-pyrazol-3-yl)quinazolin-4-amine,
6-(tert-butylsulfonyl)-N-(l ,3,4-trimethyl-lH-pyrazol-5-yl)quinazolin-4-amine,
N-(6-(tert-butylthio)-7-methoxyquinazolin-4-yl)benzo [d]thiazol-5 -amine,
N-(6-(tert-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine,
N-(6-(isopropylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine,
4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-ol,
N-(6-(tert-butylsulfonyl)-7-ethoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine,
N-(6-(tert-butylsulfonyl)-7-ethoxyquinazolin-4-yl)-N-ethylbenzo[(i]thiazol-5 -amine,
2- ((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol, N-(6-(tert-butylsulfonyl)-7-(difluoromethoxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine, N-(6-(tert-butylsulfonyl)-7-(2,2,2-trifluoroethoxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine, N-(6-(tert-butylsulfonyl)-7-(methoxymethoxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine, N-(6-(tert-butylsulfonyl)-7-(cyclohexylmethoxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine,
3- ((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propan-l-ol, N-(6-(tert-butylsulfonyl)-7-((tetrahydro-2H-pyran-4-yl)oxy)quinazolin-4-yl)benzo[(i]thiazol-
5-amine,
N-(6-(tert-butylsulfonyl)-7-(2-chloroethoxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine, (R)-l-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propan-2-ol, N-(6-(tert-butylsulfonyl)-7-propoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine,
N-(6-(tert-butylsulfonyl)-7-(2-(methylthio)ethoxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine, N-(7-(2-bromoethoxy)-6-(tert-butylsulfonyl)quinazolin-4-yl)benzo[ ]thiazol-5-amine,
4- (benzo[<i]thiazol-5-ylamino)-6-(tert-butylthio)quinazolin-7-ol,
N-(6-(tert-butylthio)-7-isopropoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine,
N-(6-(ter^butylsulfonyl)-7-isopropoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine,
ethyl 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)-2- methylpropanoate,
2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)-2- methylpropan- 1 -ol,
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-7-ethenyl-4-quinazolinamine, N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-7-ethyl-4-quinazolinamine,
N-(6-(tert-butylsulfonyl)-7-chloroquinazolin-4-yl)benzo[(i]thiazol-5-amine,
6-(tert-butylsulfonyl)-7-chloro-N-(4,5-dimethyl-lH-pyrazol-3-yl)quinazolin-4-amine, 6- [( 1 , 1 -dimethylethyl)sulfonyl] -N-(5 -fluoro- IH-pyrazolo [3 ,4-£]pyridin-3 -yl)-7-(methyloxy)- 4-quinazolinamine,
6-(fert-butylsulfonyl)-N-(4-chloro-3 -methoxyphenyl)-7-methoxyquinazolin-4-amine,
5- ((6-(tert-butylsulfonyl)-7-methoxyquinazolin-4-yl)amino)-2-chlorophenol,
6- (tert-butylsulfonyl)-7-methoxy-N-(3-methyl-lH-indazol-6-yl)quinazolin-4-amine,
6-(tert-butylsulfonyl)-N-(4-chloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine,
6-(tert-butylsulfonyl)-N-(lH-indazol-6-yl)-7-methoxyquinazolin-4-amine,
6-(tert-butylsulfonyl)-N-(4,5-dimethyl-lH-pyrazol-3-yl)-7-methoxyquinazolin-4-amine,
(E)-3-(4-(benzo[ ]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)prop-2-en-l-ol, 2-((4-(benzo[ ]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol,
(R)-methyl 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)propanoate,
(S)-methyl 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)propanoate,
methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)propanoate,
(R)-2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propan-l-ol, (S)-2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propan-l-ol, 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propan-l-ol, 6-(tert-butylsulfonyl)-4-((4-chloro-2-fluorophenyl)amino)quinazolin-7-ol, N-(6-(tert-butylsulfinyl)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine, 2-((4-(benzo[ ]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acetamide, 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acetic acid, N-(6-(ter^butylsulfonyl)-7-(2-(methylsulfonyl)ethoxy)quinazolin-4-yl)benzo[ ]thiazol-5- amine,
N-(6-(ter^butylsulfonyl)-7-(2-(isopropylsulfonyl)ethoxy)quinazolin-4-yl)benzo[(i]thiazol-5- amine,
(E)-methyl 3-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)acrylate,
(E)-3-((4-(benzo[ ]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acrylamide, (E)-3-((4-(benzo[ ]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acrylic acid, N-(6-(tert-butylsulfonyl)-7-(vinyloxy)quinazolin-4-yl)benzo[(i]thiazol-5-amine,
4-(benzo[ ]thiazol-5-ylamino)-7-methoxy-N,N-dimethylquinazoline-6-sulfonamide,
4-(benzo[ ]thiazol-5-ylamino)-N-isopropyl-7-methoxyquinazoline-6-sulfonamide,
N-(7-methoxy-6-(pyrrolidin- 1 -ylsulfonyl)quinazolin-4-yl)benzo[<i]thiazol-5 -amine,
N-(7-methoxy-6-(morpholinosulfonyl)quinazolin-4-yl)benzo[(i]thiazol-5-amine,
4-(benzo[ ]thiazol-5-ylamino)-N-(2-hydroxyethyl)-7-methoxyquinazoline-6-sulfonamide, 4-(benzo[<i]thiazol-5-ylamino)-7-methoxy-N-(tetrahydro-2H-pyran-4-yl)quinazoline-6- sulfonamide,
4-(benzo[<i]thiazol-5-ylamino)-N-(2-hydroxy-2-methylpropyl)-7-methoxyquinazoline-6- sulfonamide,
l-((4-(benzo[ ]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)pyrrolidin-3-ol, 4-(benzo[<i]thiazol-5-ylamino)-N-(2-hydroxypropyl)-7-methoxyquinazoline-6- sulfonamide,
4-(benzo[ ]thiazol-5-ylamino)-7-methoxy-N-(2-methoxyethyl)quinazoline-6-sulfonamide, 4-(benzo[<i]thiazol-5-ylamino)-7-methoxy-N-(oxetan-3-yl)quinazoline-6-sulfonamide, 4-(benzo[<^thiazol-5-ylamino)-N-(2-(dimethylamino)ethyl)-7-methoxyquinazoline-6- sulfonamide,
l-((4-(benzo[<i]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)pyrrolidine-2- carboxylic acid,
1 -(4-((4-(benzo[(i]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)piperazin- 1 - yl)ethanone, N-(2-(lH-tetrazol-5-yl)ethyl)-4-(benzo[ ]thiazol-5-ylamino)-7-methoxyquinazoline-6- sulfonamide,
4-(benzo[<i]thiazol-5-ylamino)-7-methoxy-N-((tetrahydro-2H-pyran-4- yl)methyl)quinazoline-6-sulfonamide,
or a salt, particularly a pharmaceutically acceptable salt, thereof.
Specifically, this invention is directed to N-l,3-benzothiazol-5-yl-6-[(l,l- dimethylethyl)sulfonyl]-4-quinazolinamine or a salt, particularly a pharmaceutically acceptable salt, thereof.
This invention is also directed to N-l,3-benzothiazol-5-yl-6-[(l- methylethyl)sulfonyl]-4-quinazolinamine, or a salt, particularly a pharmaceutically acceptable salt, thereof.
This invention is further directed to N-(6-(tert-butylsulfonyl)-7-methoxyquinazolin- 4-yl)benzo[<i]thiazol-5 -amine or a salt, particularly a pharmaceutically acceptable salt, thereof.
Specifically, this invention is directed to 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)ethanol or a salt, particularly a pharmaceutically acceptable salt, thereof.
Accordingly, a compound of the invention includes a compound of Formula (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
Accordingly, a compound of the invention includes a compound of Formula (I), particularly the specific compounds described herein, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. In one embodiment, the invention is directed to a method of inhibiting RIP2 kinase comprising contacting a cell with a compound of the invention. In another embodiment, the invention is directed to a method of treating a RIP2 kinase-mediated disease or disorder comprising administering a therapeutically effective amount of a compound of the invention to a human in need thereof. The invention is still further directed to the use of a compound of the invention or a pharmaceutical composition comprising a compound of the invention to inhibit RIP2 kinase and/or treat a RIP2 kinase- mediated disease or disorder.
The compounds according to Formula (I) may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral centers, such as a chiral carbon, or particularly, a chiral -SO- moiety, may also be present in the compounds of this invention. Where the stereochemistry of a chiral center present in a compound of this invention (e.g., compound name) or in any chemical structure illustrated herein is not specified, the compound, compound name, or structure is intended to encompass all individual stereoisomers and all mixtures thereof. Thus, compounds according to Formula (I) containing one or more chiral center may be present as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers. For example, each of (i?)-N-(6-(tert-butylsulfinyl)-7-methoxyquinazolin-4- yl)benzo [d]thiazol-5 -amine and (5)-N-(6-(tert-butylsulfinyl)-7-methoxyquinazolin-4- yl)benzo[<i]thiazol-5 -amine are encompassed by the chemical name N-(6-(tert- butylsulfinyl)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine.
Individual stereoisomers of a compound according to Formula (I) which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent. The skilled artisan will appreciate that where the desired stereoisomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired form. Alternatively, specific stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
It is to be understood that a solid form of a compound of the invention may exist in crystalline forms, non-crystalline forms or a mixture thereof. Such crystalline forms may also exhibit polymorphism (i.e. the capacity to occur in different crystalline forms). These different crystalline forms are typically known as "polymorphs." Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
Because of their potential use in medicine, the salts of the compounds of
Formula (I) are preferably pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse J.Pharm.Sci (1977) 66, pp 1-19. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
When a compound of the invention is a base (contains a basic moiety), a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as /?-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like.
Suitable addition salts include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxynaphthoate, isethionate, itaconate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate,
methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmate, palmitate, pantothenate,
phosphate/diphosphate, pyruvate, polygalacturonate, propionate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate. Other exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-l,4-dioate, hexyne-l,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, γ-hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene- 1 -sulfonate and naphthalene-2-sulfonate.
If an inventive basic compound is isolated as a salt, the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pKa than the free base form of the compound.
When a compound of the invention is an acid (contains an acidic moiety), a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
Certain of the compounds of the invention may form salts with one or more equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety). The present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention into another pharmaceutically acceptable salt of a compound of this invention. For solvates of the compounds of Formula (I), including solvates of salts of the compounds of Formula (I), that are in crystalline form, the skilled artisan will appreciate that pharmaceutically acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and EtOAc, or they may involve water as the solvent that is incorporated into the crystalline lattice. Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as "hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates, particularly hydrates. It is to be understood that the term "a salt, particularly a pharmaceutically acceptable salt, thereof, or hydrate thereof encompasses a salt of a compound of Formula (I), a pharmaceutically acceptable salt of a compound of Formula (I), a hydrate of a compound of Formula (I), a hydrate of a salt of a compound of Formula (I), and a hydrate of a pharmaceutically acceptable salt of a compound of Formula (I).
Because the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
GENERAL SYNTHETIC METHODS
The compounds of Formula (I) may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist. The syntheses provided in these Schemes are applicable for producing compounds of the invention having a variety of different substituent groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula (I), they are illustrative of processes that may be used to make the compounds of the invention.
Intermediates (compounds used in the preparation of the compounds of the invention) may also be present as salts. Thus, in reference to intermediates, the phrase "compound(s) of formula (number)" means a compound having that structural formula or a pharmaceutically acceptable salt thereof.
4-Chloroquinazoline intermediates may be from the appropriately functionalized nitrobenzoic acid via reduction of the nitro group to an aniline followed by condensation with formamide or formimamide and cyclization to the 4-quinazolinone. Conversion to the chloroquinazoline could be accomplished with POCI3 or SOCl2 at elevated temperatures. Scheme 1
Figure imgf000043_0001
Additional starting anilines may be synthesized via benzoic acids by protecting the acid as an ester followed by halogenation. Reaction with formimamide then provides the quinazolinone which could then be converted to the 4- chloroquinazoline as in Scheme 1. Scheme 2
Figure imgf000044_0001
Palladium catalyzed coupling of the iodoquinazolines with thiols may provide
6-alkylthioquinazo lines which could be final products, or further subjected to oxidation with Oxone to afford the corresponding sulfone final products. Sulfoxides may also be obtained by this route through carefully monitoring the reaction. Additionally, any sulfides at R3 may be oxidized to sulfones in this manner.
Figure imgf000044_0002
Substitution at C6 could also be installed prior to installation of the "A" moiety. A palladium catalyzed coupling of a thiol with the 6-iodoquinazolinone can provide a sulfide which can subsequently be oxidized to the sulfone. Chlorination with POCI3 or SOCl2 may provide the 4-chloroquinazoline.
Scheme 4
Figure imgf000044_0003
Anilines/amines could be reacted with 4-chloro-quinazo lines under basic or acidic conditions to afford 4-aminoquinazolines which could be final compounds or used as intermediates for further synthesis. Scheme 5
H2N' A
Figure imgf000045_0001
7-Hydroxyquinazolines could be synthesized by dealkylation of the
7-methoxyquinazolines with a sodium alkylthiolate.
Scheme 6
Figure imgf000045_0002
Additional alkoxy substitution at C7 can be installed by alkylation of the
7-hydroxyquinazoline. In some cases, alkylation of the secondary amine may be observed. When Boc-protected haloalkylamines are used, a subsequent step with treatment of HCI is necessary to remove the Boc protecting group.
Scheme 7
Figure imgf000045_0003
In select cases, the sulfide at C6 could be installed while dealkylating C7 methoxyquinazoline with the appropriate sodium alkylthiolate. Final product may be obtained following alkylation of the resultant C7 hydroxyl and oxidation to the sulfone. Scheme 8
RaX,
Figure imgf000045_0004
Substituted hydroxyethyl chains at C7 could be accessed through reduction of an ester that was installed as in Scheme 8.
Scheme 9
Figure imgf000046_0001
The 7-ethylquinazoline could synthesized via a Stille coupling with the C7 triflate to provide the ethylenebenezene followed by hydrogeno lysis.
Scheme 10
Figure imgf000046_0002
Alternatively, the triflate can undergo a palladium catalyzed reaction to install the allylic alcohol.
Scheme 11
Figure imgf000046_0003
5-Fluoro-lH-pyrazolo[3,4-¾]pyridin-3-amine may be synthesized from 2-chloro-5- fluoro-3-pyridinecarboxylic acid. Formation of the acylchloride followed by the addition of ammonia can provide the amide which may be subsequently converted to the nitrile. Treatment with hydrazine may provide the azaindazole. Scheme 12
F\^¾^C02H 11 .. ( (CCOOCCII))22,, D DMMFF,, D DCCMM ONH2 TFAA, NEt3
N CI 2. NH3, dioxane N CI DCM, 0 °C
Figure imgf000047_0001
3,4-Dimethyl-lH-pyrazol-5-amine may be synthesized by alkylation of 3-amino-2- methylacrylonitrile followed by a cyclization with hydrazine.
Scheme 13
Figure imgf000047_0002
The pyrazolamine can be further methylated by reaction with formic acid followed by reduction with borohy dride .
Scheme 14
Figure imgf000047_0003
U 2 lXf \ ~ refiux " H N wX \ * ^ wXf
"A" groups may be installed via a C4 sulfide intermediate. Treatment of the 4-chloro-7-methoxyquinazo lines with sodium ethanethiolate provides the 4-ethylsulfide-7- hydroxyquinoazolines. These 4-alkythio-quinazoline intermediates may be directly treated with an excess of amine (A-NH2) under acidic microwave conditions to provide final products. Alternatively, the intermediates could be alkylated at R3 to afford the hydroxy ethyl ethers before undergoing reaction with amine (A-NH2).
Scheme 15
Figure imgf000047_0004
Hydrolysis of esters to carboxylic acids (on R3 side chains) may be accomplished with LiOH (X = any alkyl chain). Scheme 16
Figure imgf000048_0001
Direct reaction of a R phenol with acrylate provides an unsaturated ester.
Scheme 17
Figure imgf000048_0002
Elimination of an alkyl bromide under thermal conditions provides a vinyl ether. Scheme 18
Figure imgf000048_0003
Sulfonamides may be obtained through the sulfonyl chloride. Formation of the benzylthioether via a palladium catalyzed reaction at the 6-iodoquinazoline followed by treatment with NCS under acidic conditions provided the sulfonyl chloride. Treatment with an amine or ammonia affords the sulfonamide.
Scheme 19
NCS, AcOH/H20
Figure imgf000048_0004
Figure imgf000048_0005
The compounds of this invention may be particularly useful for treatment of RIP2 kinase-mediated diseases or disorders, particularly, uveitis, interleukin-1 converting enzyme (ICE, also known as Caspase-1) associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis (specifically rheumatoid arthritis), inflammatory bowel disorders (such as ulcerative colitis and Crohn's disease), early-onset and extraintestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organs (specifically kidney) in response ischemia induced by cardiac surgery, organ transplant, sepsis and other insults, liver diseases (non-alcohol steatohepatitis, alcohol steatohepatitis, and autoimmune hepatitis), allergic diseases (such as asthma), transplant reactions (such as graft versus host disease), autoimmune diseases (such as systemic lupus erythematosus, and multiple sclerosis), and granulomateous disorders (such as sarcoidosis, Blau syndrome, early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease).
The compounds of this invention may be particularly useful in the treatment of uveitis, ICE fever, Blau Syndrome, early-onset sarcoidosis, ulcerative colitis, Crohn's disease, Wegener's granulamatosis and sarcoidosis.
Treatment of RIP2 kinase-mediated diseases or disorders, or more broadly, treatment of immune mediated diseases including, but not limited to, allergic diseases, autoimmune diseases, prevention of transplant rejection and the like, may be achieved using a compound of this invention as a monotherapy, or in dual or multiple combination therapy, particularly for the treatment of refractory cases, such as in combination with other anti-inflammatory and/or anti-TNF agents, which may be administered in
therapeutically effective amounts as is known in the art.
For example, the compounds of this invention may be administered in combination with corticosteroids and/or anti-TNF agents to treat Blau syndrome, early-onset sarcoidosis; or in combination with anti-TNF biologies or other anti-inflammatory biologies to treat Crohn's Disease; or in combination with 5 -ASA (mesalamine) or sulfasalazine to treat ulcerative colitis; or in combination with low-dose corticosteroids and/or methotrexate to treat Wegener's granulamatosis or sarcoidosis or interstitial pulmonary disease; or in combination with a biologic (e.g. anti-TNF, anti-IL-6, etc.) to treat rheumatoid arthritis; or in combination with anti-IL6 and/or methotrexate to treat ICE fever. Examples of suitable anti-inflammatory agents include corticosteroids, particularly low-dose corticosteroids (such as Deltasone® (prednisone)) and anti-inflammatory biologies (such as Acterma® (anti-IL6R mAb) and Rituximab® (anti-CD20
mAb)). Examples of suitable anti-TNF agents include anti-TNF biologies (such as Enbrel® (etanecerpt)), Humira® (adalimumab), Remicade® (infliximab) and Simponi® (golimumab)).
This invention also provides a compound of Formula (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof, for use in therapy. This invention specifically provides for the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as an active therapeutic substance in the treatment of a RIP2 kinase-mediated disease or disorder, for example the diseases and disorders recited herein; more specifically, for use in the treatment of a disease mediated by inhibition of RIP2 kinase.
The invention also provides for the use of a compound of Formula (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a RIP2 kinase-mediated disease or disorder, for example the diseases and disorders recited herein.
A therapeutically "effective amount" is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein. Thus, e.g., a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to modulate or inhibit the activity of RIP2 kinase such that a disease condition which is mediated by that activity is reduced, alleviated or prevented. The amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pIC5o), efficacy (EC50), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art. Likewise, the duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or disorder and its severity and the specific composition and method being used, but can nevertheless be determined by one of skill in the art.
"Treating" or "treatment" is intended to mean at least the mitigation of a disease or disorder in a patient. The methods of treatment for mitigation of a disease or disorder include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a mediated disease or disorder. Specific diseases and disorders that may be particularly susceptible to treatment using a compound of this invention are described herein.
The compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
Parenteral administration refers to routes of administration other than enteral, transdermal, or by inhalation, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion. Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages. Topical administration includes application to the skin.
The compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the disease or disorder being treated, the severity of the disease or disorder being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
For use in therapy, the compounds of the invention will be normally, but not necessarily, formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, the invention also is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable excipient.
The pharmaceutical compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection. Alternatively, the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form. For oral application, for example, one or more tablets or capsules may be administered. A dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula (I), or a salt, particularly a pharmaceutically acceptable salt, thereof). When prepared in unit dosage form, the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
The pharmaceutical compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
As used herein, "pharmaceutically acceptable excipient" means a material, composition or vehicle involved in giving form or consistency to the composition. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided. In addition, each excipient must of course be of sufficiently high purity to render it pharmaceutically acceptable.
The compounds of the invention and the pharmaceutically acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration. Conventional dosage forms include those adapted for (1) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition. For example, certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body. Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.
Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will appreciate that certain pharmaceutically acceptable excipients may serve more than one function and may serve alternative functions depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation.
Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically acceptable excipients in appropriate amounts for use in the invention. In addition, there are a number of resources that are available to the skilled artisan which describe pharmaceutically acceptable excipients and may be useful in selecting suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
The pharmaceutical compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
In one aspect, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch), gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
EXAMPLES
The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the invention.
The invention also includes various deuterated forms of the compounds of
Formula (I). Each available hydrogen atom attached to a carbon atom may be
independently replaced with a deuterium atom. A person of ordinary skill in the art will know how to synthesize deuterated forms of the compounds of Formula (I). For example, deuterated pyrazole alkyl groups or deuterated alkyl-thioquinazolines or alkyl- sulfonylquinazo lines may be prepared by conventional techniques (see for example:
according to the method of Preparation 7 using iodomethane- i, available from Aldrich Chemical Co., Milwaukee, WI, Cat. No. 176036, or the method of Scheme 13 using methane-iii-thiol, Cat. No. 614904, respectively). Employing such compounds will allow for the preparation of compounds of Formula (I) in which various hydrogen atoms are replaced with deuterium atoms. Halogen substitution on the quinazoline core may also be converted the deuterated form via a lithium halogen exchange followed by a quench with MeOH-<¾.
Names for the intermediate and final compounds described herein were generated using the software naming program ACD/Name Pro V6.02 available from Advanced Chemistry Development, Inc., 110 Yonge Street, 14th Floor, Toronto, Ontario, Canada, M5C 1T4 (https://www.acdlabs.com/) or the naming program in ChemDraw, Struct=Name Pro 12.0, as part of ChemBioDraw Ultra, available from CambridgeSoft. 100
CambridgePark Drive, Cambridge, MA 02140 USA (www.cambridgesoft.com). It will be appreciated by those skilled in the art that each naming program may generate a different
\ ° °
— -s
name for the same structurally depicted chemical group/moiety, e.g., ^ may be named as a tert-butylsulfonyl or as a (l,l-dimethylethyl)sulfonyl group/moiety. In addition, it will be appreciated by those skilled in the art that in certain instances this program will name a structurally depicted compound as a tautomer of that compound. It is to be understood that any reference to a named compound or a structurally depicted compound is intended to encompass all tautomers of such compounds and any mixtures of tautomers thereof.
In the following experimental descriptions, the following abbreviations may be used:
Figure imgf000055_0001
EDC 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide
equiv equivalents
Et ethyl
Et3N or TEA triethylamine
Et20 diethyl ether
EtOAc ethyl acetate
h, hr hour(s)
HATU 0-(7-Azabenzotriazol-lyl)-iV,iV,iV',iV'-tetramethylyronium hexafluorophosphate
HC1 hydrochloric acid
IC1 iodine monochloride
z'-Pr2NEt Ν',Ν '-diisopropylethylamine
KOi-Bu potassium ieri-butoxide
LCMS liquid chromatography-mass spectroscopy
LiHDMS lithium hexamethyldisilazide
Me methyl
MeOH or CH3OH methanol
MgS04 magnesium sulfate
min minute(s)
MS mass spectrum
microwave
NaBH4 sodium borohydride
Na2C03 sodium carbonate
NaHCOj sodium bicarbonate
NaOH sodium hydroxide
Na2S04 sodium sulfate
N2H2 hydrazine
NH4CI ammonium chloride
NiCl2-6H20 nickel (II) chloride hexahydrate
NMP iV-methyl-2-pyrrolidone
Ph phenyl
POCI3 phosphoryl chloride
rt room temperature
satd. saturated
SPE solid phase extraction
TFA trifluoroacetic acid
THF tetrahydrofuran
retention time Preparation 1
6-(methylthio)-4(lH)-quinazolinone
Figure imgf000057_0001
5-(Methylthio)-2-nitrobenzoic acid (1.0 g, 4.7 mmol), zinc (1.8 g, 28 mmol), and MeOH (38 mL) were purged with nitrogen for 10 min and cooled to 0°C. Ammonium formate (2.96 g, 46.9 mmol) was added in several portions and the reaction was left to stir at rt overnight. After 18 h, the milky- white reaction was diluted with acetone and filtered. The solid was collected and placed in a round bottom flask with formamide (9.35 mL, 235 mmol). The reaction was heated to 150°C for 30 min. After cooling to rt, the mixture was partitioned between satd. NaHC03 and Et20. The aqueous layer was extracted with Et20 (5x). The combined organic portions were dried over MgS04 and concentrated to yield 350 mg of crude product which was dry-loaded onto silica and purified via column chromatography (Biotage SP-1, 100% EtOAc) to afford 120 mg of pure material. The aqueous layer was extracted again with 15% MeOH/EtOAc (3x). The combined organic portions were dried over MgS04 and concentrated to yield 4 g of formamide and desired product. The crude product was dry-loaded onto silica and purified via column
chromatography (Biotage SP-1, 100% EtOAc) which removed the -35% of the formamide.
Chromatography was repeated (2x) to yield pure product (100 mg) which was combined with the earlier 120 mg to provide 6-(methylthio)-4(lH)-quinazolinone (215 mg, 1.12 mmol, 23.9% yield). MS (m/z) 193 (M+H+); 1H NMR (400 MHz, DMSO- 6) δ 12.29 (br s., 1H), 8.05 (s, 1H), 7.85 (d, J= 2.3 Hz, 1H), 7.67 - 7.74 (m, 1H), 7.56 - 7.63 (m, 1H), 2.57 (s, 3H)
Preparation 2
- 1 ,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine
Figure imgf000057_0002
Step 1. 4-chloro-6-iodoquinazoline: 6-iodo-4(lH)-quinazolinone (10 g, 37 mmol) was weighed into a 250 mL flask. Thionyl chloride (100 mL, 1.4 mmol) and DMF (0.5 mL, 6.5 mmol) were added to give a grey suspension. The mixture was heated to reflux. Heating was continued for 6 h and then the mixture was cooled on ice bath for 1 h. A yellow solid precipitated and was collected by filtration to afford 8.6 g (77%) of the title compound.
Step 2. N-l,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine: To a solution of 4- chloro-6-iodoquinazoline (2.60 g, 8.95 mmol) in isopropanol (60 mL) was added 1,3- benzothiazol-5 -amine (1.479 g, 9.85 mmol). The mixture was then placed in oil bath preheated to 90°C. The reaction was complete in 30 min., and the solution was allowed to cool to room temperature. A yellow solid precipitated and was filtered and dried to provide 3.6 g (91%) of the title compound.
The following intermediate, N-(5-fluoro-lH-indazol-3-yl)-6-iodo-4- quinazolinamine, was made in the same manner:
Figure imgf000058_0001
Preparation 3
4-chloro-6- [( 1 -methylethyl)sulfonyl] quinazoline
Figure imgf000058_0002
Step 1. 6-[(l-methylethyl)thio]-4(lH)-quinazolinone: To a solution of 6-iodo- 4(lH)-quinazolinone (3.0 g, 11.0 mmol), 2-propanethiol (1.1 mL, 12.1 mmol) and Et3N (4.6 mL, 33.1 mmol) in DMF (40 mL) was added Pd(Ph3P)4 (1.27 g, 1.10 mmol) under nitrogen. The solution was stirred at 90 °C for 1 h. The reaction mixture was allowed to cool to rt and DMF was removed in vacuo. The crude material was purified by column chromatography (0 to 5% MeOH/CH2Cl2) to provide 6-[(l-methylethyl)thio]-4(lH)- quinazolinone (1.8 g, 7.4 mmol, 67% yield). MS (m/z): 221(M+H). Step 2. 6-[(l-methylethyl)sulfonyl]-4(lH)-quinazolinone: 6-[(l-Methylethyl)thio]- 4(lH)-quinazolinone (500 mg, 2.27 mmol) was dissolved in MeOH and water. Oxone (2.8 g, 4.5 mmol) was then added and the mixture stirred for 1 h. The reaction mixture was filtered. The solution was concentrated and crude material was purified by column chromatography (starting with 100% EtOAc to a mixture of 20% EtOAc with 80% of 10% NH4OH in IPA). The collection was triturated with Et20 to provide 700 mg product with 70% purity. MS (m/z): 253 (M+H).
Step 3. 4-chloro-6-[(l-methylethyl)sulfonyl]quinazoline: 6-[(l-Methylethyl)thio]- 4(lH)-quinazolinone (0.20 g, 0.91 mmol), DMF (0.1 mL) and thionyl chloride (5 mL) were place in a sealed tube and heated at 85°C for 5 h. LCMS showed 85% of starting material was converted to product. The solvent was removed in vacuo to provide the title compound (0.20 g crude material). MS (m/z): 271 (Μ+Η).
Preparation 4
5-fluoro-lH-pyrazolo[3,4-b]pyridin-3-amine
Figure imgf000059_0001
Figure imgf000059_0002
Step 1. 2-chloro-5-fluoro-3-pyridinecarboxamide: 2-Chloro-5-fluoro-3- pyridinecarboxylic acid (20 g, 110 mmol) was dissolved in CH2C12 (400 mL), and then DMF (88 nL, 1.1 mmol) was added at 0°C. After the DMF addition, oxalyl chloride (26 mL, 300 mmol) was added dropwise at 0°C. The reaction mixture was stirred at rt for 16 h, and concentrated in vacuo. The resulting yellow liquid was dissolved in 1,4-dioxane (400 mL), cooled to 0°C and NH3 (gas) (19.4 g, 1140 mmol) was bubbled through the solution for 30 min. The mixture was stirred at rt for 16 h. The resulting white mixture was filtered and the filtrate was concentrated to give the desired product as a white solid (18 g, 89% yield). MS (m/z) 175 (M+H+); 1H NMR (400 MHz, DMSO-d6) δ ppm 8.53 (d, 1 H), 8.10 (s, 1 H), 8.00 (dd, 1 H), 7.88 (s, 1 H).
Step 2. 2-chloro-5-fluoro-3-pyridinecarbonitrile: 2-Chloro-5-fluoro-3- pyridinecarboxamide (18 g, 102 mmol) was suspended in CH2CI2 (500 mL), and then Et3N (31 mL, 220 mmol) was added at 0°C. Trifluoroacetic anhydride (TFAA) (16 mL, 1 10 mmol) was added dropwise to the reaction mixture at 0°C. The white carboxamide starting material disappeared after 20 min at 0°C, indicating the completion of the reaction. The reaction mixture was stirred at 0°C for 1 h. The reaction mixture was diluted with CH2CI2, and then washed with satd. NaHC03(aq). The organic layer was washed with brine, dried over MgS04, filtered and the filtrate was concentrated to a brown residue. The residue was purified by column chromatography (8%-20% EtOAc/hexanes; 330g column). Collected fractions were combined and concentrated to give the desired product as a white solid (15 g, 96% yield). MS (m/z) 157 (M+H+). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.68 (dd, 1 H), 8.83 (d, 1 H).
Step 3. 5-fluoro-lH-pyrazolo[3,4-¾]pyridin-3-amine: 2-Chloro-5-fluoro-3- pyridinecarbonitrile (15.3 g, 98 mmol) was dissolved in 1-butanol (300 mL), and then hydrazine monohydrate (16.82 mL, 293 mmol) was added, followed by hydrochloric acid (4N in 1 ,4-dioxane) (0.244 mL, 0.977 mmol). The reaction mixture was maintained at 70°C for 4 h, and the resulting yellow crystalline solid was collected by filtration (12.5 g, 84% yield). MS (m z) 153 (M+H+). 1H NMR (400 MHz, DMSO-d6) δ ppm 5.56 (s, 2 H), 7.97 (dd, 1 H), 8.39 (m, 1 H), 12.07 (s, 1 H).
Preparation 5
6-(tert-butylsulfonyl)-4,7-dichloroquinazoline
Figure imgf000060_0001
Step 1. 7-chloro-6-iodo-4(lH)-quinazolinone: A solution of methyl 2-amino-4- chloro-5-iodobenzoate (3.4 g, 10.9 mmol) and imidoformamide (3.4 g, 32.7 mmol) in 2- methoxyethanol (15 mL) was stirred at 125°C for 7 h. The reaction mixture was allowed to cool to rt and the residue suspended in water. The solid was collected by filtration, washed with water and dried under vacuum (50 °C) to give 3.2 g of the title compound (96%). MS: m/z: 307 [M+H]+.
Step 2. 7-chloro-6-[(l,l-dimethylethyl)thio]-4(lH)-quinazolinone: To a solution of 6,7-¾z5[(l,l-dimethylethyl)thio]-4(lH)-quinazolinone (500 mg, 1.6 mmol), 2-methyl-2- propanethiol (162 mg, 1.8 mmol), Et3N (0.68 mL, 4.9 mmol) in DMF (5 mL) was added Pd(Ph3P)4 (189 mg, 0.16 mmol). The reaction mixture was stirred at 90°C for 1 h. Solvent was removed in vacuo. The crude material was purified by column chromatography (0 to 5% MeOH/CH2Cl2) to provide 0.37 g of the title compound (84%). MS: m/z: 269 [M+H]+.
Step 3. 7-chloro-6-[(l,l-dimethylethyl)sulfonyl]-4(lH)-quinazolinone: To a solution of 7-chloro-6-[(l,l-dimethylethyl)thio]-4(lH)-quinazolinone (370 mg, 1.4 mmol) in THF (8 mL) and water (2 mL) was added oxone (1.9 g, 3.0 mmol) and stirred overnight. Aq. NaHC03 was added to neutralize the solution to pH=7. The solution was extracted with EtOAc, dried over Na2S04, filtered, and evaporated. Crude material was purified by column chromatography (0 to 8% MeOH/CH2Cl2) to give 0.30 g product (yield 64%). MS: m/z: 301 [M+H]+.
Step 4. 4,7-dichloro-6-[(l,l-dimethylethyl)sulfonyl]quinazoline: To a solution of
7-chloro-6-[(l,l-dimethylethyl)sulfonyl]-4(lH)-quinazolinone (180 mg, 0.60 mmol), POCl3 (0.22 mL, 2.39 mmol) in 1 ,2-dichloroethane (5 mL) was added DIPEA (0.52 mL, 3.0 mmol). The reaction mixture was heated at 80°C for 4 h and then cooled to rt. The solvent was removed under high vacuum. The residue was treated with satd. aq. NaHC03 and extracted with CH2C12. The organic extract was dried over Na2S04. The organic extract was filtered and concentrated for use in the next step (166 mg of title compound). MS: m/z: 319 [M+H]+. Preparation 6
-butylsulfonyl)-4-chloro-7-methoxyquinazoline oxone
Figure imgf000062_0001
Figure imgf000062_0002
Step 1. 6-[(l,l-dimethylethyl)thio]-7-(methyloxy)-4(lH)-quinazolinone: To a solution of 6-iodo-7-(methyloxy)-4(lH)-quinazolinone(1.0 g, 3.3 mmol), 2-methyl-2- propanethiol (0.36 g, 4.0 mmol), Et3N (1.4 mL, 9.9 mmol) in DMF (5 mL) was added Pd(Ph3P)4 (0.38 g, 0.33 mmol). The reaction mixture was stirred at 90°C for 1 h. Solvent was removed in vacuo. The crude material was purified by column chromatography (0 to 5% MeOH/CH2Cl2) to provide 0.90 g of the title compound (93%). MS:m/z: 265 [M+H]+.
Step 2. 6-[(l,l-dimethylethyl)sulfonyl]-7-(methyloxy)-4(lH)-quinazolinone:
6-[(l,l-dimethylethyl)thio]-7-(methyloxy)-4(lH)-quinazolinone (900 mg, 3.4 mmol) was dissolved in MeOH (10 mL), THF (10 mL) and water (0.4 mL). Oxone (4.2 g, 6.8 mmol) was added and reaction mixture was stirred at rt overnight. The solution was filtered, and the solid was washed with CH2C12 and MeOH. The solvent was evaporated. The crude material was purified by column chromatography (0 to 10% MeOH/CH2Cl2). 1.1 g of the title compound as collected with a purity of 74%. MS:m/z: 297.2 [M+H]+.
Step 3. 4-chloro-6-[(l , 1 -dimethylethyl)sulfonyl]-7-(methyloxy)quinazoline:
6-[(l,l-Dimethylethyl)sulfonyl]-7-(methyloxy)-4(lH)-quinazolinone (60 mg, 0.20 mmol) and POCl3 (2 mL, 21.5 mmol) and the reaction mixture was heated at 80°C for 4h. The solution was allowed to cool to rt. POCl3 was removed under high vacuum. The residue was treated with satd. aqueous NaHC03 and extracted with CH2C12. The organic extract was dried over Na2S04, filtered, and concentrated. MS:m/z: 315, 317 [M+H]+. Preparation 7
3,4-Dimethyl-lH-pyrazol-5-
Figure imgf000063_0001
Stepl. 3-amino-2-methyl-2-butenenitrile: To a suspension of NaH (11.7 g, 292 mmol) in toluene (100 mL) at 30°C was added a solution of (2Z)-3-amino-2-butenenitrile (20 g, 244 mmol) in toluene (400 mL) and the reaction mixture was stirred for 10 min. lodomethane (15.23 mL, 244 mmol) was added and the reaction was cooled with cold water to maintain a temperature of 40 °C. The reaction was then cooled to 30°C and stirred overnight. An orange solid formed and was collected via filtration washing with toluene. The solid was suspended in water (400 mL) and stirred for 1 h. The solid was then filtered washing with water and air dried for 15 min, then placed under vacuum overnight (6.7 g, 29%). The mother liquor was concentrated under vacuum and the resulting residue dissolved in EtOAc to give a biphasic solution with mineral oil. The layers were separated and the EtOAc was removed under vacuum; the resulting solid was recrystallized from benzene to give the title compound (2.8 g, 12%). 1H NMR (400 MHz, DMSO- 6) δ ppm 1.57 (s, 3 H) 1.92 (s, 3 H) 6.12 (br. s., 2 H); MS (m/z) 97 (M+H+).
Step 2. 3,4-dimethyl-lH-pyrazol-5-amine: To a solution of 3-amino-2-methyl-2- butenenitrile (1.0 g, 10.4 mmol) in ethanol (10.4 mL) was added hydrazine (0.60 mL, 10.4 mmol). The resulting mixture was heated to 75°C for 16 h open to atmosphere. The reaction was concentrated onto silica gel and purified via flash chromatography eluting with 0-10% MeOH in CH2C12 to give the title compound as a yellow oil (710 mg, 61%). 1H NMR (400 MHz, DMSO- 6) δ ppm 1.72 (s, 3 H) 1.99 (s, 3 H) 3.99 - 4.50 (m, 2 H) 10.72 - 11.07 (m, 1 H); MS (m/z) 112 (M+H+).
Preparation 8
N,4,5-trimethyl- lH-pyrazol-3-
Figure imgf000063_0002
Step 1. (4,5-dimethyl-lH-pyrazol-3-yl)formamide. A mixture of 4, 5 -dimethyl- 1H- pyrazol-3 -amine (1.92 g, 17.3 mmol) in formic acid (10 mL) was stirred under nitrogen at reflux for 2 h. The reaction mixture was cooled to rt and concentrated to yield the title compound as a solid. LCMS (m/z): 140 (M+H+).
Step 2. N,4,5-trimethyl-lH-pyrazol-3-amine. A mixture of (4,5-dimethyl-lH- pyrazol-3-yl)formamide (2.47 g, 17.7 mmol) and BH3 »THF (53.1 mL of a 1.0 M solution in THF, 53.1 mmol) was stirred under nitrogen at rt for 3 h. The mixture was then cooled to 0°C and quenched with MeOH (dropwise addition). The crude product was purified via column chromatography using 0-7% MeOH:CH2Cl2 gradient, 80 g column to yield 0.70 g of the title compound as a colorless viscous oil. 1H NMR (400 MHz, DMSO-d6) δ 10.27 - 11.36 (m, 1H), 4.56 (br. s., 1H), 2.64 (s, 3H), 2.00 (s, 3H), 1.71 (s, 3H); LCMS (m/z): 126 (M+H+).
Example 1
4-methyl-3 - { [6-(methylthio)-4-quinazolinyl] amino } phenol
Figure imgf000064_0001
A mixture of 6-(methylthio)-4(lH)-quinazolinone (200 mg, 1.1 mmol) and phosphorus oxychloride (5.0 mL, 53 mmol) was heated at 110°C for 3 h. Toluene was added and the reaction was concentrated to dryness. To the crude 4-chloro-6- (methylthio)quinazoline (249 mg, 1.18 mmol) in NMP (9.6 mL) were added potassium carbonate (490 mg, 3.5 mmol) and 3-amino-4-methylphenol (145 mg, 1.18 mmol). The reaction was heated at 100°C for 30 min, cooled to rt, and partitioned between EtOAc and satd. NaHC03. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were washed with brine (3x), dried over MgS04, dry-loaded onto silica and chromatographed (Biotage SP-1, 25%- 100% EtOAc/hexane) to yield 4-methyl-3-{[6-
(methylthio)-4-quinazolinyl] amino} phenol (140 mg, 0.471 mmol, 39.9% yield). MS (m z) 298 (M+H+); 1H NMR (400 MHz, DMSO-d6) δ 9.60 (s, 1H), 9.30 (s, 1H), 8.35 (s, 1H), 8.19 (d, J= 2.0 Hz, 1H), 7.62 - 7.78 (m, 2H), 7.09 (d, J= 8.3 Hz, 1H), 6.73 (d, J
1H), 6.65 (dd, J= 8.1, 2.5 Hz, 1H), 2.63 (s, 3H), 2.05 (s, 3H).
Example 2
4-methyl-3 - { [6-(methylsulfonyl)-4-quinazolinyl] amino } phenol
Figure imgf000065_0001
To a suspension of 4-methyl-3-{[6-(methylthio)-4-quinazolinyl] amino} phenol (130 mg, 0.44 mmol) in MeOH (2.5 mL) and water (2.5 mL) was added Oxone® (322 mg, 0.525 mmol). The reaction was stirred at rt for 30 min and concentrated to near dryness under a stream of nitrogen. The residue was partitioned between EtO Ac and satd. NaHC03. The aqueous layer was extracted with EtO Ac (2x) and the combined organic extracts were washed with brine (lx), dried over MgS04 and concentrated to dryness to yield pure 4- methyl-3-{[6-(methylsulfonyl)-4-quinazolinyl] amino} phenol (110 mg, 0.334 mmol, 76% yield). MS (m/z) 330 (M+H+); 1H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 9.33 (s, 1H), 9.15 (d, J= 2.0 Hz, 1H), 8.53 (s, 1H), 8.27 (dd, J= 8.7, 1.9 Hz, 1H), 7.94 (d, J= 8.8 Hz, 1H), 7.10 (d, J= 8.3 Hz, 1H), 6.72 (d, J= 2.5 Hz, 1H), 6.66 (dd, J= 8.2, 2.4 Hz, 1H), 3.34 (s, 3H), 2.06 (s, 3H).
Example 3
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)thio]-4-quinazolinamine
Figure imgf000065_0002
A 20 mL microwave vial was charged with N-l,3-benzothiazol-5-yl-6-iodo-4- quinazolinamine (182 mg, 0.270 mmol), Pd(Ph3P)4 (31.2 mg, 0.027 mmol) and 2-methyl- 2-propanethiol (0.032 mL, 0.284 mmol). The flask was then evacuated and backfilled with nitrogen three times. 1,4-Dioxane (10 mL) was then added followed by Et3N (0.25 mL, 1.794 mmol). The yellow suspension was sparged with argon for 5 min, then sealed and heated to 60°C in a heating block. After 18 hr the reaction was cooled to rt and
concentrated directly to afford a dark red oil. The crude material was purified via column chromatography (25 g SNAP column, 0-15% MeOH/CH2Cl2). The combined fractions containing the desired product appeared to be ~ 80% pure.
Example 4
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-4-quinazolinamine
Oxone
Figure imgf000066_0001
ve vial was ch — , MeOH arged with N - 1
A 20 mL microwa -l,3 *-bwenzothiazol-5-yl-6-iodo-4- quinazolinamine (182 mg, 0.270 mmol), Pd(Ph3P)4 (31.2 mg, 0.027 mmol) and 2-methyl- 2-propanethiol (0.032 mL, 0.284 mmol). The flask was then evacuated and backfilled with nitrogen three times. 1,4-Dioxane (10 mL) was then added followed by Et3N (0.25 mL, 1.794 mmol). The yellow suspension was sparged with argon for 5 min, then sealed and heated to 60°C in a heating block. After 18 hr the reaction was cooled to rt and
concentrated directly to afford a dark red oil. The crude material was purified via column chromatography (25 g SNAP column, 0-15% MeOH/CH2Cl2). The combined fractions containing the desired product appeared to be ~ 80% pure.
Alternatively, this reaction can be run in solvents other than 1 ,4-dioxane, including DMF, and at temperatures other than 60°C as appropriate for each substrate.
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)thio]-4-quinazolinamine (150 mg, 0.327 mmol) was dissolved in MeOH (10 mL) in a 20 mL scintillation vial. To this deep red solution was added oxone (300 mg, 0.488 mmol) and the reaction was stirred at rt. After 1 hr the reaction was treated with 5 mL of (5: 1 Na2S203/NaHC03) for 5 min then poured into 50mL sat. aq. bicarbonate solution. The mixture was diluted with 50mL H20 and then extracted with CH2C12 (50 mL x 3) and EtOAc (50mL). The combined organics were concentrated and the crude material was purified via column chromatography (25 g SNAP column, 0 - 8% MeOH/CH2Cl2) to afford 37 mg (26%) of the title compound. MS (m/z) 399.1 (M+H+). 1H NMR (DMSO-d6) δ: 10.65 (br. s., 1H), 9.44 (s, 1H), 9.26 (s, 8.75 (s, 1H), 8.64 (s, 1H), 8.10 - 8.28 (m, 2H), 7.99 (d, J = 8.6 Hz, 1H), 7.89 - 7.96 (n 1H), 1.33 (s, 9H).
Select compounds were purified by reverse phase HPLC.
The following examples were prepared in the same manner:
Figure imgf000068_0001
Example 9
N-l,3-benzothiazol-5-yl-6-(tetrahydro-2H-pyran-4-ylsulfonyl)-4-quinazolinamine
Figure imgf000069_0001
Step 1. 3-{[4-(l,3-benzothiazol-5-ylamino)-6-quinazolinyl]thio}-3-methyl-l- butanol: To a solution of N-l,3-benzothiazol-5-yl-6-iodo-4-quinazolinamine (202 mg, 0.500 mmol), 3-mercapto-3-methyl-l-butanol (60 mg, 0.50 mmol), potassium tert-butoxide (168 mg, 1.50 mmol) and (oxydi-2,l-phenylene)bis(diphenyl phosphine) (27 mg, 0.05 mmol) in dioxane (4 mL) was added Pd2dba3 (46 mg, 0.05 mmol) and the mixture was sparged with N2 for 10 min. The reaction was complete in 2 h. Solvent was removed and the crude material was purified via column chromatography (0 to 5% MeOH/CH2Cl2) to afford 142 mg of the title compound (72%). MS: m/z: 397 [M+H]+
Cesium carbonate may also be used as the base in these coupling reactions. An equivalent of triethamine may also be added when the starting quinazoline is an HCl salt.
Step 2. 3-{[4-(l,3-benzothiazol-5-ylamino)-6-quinazolinyl]sulfonyl}-3-methyl-l- butanol : 3 - { [4-( 1 ,3 -benzothiazol-5 -ylamino)-6-quinazolinyl]thio } -3 -methyl- 1 -butanol (140 mg, 0.35 mmol) and oxone (434 mg, 0.71 mmol) were suspended in MeOH (2 mL) and the mixture was stirred at rt for 5 h. Upon filtration the cake was washed with MeOH and the filtrate was concentrated. The crude material was purified via column
chromatography (0 to 8% MeOH/CH2Cl2) to afford 3-{[4-(l,3-benzothiazol-5-ylamino)-6- quinazolinyl]sulfonyl}-3-methyl-l-butanol (67 mg, 0.15 mmol, 42% yield). MS: m/z: 429 [M+H]+; 1H NMR (DMSO-d6) δ: 10.66 (s, 1H), 9.44 (s, 1H), 9.25 (d, J = 1.5 Hz, 1H), 8.76 (s, 1H), 8.64 (d, J = 1.8 Hz, 1H), 8.13 - 8.30 (m, 2H), 7.89 - 8.07 (m, 2H), 4.58 (t, J = 4.8 Hz, 1H), 3.58 (d, J = 5.3 Hz, 2H), 1.86 (t, J = 6.9 Hz, 2H), 1.34 (s, 6H).
EtOH and water (1 : 1) may also be used as the solvent mixture. The following example was prepared in a similar manner:
Figure imgf000070_0002
Example 11
N-(5-fluoro-lH-indazol-3-yl)-6-[(l-methylethyl)sulfonyl]-4-quinazolinamine
Figure imgf000070_0001
To a solution of 4-chloro-6-[(l-methylethyl)sulfonyl]quinazoline (100 mg, 0.37 mmol) in isopropanol (1 mL) was added 5-fluoro-lH-indazol-3-amine (56 mg, 0.37 mmol). The reaction mixture was stirred at 90°C for 1 h. The solvent was removed in vacuo and the crude material was purified by HPLC to give 23 mg of the title compound. MS (m/z): 386 (M+H). 1H NMR (DMSO-d6) δ: 13.01 (br. s., 1H), 9.19 (br. s., 1H), 8.54 (br. s., 1H), 8.17 (br. s., 1H), 7.95 (br. s., 1H), 7.58 (dd, J = 9.1, 4.3 Hz, 1H), 7.44 (br. s., 1H), 7.29 (td, J = 9.1, 2.3 Hz, 1H), 3.48 - 3.65 (m, 1H), 1.25 (d, J = 6.8 Hz, 6H).
The following compounds were prepared using procedures analogous to those described above using the appropriate commercial amine. Examples 11 and 12 were neutralized with Et3N before being concentrated for purification. Some reactions varied in temperature and solvent.
Figure imgf000071_0001
Example 15
N-(6-(tert-butylthio)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine
Figure imgf000071_0002
Step 1. Methyl 2-amino-4-methoxybenzoate: To a solution of 2-amino-4- (methyloxy) benzoic acid (5 g, 30 mmol) in MeOH (30 mL) and toluene (60 mL) was added trimethylsilyldiazomethane (30 mL, 60 mmol). The reaction mixture was stirred at 0°C for 1 h. The reaction mixture was allowed to warm to rt and solvent was removed in vacuo. The crude material was purified by column chromatography (0 to 15%
EtOAC/hexanes) to provide 4.2 g of the title compound (74%). MS: m/z: 182 [M+H]+.
Step 2. Methyl 2-amino-5-iodo-4-methoxybenzoate: Methyl 2-amino-4- (methyloxy) benzoate (3.78 g, 20.86 mmol) was dissolved in 25 mL of water, 15 mL of ethanol and 2.2 mL of concentrated HCl. A solution of ICl (1.1 mL, 21.9 mmol) in 3.8 mL concentrated HCl and 14 mL of water at 5 °C was added to the aniline solution. The reaction was stirred overnight and was then filtered to obtain 6.9 g of a light brown solid. MS: m/z: 308 [M+H]+
Step 3. 6-iodo-7-methoxyquinazolin-4(lH)-one: A solution of methyl 2-amino-5- iodo-4-(methyloxy)benzoate (2 g, 6.5 mmol) and imidoformamide (2.0 g, 19.5 mmol) in 2- methoxyethanol (15 mL) was stirred at 125°C for 6 h. The solvent was removed in vacuo, and the residue was suspended in water and the solid was collected by filtration, washed with water and dried under vacuum (50 °C) to afford 2.1 g of the title compound (96%> pure). MS: m/z: 303 [M+H]+.
Step 4. 4-chloro-6-iodo-7-(methyloxy)quinazoline: 6-Iodo-7-(methyloxy)-4(lH)- quinazolinone (2.0 g, 6.6 mmol), POCl3 (3.1 mL, 33.1 mmol) and DIPEA (6.9 mL, 40 mmol) were combined in DCE (50 mL) a round bottom flask. The reaction mixture was heated at 80°C for 5 h, followed by heating at 70°C for 10 h. The reaction mixture was allowed to cool to rt. A yellow solid was precipitated out. The solid was filtered. The solution was concentrated and neutralized with satd. NaHC03, extracted with CH2CI2 and dried over Na2S04. The mixture was filtered, and the solvent was removed in vacuo.
Solid portions were combined to obtain 2.0 g of the title compound (88%). MS: m/z: 321 [M+H]+.
Step 5. N-l,3-benzothiazol-5-yl-6-iodo-7-(methyloxy)-4-quinazolinamine: To a solution of 4-chloro-6-iodo-7-(methyloxy)quinazoline (2.0 g, 5.4 mmol) in isopropanol (30 mL) was added l,3-benzothiazol-5-amine (1.2 g, 8.1 mmol). The suspension was heated in oil bath at 90°C (preheated). The reaction mixture stirred at this temperature for 30 min. A yellow solid precipitated out as the reaction mixture was allowed to cool to rt. The solid was filtered to provide 2.1 g of the title compound (77%, 93% pure). MS: m/z: All
[M+H]+.
Step 6. N-(6-(tert-butylthio)-7-methoxyquinazolin-4-yl)benzo [d]thiazol-5 -amine : To a solution of N-l,3-benzothiazol-5-yl-6-iodo-7-(methyloxy)-4-quinazolinamine (2.1 g, 4.5 mmol), 2-methyl-2-propanethiol (483 mg, 5.35 mmol), Et3N (1.9 mL, 13.4 mmol) in DMF (5 mL) was added Pd(Ph3P)4 (516 mg, 0.45 mmol). The reaction mixture was stirred at 90°C for 1 h. Most of DMF was removed in vacuo. The crude material was triturated with MeOH. The red solid was filtered and washed with Et20 to provide 1.7 g of the title compound as an off white solid (96%). MS: m/z: 397 [M+H]+.
The following compound, N-(6-(isopropylthio)-7-methoxyquinazolin-4- yl)benzo[<i]thiazol-5 -amine (used only as an intermediate and not submitted for testing against RIP2 kinase), was made in a similar manner:
Figure imgf000073_0001
Example 16
-butylsulfonyl)-7-methoxyquinazol -4-yl)benzo[(i]thiazol-5-amine
Figure imgf000073_0002
To a solution of N-(6-(fert-butylthio)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5- amine (1.2 g, 2.5 mmol) in THF (20 mL) and water (2 mL) was added oxone (3.1 g, 5.0 mmol). The reaction mixture was stirred at rt for 8 h. Satd. aq. NaHC03 was added to the reaction mixture to adjust to pH~7. The mixture was extracted with EtOAc (100 mL x 2) and CH2C12 (100 mL x 2), dried over Na2S04, and filtered. The solvent was removed in vacuo and crude material was purified by column chromatography (0 to 8%
MeOH/CH2Cl2) to provide 530 mg of the title compound (19%). MS: m/z: 429 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.34 (s, 9 H), 4.01 (s, 3 H), 7.40 (s, 1 H), 7.89 (dd, J = 8.80, 1.78 Hz, 1 H), 8.17 (d, J= 8.80 Hz, 1 H), 8.59 (d, J= 1.78 Hz, 1 H), 8.64 (s, 1 H), 9.14 (s, 1 H), 9.42 (s, 1 H), 10.55 (s, 1 H).
The following example was prepared in a similar manner:
Figure imgf000074_0002
Example 18
4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-ol
Figure imgf000074_0001
To a solution of N-(6-(tert-butylsulfonyl)-7-methoxyquinazolin-4- yl)benzo[<i]thiazol-5 -amine (2.0 g, 4.7 mmol) in DMF (30 mL) was added sodium isopropylthiolate (2.7 g, 28.0 mmol), and the solution was stirred at 150°C for 1 h. Solvent was removed in vacuo. 1 N aq. HC1 was added to reaction mixture to neutralize to pH =6. A yellow solid precipitated out, which was filtered and purified by column
chromatography (0 to 5% MeOH/CH2Cl2) to provide 1.5 g of the title compound (65%). MS: m/z: 415 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.15 - 1.46 (s, 9 H), 7.21 (s, 1 H), 7.89 (dd, J= 8.72, 1.78 Hz, 1 H), 8.16 (d, J= 8.72 Hz, 1 H), 8.55 (s, 1 H), 8.58 (d, J = 1.78 Hz, 1 H), 9.07 (s, 1 H), 9.42 (s, 1 H), 10.47 (s, 1 H), 1 1.45 (br. s., 1 H). Examples 19 and 20
(tert-butylsulfonyl)-7-ethoxyquinazolin-4-yl)benzo [d]thiazol-5 -amine and N-(6-(tert- butylsulfonyl)-7-ethoxyquinazolin-4-yl)-N-ethylbenzo[(i]thiazol-5-amine
Figure imgf000075_0001
To a solution of 4-(l,3-benzothiazol-5-ylamino)-6-[(l,l-dimethylethyl)sulfonyl]-7- quinazolinol (66 mg, 0.15 mmol) in DMF (1 mL) was added K2CO3 (62 mg, 0.45 mmol). The solution was stirred at rt for 10 min. Iodoethane (35 mg, 0.23 mmol) was then added, and the reaction mixture was stirred at rt for 30 min. Solid precipitate was filtered out, and solution was concentrated for purification. The crude material was purified by HPLC. The two products were not separable. The TFA salts were neutralized by passing the material through a carbonate cartridge. The mixture was repurified by column chromatography (0 to 4% MeOH/CH2Cl2) to isolate 13 mg of N-(6-(tert-butylsulfonyl)-7-ethoxyquinazolin-4- yl)benzo[ ]thiazol-5-amine (20%). MS: m/z: 443 [M+H]+; 1H NMR (400 MHz, DMSO- d6) δ 1.35 (s, 9 H), 1.42 (t, J= 6.96 Hz, 3 H), 4.30 (q, J= 6.96 Hz, 2 H), 7.36 (s, 1 H), 7.89 (d, J= 8.84 Hz, 1 H), 8.16 (d, J= 8.84 Hz, 1 H), 8.58 (. s., 1 H), 8.62 ( s., 1 H), 9.13 (s, 1 H), 9.42 (s, 1 H), 10.54 (s, 1 H). In addition, 7% of the over alkylation product N-(6-(tert- butylsulfonyl)-7-ethoxyquinazolin-4-yl)-N-ethylbenzo[(i]thiazol-5 -amine was obtained and isolated. MS:m/z: 471 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.18 - 1.38 (m, 12 H), 1.41 (t, J = 6.95 Hz, 3 H), 4.15 (q, J = 7.07 Hz, 2 H), 4.33 (q, J = 7.07 Hz, 2 H), 6.99 (s, 1 H), 7.15 (dd, J = 8.34, 1.77 Hz, 1 H), 7.67 (d, J = 1.52 Hz, 1 H), 7.98 (d, J = 8.59 Hz, 1 H), 8.04 (s, 1 H), 8.66 (s, 1 H), 9.30 (s, 1 H).
Example 21
2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol
Figure imgf000076_0001
4-(Benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-ol (8.0 g, 19.3 mmol) and K2CO3 (5.9 g, 42.5 mmol) were dissolved in 98 ml DMF and stirred 2 min before adding 2-bromoethanol (5.1 mL, 72.4 mmol). The mixture was heated for 3 h at 70°C, and then cooled to rt and stirred for 18 h. Water (300 mL) was added, and the resulting solid was filtered and washed with water. The wet cake was slurried again in water and filtered to give a tan solid. The solid was dissolved in hot EtOAc/MeOH (150 mL/50 mL) and cooled to rt to give a white solid precipitate which was filtered and dried under vacuum to give the product as a white solid (2.4 g). The resulting filtrate was evaporated to dryness, triturated with EtOAc, filtered, and dried to give a light brown solid (3.1 g). The solids were combined (5.5 g, 62% yield). Several batches of this material were combined to give 15 g of input material. To this solid was added water (150 mL). The mixture was sonicated, and stirred for 15 min at rt. The solid was filtered and dried under vacuum at 70°C for 3 days to give the title compound as a solid (14.8 g, 98% recovery). MS: m/z: 459 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.36 (s, 9 H), 3.81 (q, J= 4.80 Hz, 2 H), 4.28 (t, J= 4.80 Hz, 2 H), 4.81 (t, J= 4.80 Hz, 1 H), 7.41 (s, 1 H), 7.89 (d, J= 8.40 Hz, 1 H), 8.17 (d, J= 8.40 Hz, 1 H), 8.58 (s, 1 H), 8.63 (s, 1 H), 9.14 (s, 1 H), 9.42 (s, 1 H), 10.55 (s, 1 H).
The following compounds were prepared using procedures analogous to those described above using the appropriate alkylating agent. Isolation and purification methods vary depending upon the substrate.
Figure imgf000077_0001
yl)benzo [d] thiazol- 5 - amine H)
Figure imgf000078_0001
yl)oxy)propan-2-ol
Figure imgf000079_0001
Example 33
-5-ylamino)-6-(tert-butylthio)quinazolin-7-ol
Figure imgf000079_0002
To a solution of N-l,3-benzothiazol-5-yl-6-iodo-7-(methyloxy)-4-quinazolinamine (100 mg, 0.23 mmol) in DMF (2 mL) was added sodium 2-methyl-2-propanethiolate (258 mg, 2.30 mmol). The reaction mixture was stirred at 150 °C for 3 days. The solvent was evaporated under vacuum and crude material was purified by column chromatography to provide 45 mg of the title compound (49%). MS: m/z: 383 [M+H]+.
Example 34
t-butylthio)-7-isopropoxyquinazolin-4- l)benzo[(i]thiazol-5-amine
Figure imgf000080_0001
To a solution of 4-(l,3-benzothiazol-5-ylamino)-6-[(l,l-dimethylethyl)thio]-7- quinazolinol (25 mg, 0.065 mmol) and CS2CO3 (63.9 mg, 0.20 mmol) in DMF (1 mL) was added 2-iodopropane (22 mg, 0.13 mmol). The solution was stirred at rt for 2 h. Solvent was removed in vacuo and the crude material was purified by column chromatography (0 to 10% MeOH/CH2Cl2) to provide 14 mg of the title compound (48%). MS: m/z: 425
[M+H]+. 1H NMR (DMSO-de) δ: 10.04 (s, 1H), 9.41 (s, 1H), 8.84 (s, 1H), 8.70 (d, J = 1.8 Hz, 1H), 8.58 (s, 1H), 8.14 (d, J = 8.6 Hz, 1H), 7.94 (dd, J = 8.7, 1.9 Hz, 1H), 7.23 (s, 1H), 4.90 (dt, J = 12.1, 6.1 Hz, 1H), 1.38 (d, J = 6.1 Hz, 6H), 1.31 (s, 9H). Example 35
N-(6-(tert-butylsulfonyl)-7-isopropoxyquinazolin-4-yl)benzo[(i]thiazol-5-amine
Figure imgf000080_0002
To a solution of N-l,3-benzothiazol-5-yl-6-[(l,l-dimethylethyl)thio]-7-[(l- methylethyl)oxy]-4-quinazolinamine (100 mg, 0.24 mmol) in MeOH (2 mL) and water (0.4 mL) was added oxone (290 mg, 0.47 mmol), and the reaction mixture was stirred at rt for one h. Solid was filtered out. The remaining solution was concentrated and residue was purified by HPLC and basified by carbonate cartridge to give 25 mg of the title compound 22%). MS: m/z: 457 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.31 (s, 9 H), 1.38 (d, J = 6.06 Hz, 6 H), 4.90 (dt, J= 12.13, 6.06 Hz, 1 H), 7.23 (s, 1 H), 7.94 (dd, J= 8.72, 1.89 Hz, 1 H), 8.14 (d, J= 8.59 Hz, 1 H), 8.58 (s, 1 H), 8.70 (d, J= 1.77 Hz, 1 H), 8.84 (s, 1 H), 9.41 (s, 1 H), 10.04 (s, 1 H)
Example 36
Ethyl 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)-2- meth lpropanoate
Figure imgf000081_0001
A suspension of 4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- ol (250 mg, 0.60 mmol) and potassium carbonate (250 mg, 1.81 mmol) in DMF (3 mL) was stirred at rt for 2 min before ethyl 2-bromo-2-methylpropanoate (99 μΐ, 0.66 mmol) was added, then stirred at 60°C for 1 h. The reaction mixture was partitioned between EtOAc and water, the organic washed with satd. NH4C1 and dried over MgS04 and concentrated to an oil. The residue was purified via column chromatography (30% to 100% in EtOAc in hexanes; 40g silica gel cartridge column). The pooled fractions were concentrated in vacuo to give a white solid, ethyl 2-((4-(benzo[<i]thiazol-5-ylamino)-6- (tert-butylsulfonyl)quinazolin-7-yl)oxy)-2-methylpropanoate (101 mg, 32% yield). 1H NMR (CHLOROFORM-;/) δ: 9.06 (s, 1 H), 8.68 - 8.79 (m, 2 H), 8.51 - 8.63 (m, 1 H), 7.99 (d, J= 8.6 Hz, 1 H), 7.76 (dd, J = 8.6, 2.0 Hz, 1 H), 7.28 (s, 1 H), 7.15 (br. s., 1 H), 4.31 (q, J = 7.1 Hz, 2 H), 1.79 (s, 6 H), 1.47 (s, 9 H), 1.28 (t, J= 7.1 Hz, 3 H). MS (m/z): 529.0 (M+H+). Example 37
2-((4-(Benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)- -methylpropan- 1 -ol
Figure imgf000082_0001
To a solution of ethyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)-2-methylpropanoate (134 mg, 0.25 mmol) in THF (2.4 mL) at rt was slowly added LAH (127 μΐ, 0.13 mmol). After stirring for 30m, the reaction mixture was concentrated to an oil, and preabsorbed on silica. The residue was purified via column chromatography (EtOAc to a 3:5 mixture of a 10% NH4OH in IP A
solution:EtOAc; 40g silica gel cartridge column). The pooled fractions were concentrated in vacuo to give a white solid, 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)-2-methylpropan-l-ol (43 mg, 35% yield). 1H NMR (CHLOROFORM-;/) δ: 9.07 (s, 1 H), 8.67 - 8.78 (m, 2 H), 8.52 - 8.63 (m, 1 H), 7.97 (d, J = 8.6 Hz, 1 H), 7.77 (dd, J= 8.6, 1.8 Hz, 1 H), 7.59 (br. s., 1 H), 7.28 (s, 1 H), 4.04 (m, 1 H), 3.58 - 3.76 (m, 2 H), 1.64 (s, 6 H), 1.43 (s, 9 H). MS (m/z) 487.1 (M+H+).
Example 38
N-l,3-benzothiazol-5-yl-6-[(l,l-dimethylethyl)sulfonyl]-7-ethenyl-4-quinazolinamine
Figure imgf000082_0002
Step 1. 4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl trifluoromethanesulfonate: To an ice cooled solution of 4-(benzo[d]thiazol-5-ylamino)-6- (tert-butylsulfonyl)quinazolin-7-ol (346 mg, 0.83 mmol) in pyridine (6 mL) was slowly added triflic anhydride (421 μΐ, 2.50 mmol). The reaction was warmed to rt over 5 min. The reaction mixture was triturated from CH2CI2. The solid residue was purified via column chromatography (10% to 100% in EtOAc in hexanes; 40 g silica gel cartridge column). The fractions were pooled and concentrated in vacuo to provide 4- (benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl
trifluoromethanesulfonate as a yellow solid (72 mg, 18% yield). 1H NMR
(CHLOROFORM- ) δ: 9.02 - 9.13 (m, 1H), 8.90 (d, J = 5.3 Hz, 1H), 8.77 - 8.85 (m, 1H), 8.58 - 8.66 (m, 1H), 8.15 - 8.25 (br. s., 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.95 (t, J = 6.6 Hz, 1H), 7.80 (d, J = 8.7 Hz, 1H), 1.44 (s, 9H). MS (m/z) 546.9 (M+H+).
Step 2. N-(6-(tert-butylsulfonyl)-7-vinylquinazolin-4-yl)benzo [ ]thiazol-5 -amine : To a solution of 4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl trifluoromethanesulfonate (60.0 mg, 0.091 mmol) and vinyltri-n-butyltin (37.1 μΐ, 0.126 mmol) in DMF (1.01 mL) was added PdCl2(dppf)-CH2Ci2 adduct (18 mg, 0.02 mmol). The reaction was heated at 150°C for 20 min in a microwave reactor. The residue was purified via column chromatography (10% to 100% in EtOAc in hexanes; 40 g silica gel cartridge column). The fractions were pooled and concentrated in vacuo to provide N-(6- (tert-butylsulfonyl)-7-vinylquinazolin-4-yl)benzo[(i]thiazol-5-amine (40 mg, 86%> yield) as an oil. 1H NMR (DMSO-d6) δ: 10.64 - 10.78 (m, 1H), 9.45 (s, 1H), 9.21 (s, 1H), 8.76 (s, 1H), 8.59 (d, J = 2.0 Hz, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.90 (dd, J = 8.6, 2.0 Hz, 1H), 7.69 - 7.83 (m, 1H), 7.46 - 7.68 (m, 1H), 6.05 (d, J = 17.2 Hz, 1H), 5.58 (d, J = 11.9 Hz, 1H), 1.32 (s, 9H). MS (m/z) 425.0 (M+H+).
Example 39
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-7-ethyl-4-quinazolinamine
Figure imgf000083_0001
To a solution of N-(6-(fert-butylsulfonyl)-7-vinylquinazolin-4-yl)benzo[(i]thiazol-5- amine (40 mg, 0.094 mmol) in EtOH/THF (9.4 niL) was added 10% Pd/C (15 mg). The solution was purged with nitrogen then hydrogenated at atmospheric pressure with a hydrogen balloon for 21 h, when another 20 mg of Pd/C was added. The reaction was hydrogenated another 4h. Some olefin was still present in the reaction mixture. The mixture was filtered through glass filter paper and the residue was subjected to the original reaction conditions and continued hydrogenation until complete in 18h. The reaction mixture was filtered through glass filter paper and concentrated in vacuo. The residue was purified via reverse phase chromatography (6% to 75% 0.1% TFA in MeCN in 0.1% TFA in water; 5um 30x150 mm Waters Sunfire column, 15 min gradient). The pure fraction was partitioned between EtOAc and satd. NaHCCh, the organic layer was washed with brine, then dried over MgS04 and concentrated in vacuo to obtain N-(6-(tert- butylsulfonyl)-7-ethylquinazolin-4-yl)benzo [ ]thiazol-5 -amine (7.5 mg, 19% yield). 1H NMR (DMSO-d6) δ: 10.67 (s, 1H), 9.42 (s, 1H), 9.18 (s, 1H), 8.69 (s, 1H), 8.57 (d, J = 2.0 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 8.7, 2.0 Hz, 1H), 7.82 (s, 1H), 3.20 (td, J = 7.3 Hz, 2H), 1.33 (s, 9H), 1.16 (t, J = 7.3 Hz, 3H). MS (m/z) 427.1 (M+H+).
Example 40
-butylsulfonyl)-7-chloroquinazolin-4-yl)benzo[(i]thiazol-5-amine
Figure imgf000084_0001
To a solution of 4,7-dichloro-6-[(l,l-dimethylethyl)sulfonyl]quinazoline (60 mg, 0.15 mmol) in N-methyl-2-pyrrolidone (1 mL) was added l,3-benzothiazol-5-amine (27 mg, 0.18 mmol). The reaction mixture was heated at 90°C for 20 min. The solution was allowed to cool to rt. The reaction mixture was filtered and the filtrate was purified by HPLC and free based with a carbonate SPE cartridge to provide 21 mg of the title compound (32%). MS: m/z: 433.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 1.24 (d, 9 H), 7.87 - 8.07 (m, 2 H), 8.14 - 8.31 (m, 2 H), 8.66 (d, J= 1.77 Hz, 1 H), 8.77 (s, 1 H), 9.27 (d, J= 1.52 Hz, 1 H), 9.44 (s, 1 H), 10.63 (s, 1 H). The following compound was prepared using procedures analogous to those described above using the appropriate amine.
Figure imgf000085_0002
Example 42
6-[(l,l-dimethylethyl)sulfonyl]-N-(5-fluoro-lH-pyrazolo[3,4-¾]pyridin-3-yl)-7- -4-quinazolinamine
Figure imgf000085_0001
In a flask was combined 4-chloro-6-[(l,l-dimethylethyl)sulfonyl]-7- (methyloxy)quinazoline (100 mg, 0.32 mmol), 5-fluoro-lH-pyrazolo[3,4-¾]pyridin-3- amine (58 mg, 0.38 mmol) in NMP (1 mL). The reaction mixture was heated at 80°C for lh. The solution was allowed to cool to rt. The solid was filtered out and remaining solution was concentrated and residue was purified by HPLC to provide 20 mg of the title compound. MS:m/z: 431 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.24 - 1.36 (s, 9 H), 3.98 (s, 3 H), 7.27 ( s., 1 H), 8.02 (s, J = 8.72, 2.65 Hz, 1 H), 8.42 (s, 1 H), 8.54 (s, 2 H), 9.04 (s, 1 H).
Alternatively, these reactions can be performed in EtOH with a catalytic amount of
HC1.
The following compounds were prepared using procedures analogous to those described. met oxyqunazo n- -amne
Figure imgf000086_0001
:H NMR (DMSO-d6) δ: 13.03
(br. s., 1H), 10.51 (br. s., 1H),
9.14 (s, 1H), 8.65 (s, 1H), 8.14
47 412 (s, 1H), 8.05 (s, 1H), 7.76 (d, J
= 8.6 Hz, 1H), 7.48 (dd, J =
6-(tert-butylsulf onyl)-N-( 1 H- 8.6, 1.3 Hz, 1H), 7.39 (s, 1H), indazol-6-yl)-7- 4.01 (s, 3H), 1.33 (s, 9H) methoxyquinazolin-4-amine
Example 48
t-but lsulfonyl)-N-(4,5-dimethyl-lH-pyrazol-3-yl)-7-methoxyquinazolin-4-amine
Figure imgf000087_0001
In a flask was combined 6-[(l , l-dimethylethyl)sulfonyl]-7-(methyloxy)-4(lH)- quinazolinone (60 mg, 0.20 mmol) and P0C13 (2 mL, 21.5 mmol), and the reaction mixture was heated at 80°C for 4h. The solution was allowed to cool to rt. POCI3 was removed under high vacuum. The residue was treated with satd. aq. NaHC03 and extracted with CH2CI2. The organic extract was dried over Na2S04. The solvent was removed and crude material was dissolved in NMP (1 mL) followed by addition of 4,5-dimethyl-lH-pyrazol- 3-amine(27 mg, 0.24 mmol). The reaction mixture was heated at 80°C for 1 h. The solution was allowed to cool to rt. The solid was filtered out and the remaining solution was concentrated and residue was purified by HPLC to provide 6.0 mg of the title compound. MS (m/z): 390 (M+H); 1H NMR (400 MHz, DMSO-d6) δ 1.30 (s, 9 H), 2.21 (s, 6 H), 4.00(s, 3 H), 7.91 (s, 1 H), 8.65 (s, 1 H), 9.1 1 (s, 1 H), 10.19 (br. s., 1 H), 12.32 (br. s., 1 H). Example 49
(E)-3-(4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)prop-2-en-l-ol
Figure imgf000088_0001
To a vial was added 4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl trifluoromethanesulfonate (820 mg, 1.50 mmol), Pd2dba3 (137 mg, 0.15 mmol), tri-tert-butylphosphine, tetrafluoroborate (87 mg, 0.30 mmol), and sodium carbonate (318 mg, 3.00 mmol). The vial was evacuated and backfilled with nitrogen three times before 1,4-dioxane (15 mL) and allyl acetate (0.24 mL, 2.25 mmol) were added. The reaction was heated to 90°C for three days. Upon completion, it was cooled to rt and concentrated. The residue was then passed through a C13 SPE cartridge but no separation was observed. Fractions collected were combined, concentrated, and purified by RP HPLC to afford the desired product (78 mg, 10 %). 1H NMR (DMSO-d6) d 9.35 (s, 1H), 8.61 (br. s., 1H), 8.10 - 8.22 (m, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.85 - 7.96 (m, 1H), 7.35 (br. s., 1H), 6.20 (s, 1H), 5.86 - 6.07 (m, 1H), 5.28 (s, 1H), 5.25 (d, J = 5.0 Hz, 1H), 4.63 (br. s., 1H), 1.32 (s, 9H); MS (m/z) 455.1 (M+H+).
Example 50
2-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)sulfonyl)ethanol
Figure imgf000089_0001
Step 1. 2-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6-yl)thio)ethanol: To a flask was added N-(6-iodo-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5 -amine (1 g, 2.30 mmol), Pd2dba3 (0.21 g, 0.23 mmol), and Xantphos (0.13 g, 0.23 mmol) which was then evacuated and backfilled with nitrogen three times before DMF (15 ml), TEA (0.96 ml, 6.91 mmol), and mercaptoethanol (0.17 ml, 2.42 mmol) were added. The reaction was heated to 100°C overnight. It was then cooled to rt and partially concentrated. The resulting residue was titurated with MeOH. A minimal amount of solid precipitated which was filtered to give a dark green residue. The filtrate was then diluted with ether (100 mL) but no solid formed. The solution sat for three days at rt. A suspension was observed which was filtered and the cake was washed with ether to give the desired product as a yellow solid (603 mg, 65 %). MS (m/z) 385.1 (M+H+).
Step 2. 2-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6- yl)sulfonyl)ethanol: 2-((4-(benzo[d]thiazol-5-ylamino)-7-methoxyquinazolin-6- yl)thio)ethanol (603 mg, 1.57 mmol) was taken up in acetonitrile (10 mL), ethanol (10 mL), and water (10 mL) before oxone (2.89 g, 4.71 mmol) was added. The reaction was stirred at rt for 6 hours. It was then diluted with sat aq NaHC03 (100 mL), and extracted using DCM (2 x 200 mL). The combined organics were dried over sodium sulfate, filtered through celite, and concentrated. The aqueous layer was a suspension so it was filtered to give a second crop of material which was more pure than the material from the
concentrated organics. The second crop of material was dissolved in 1 mL of DMSO and purified by RP HPLC (10 -> 50 % MeCN in water with 0.1 % TFA) on a 5 μΜ C18 OBD Sunfire 30 x 100 mm. Desired fractions were combined and concentrated to afford the product as a yellowish solid (33 mg, 17 %). 1H NMR (DMSO-d6) δ 11.27 (br. s., 1H), 9.45 (s, 1H), 9.21 (s, 1H), 8.80 (s, 1H), 8.54 (d, J = 1.8 Hz, 1H), 8.22 (d, J = 8.6 Hz, 1H), 7.84 (dd, J = 8.7, 1.9 Hz, 1H), 7.45 (s, 1H), 4.12 (s, 3H), 3.63 - 3.84 (m, 4H), 2.55 (s, MS (m/z) 417.1 (M+H+).
Example 51
(R)-methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7 yl)oxy)propanoate and (S)-M ethyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)propanoate
Figure imgf000090_0001
A suspension of 4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-ol (0.50 g, 1.21 mmol) and potassium carbonate (0.50 g, 3.62 mmol) in Ν,Ν-Dimethylformamide (DMF) (6.3 ml) was stirred for 2 minutes before methyl 2-bromopropanoate (0.15 ml, 1.57 mmol) was added. The reaction was heated for lh at 70°C. The reaction was cooled and water (20 mL) was added. The product was filtered out as a yellow solid and let dry, then triturated with 5mL MeOH. Methyl 2-((4- (benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propanoate (350 mg, 58% yield) was filtered out. The racemic mixture was resolved (Chiralpak AD-H column, 60% EtOH in hexanes with 0.1% DIE A), separating a faster eluting isomer (Rt=8.6 min) and a slower eluting isomer (Rt=13.5 min).
Each enantiomer was isolated by evaporation of solvent (R and S)-methyl 2-((4-
(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propanoate (115 mg each, combined yield: 38%). 1H NMR (400 MHz, DMSO-d6) δ ppm 10.58 (s, 1 H), 9.42 (s, 1 H), 9.18 (s, 1 H), 8.62 (s, 1 H), 8.58 (d, J=1.77 Hz, 1 H), 8.17 (d, J=8.59 Hz, 1 H), 7.77 - 7.97 (m, 1 H), 7.14 (s, 1 H), 5.32 - 5.50 (m, 1 H), 3.74 (s, 3 H), 1.61 (d, J=6.57 Hz, 3 H), 1.40 (s, 9 H). LC/MS: M+H 501.2 The racemate was made in an analogous method without the resolution.
Figure imgf000091_0002
Example 53
(R)-2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)propan-l- ol (depicted) and (S)-2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- - 1 -ol
Figure imgf000091_0001
To a solution of (R or S)-methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)propanoate (110 mg, 0.22 mmol) in THF (2mL) was added lithium aluminum hydride (220 μΐ, 0.22 mmol, 1M in THF; or 110 μΐ, 0.11 mmol, 1M in THF). The reaction was stirred at 25°C. An orange precipitate was immediately formed and the product was filtered. The solid was dissolved in 1.5 mL DMSO. The solution was filtered and the product was purified via Gilson reverse phase
chromatography (8% to 70% 0.1% TFA in MeCN in 0.1% TFA in water or 8% to 60% 0.1% TFA in MeCN in 0.1 % TFA in water; 5um 3 Ox 150 mm Waters Sunfire column) . Pure fractions were collected and partitioned between EtOAc and water/saturated sodium bicarbonate. The organic layer was separated, dried over sodium sulfate, and evaporated in vacuo to give (R or S)-2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin- 7-yl)oxy)propan-l-ol as a white solid. Enantiomer 1 (prepared from the slower eluting isomer of Example 51): 1H NMR (400 MHz, CHLOROFORM- ) δ ppm 9.08 (s, 1 H), 8.77 (s, 1 H), 8.64 (m, 2 H), 8.06 (br. s., 1 H), 8.02 (d, J=8.6 Hz, 1 H), 7.78 (dd, J=8.6, 2.0 Hz, 1 H), 7.43 (s, 1 H), 4.73 (d, J=4.0 Hz, 2 H), 3.79 (t, J=4.4 Hz, 3 H), 3.61 - 3.72 (m, 1 H), 1.49 (s, 9 H). LC/MS: 473.2
Enantiomer 2(prepared from the faster eluting isomer of Example 51): 1H NMR
(400 MHz, CHLOROFORM-;/) δ ppm 9.08 (s, 1 H), 8.77 (s, 1 H), 8.64 (s, 1 H), 8.48 (s, 1 H), 8.13 (br. s., 1 H), 8.02 (d, J=8.6 Hz, 1 H), 7.78 (dd, J=8.6, 2.0 Hz, 1 H), 7.43 (s, 1 H), 4.73 (d, J=4.0 Hz, 2 H), 3.79 (t, J=4.4 Hz, 3 H), 3.61 - 3.72 (m, 1 H), 1.49 (s, 9 H).
LC/MS: 473.2
The racemate was made in an analogous fashion.
Figure imgf000092_0002
Example 55
-(tert-butylsulfonyl)-4-((4-chloro-2-fluorophenyl)amino)quinazolin-7-ol
Figure imgf000092_0001
6-(tert-Butylsulfonyl)-4-(ethylthio)quinazolin-7-ol (144 mg, 0.44 mmol) and 4-chloro-2- fluoroaniline (0.49 mL, 4.4 mmol) were combined with one drop of HCl and heated to 150 °C in the microwave for 20 minutes. After cooling to rt, the mixture was diluted with ether and filtered. The solid ppt was taken up in MeOH (5 mL) and treated with MP carbonate resin (400 mg, 3 eq. @ 3.28 mmol/gram loading). The beads were filtered and the mother liquor concentrated and purified on silica gel (0 to 100% EtOAc followed by 0 to 10%> MeOH/DCM). Fractions containing product were combined and concentrated to provide 2 mg of the desired product (1.1%). 1H NMR (DMSO-d6) δ: 10.37 (s, 1H), 8.96 (s, 1H), 8.43 (s, 1H), 7.49 - 7.61 (m, 2H), 7.35 (d, J = 8.8 Hz, 1H), 7.20 (s, 1H), 1.34 (s, 9H); MS (m z) 410.2, 412.0 (M+H+).
Example 56
N- 6-(tert-butylsulfinyl)-7-methoxyquinazolin-4-yl)benzo[d]thiazol-5-amine
Figure imgf000093_0001
A mixture of N-(6-(tert-butylthio)-7-methoxyquinazolin-4-yl)benzo [d]thiazol-5 -amine (106 mg, 0.27 mmol) and oxone (36 mg, 0.06 mmol) was stirred for 15 min in 1 : 1
THF:water (2.6 mL) The reaction was quenched with saturated sodium bicarbonate. The resulting orange solid was filtered, dissolved in 30 mL of 1 : 1 DCM:MeOH and
preabsorbed onto silica gel. The product was purified by column chromatography (Isco CombiFlash, 75% to 100% EtOAc/Hexanes to 10% NH4OH in MeOH). The pure fractions were concentrated in vacuo and the residue was purified via Gilson reverse phase chromatography (10% to 75% of 0.1% TFA in MeCN in 0.1% TFA in water; 5um 30x150 mm Waters Sunfire column). The pure fractions were partitioned between EtOAc and aqueous saturated sodium bicarbonate. The organic layer was separated, dried over sodium sulfate, and concentrated in vacuo to give N-(6-(tert-butylsulfinyl)-7-methoxyquinazolin- 4-yl)benzo[d]thiazol-5 -amine as a white solid (40 mg, 36% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 10.46 (s, 1 H) 9.41 (s, 1 H) 8.88 (s, 1 H) 8.62 (d, J=2.0 Hz, 1 H) 8.61 (s, 1 H) 8.15 (d, J=8.6 Hz, 1 H) 7.92 (dd, J=8.34, 2.53 Hz, 1 H) 7.33 (s, 1 H) 3.99 (s, 3 H) 1.19 (s, 9 H). MS (m/z) 413.2 (M+H+). Example 57
2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acetamide
Figure imgf000094_0001
A solution of 4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-ol
(50.0 mg, 0.121 mmol) and triethylamine (12 mg, 0.12 mmol) in DMF (0.63 mL)) was stirred 2 minutes before 2-bromoacetamide (17 mg, 0.12 mmol) was added. Little reaction occurred after heating to 70°C. Solid NaH (15 mg, 0.63 mmol) was added and the reaction was heated at 100°C for 18h. The reaction mixture was filtered and the filtrate was purified via Gilson reverse phase chromatography (6% to 75% of 0.1% TFA in MeCN in 0.1% TFA in water; 5um 30x150 mm Waters Sunfire column). The pure fractions were combined and evaporated to dryness, to yield 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)acetamide (13 mg, 23% yield) as a yellow solid. 1H NMR (400 MHz, METHANOL-d4) δ ppm 9.38 (s, 1 H), 9.27 (s, 1 H), 8.80 (s, 1 H), 8.43 (d, J=1.8 Hz, 1 H), 8.23 (d, J=8.6 Hz, 1 H), 7.81 (dd, J=8.6, 1.77 Hz, 1 H), 7.21 (s, 1 H), 5.26 (s, 2 H), 1.48 (s, 9 H); MS (m/z) 471.9 (M+H+).
Example 58
enzo d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acetic acid
Figure imgf000095_0001
Step 1. Methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin- 7-yl)oxy)acetate: A suspension of 4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-ol (350 mg, 0.84 mmol) and potassium carbonate (350 mg, 2.5 mmol) in DMF (4.4 mL) was stirred 2 minutes before adding methyl 2-bromoacetate (108 μΐ, 1.14 mmol). The reaction was heated at 25°C for 6 h. The mixture was added to 15 mL water, and a yellow solid was collected by filtration and triturated with 6 mL MeOH to a thick white precipitate. The solid was filtered out to give methyl 2-((4-(benzo[d]thiazol-5- ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acetate (200 mg, 49% yield). 1H NMR (400 MHz, DMSO-de) δ ppm 10.56 - 10.61 (m, 1 H), 9.43 (s, 1 H), 9.17 (s, 1 H), 8.63 (s, 1 H), 8.57 (d, J=1.8 Hz, 1 H), 8.16 (d, J=8.6 Hz, 1 H), 7.88 (dd, J=8.6, 1.8 Hz, 1 H), 3.75 (s, 2 H), 1.38 (s, 9 H), 1.34 (s, 3 H); MS (m/z) 487.2 (M+H+).
Step 2. 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)acetic acid: To a solution of methyl 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)acetate (115 mg, 0.24 mmol) in THF (3.5 mL) was added LiOH (11 mg, 0.47 mmol) in water (1.2 mL) at 25°C. After 1 h, the reaction was concentrated to remove the THF. The residue was purified via Gilson reverse phase chromatography ( 10% to 60% of 0.1 % TFA in MeCN in 0.1 % TFA in water; 5um 3 Ox 150 mm Waters Sunfire column). The pooled fractions were concentrated to dryness in vacuo to provide 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)acetic acid (29 mg, 26% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.46 (s, 1 H), 9.22 - 9.27 (m, 1 H), 8.72 - 8.79 (m, 1 H), 8.47 - 8.56 (m, 1 H), 8.23 (d, J=8.3 Hz, 1 H), 7.83 (d, J=9.8 Hz, 1 H), 7.26 (s, 1 H), 5.08 (s, 2 H), 1.39 (s, 9 H); MS (m/z) 473.2 (M+H+).
Example 59
N-(6-(tert-butylsulfonyl)-7-(2-(methylsulfonyl)ethoxy)quinazolin-4-yl)benzo[d]thiazol-5- amine
Figure imgf000096_0001
A solution of N-(6-(tert-butylsulfonyl)-7-(2-(methylthio)ethoxy)quinazolin-4- yl)benzo[d]thiazol-5 -amine (30 mg, 0.061 mmol) in 1 : 1 THF: H20 (0.6 mL) was stirred 25 minutes with oxone (113 mg, 0.18 mmol) at 25°C. The reaction mixture was partitioned between EtOAc and aqueous saturated sodium bicarbonate. The organic layer was separated, dried over sodium sulfate and evaporated in vacuo to yield N-(6-(tert- butylsulfonyl)-7-(2-(methylsulfonyl)ethoxy)quinazolin-4-yl)benzo[d]thiazol-5-amine (12.4, 39% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 10.57 - 10.65 (m, 1 H), 9.38 - 9.51 (m, 1 H), 9.09 - 9.24 (m, 1 H), 8.65 - 8.74 (m, 1 H), 8.54 - 8.62 (m, 1 H), 8.09 - 8.22 (m, 1 H), 7.81 - 7.95 (m, 1 H), 7.46 - 7.56 (m, 1 H), 4.56 - 4.71 (m, 2 H), 3.64 - 3.75 (m, 2 H), 3.21 (s, 3 H), 1.29 - 1.40 (m, 9 H); MS (m/z) 521.1 (M+H+).
The following compounds were prepared using procedures analogous to those described in examples 21 and 60 using the appropriate thiol.
Figure imgf000097_0002
Example 61 (E)-methyl 3-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)acrylate
Figure imgf000097_0001
A suspension of 4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- ol (200 mg, 0.48 mmol) and DABCO (5 mg, 0.05 mmol) in THF (4.8 mL) was stirred 2 minutes at 25°C before adding methyl propiolate (41 mg, 0.48 mmol). After 10 minutes, the reaction mixture was partitioned between EtOAc and aqueous saturated sodium bicarbonate and back extracted with DCM. The combined organics were dried over sodium sulfate and evaporated in vacuo. The residue was purified via column
chromatography (Isco CombiFlash 50% to 100% in EtOAc in Hexanes; 40g silica gel cartridge column). The pure fractions were concentrated in vacuo to give (E)-methyl 3-((4- (benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acrylate (115 mg, 48% yield) as a white solid. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 9.09 (s, 1 H), 8.83 (s, 1 H), 8.69 (s, 1 H), 8.64 (d, J=2.0 Hz, 1 H), 8.04 (d, J=8.6 Hz, 1 H), 7.87 (d, J=12.1 Hz, 1 H), 7.78 (dd, J=8.7, 2.2 Hz, 1 H), 7.62 (s, 1 H), 5.91 (d, J=12.1 Hz, 1 H), 5.32 (s, 1 H), 1.68 (s, 3 H), 1.47 (s, 9 H); MS (m/z) 499.1 (M+H+).
The following compounds were prepared using procedures analogous to those described above using the appropriate alkyne.
Figure imgf000098_0002
Example 63
(E)-3-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acrylic acid
Figure imgf000098_0001
A suspension of (E)-methyl 3-((4-(benzo[d]thiazol-5-ylamino)-6-(tert- butylsulfonyl)quinazolin-7-yl)oxy)acrylate (115 mg, 0.23 mmol) in THF (1.2 mL) and water (1.2 mL) was stirred with LiOH (11 mg, 0.46 mmol) for 2 h at 50°C. Water and 10% citric acid (10 mL) were added and the mixture was extracted with EtOAc and DCM/20% EtOH (2x each). The combined organics were washed with brine and the organics concentrated to dryness. The residue was purified via Gilson reverse phase chromatography (10% to 75% of 0.1% TFA in MeCN in 0.1% TFA in water; 5um 30x150 mm Waters Sunfire column). Pure fractions were partitioned between EtOAc and saturated sodium bicarbonate followed by brine. The organic layer was dried over magnesium sulfate and concentrated in vacuo to provide (E)-3-((4-(benzo[d]thiazol-5- ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)acrylic acid (10.5 mg, 9% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 11.01 - 11.17 (m, 1 H), 9.45 (s, 1 H), 9.29 (s, 1 H), 8.72 - 8.84 (m, 1 H), 8.49 - 8.60 (m, 1 H), 8.24 (d, J=8.6 Hz, 1 H), 7.97 (d, J=12.0 Hz, 1 H), 7.81 - 7.84 (m, 1 H), 7.68 (s, 1 H), 5.73 (d, J=12.0 Hz, 1 H), 1.37 (s, 9 H); MS (m/z) 484.9 (M+H+).
Example 64
N-(6-(tert-butylsulfonyl)-7-(vinyloxy)quinazolin-4-yl)benzo[d]thiazol-5-amine
Figure imgf000099_0001
A solution of N-(7-(2-bromoethoxy)-6-(tert-butylsulfonyl)quinazolin-4- yl)benzo[d]thiazol-5 -amine (25 mg, 0.05 mmol) and 2-(pyridin-4-yl)ethanol (15 mg, 0.12 mmol) was heated in DMF (939 μΐ) at 70°C. After 10 minutes, 60% NaH (10 mg, 0.25 mmol) was added and heated 1 min. The residue was filtered, then purified via Gilson reverse phase chromatography (10% to 75% of 0.1% TFA in MeCN in 0.1% TFA in water; 5um 30x100 mm Waters Sunfire column). Pure fractions were partitioned between EtOAc and sat'd sodium bicarbonate, then washed with brine. The organic layer was dried over magnesium sulfate and concentrated in vacuo to provide N-(6-(tert-butylsulfonyl)-7- (vinyloxy)quinazolin-4-yl)benzo[d]thiazol-5 -amine (7.5 mg, 36%> yield).
1H NMR (400 MHz, DMSO-d6) δ ppm 10.63 - 10.69 (m, 1 H), 9.43 (s, 1 H), 9.17 - 9.33
(m, 1 H), 8.65 - 8.70 (m, 1 H), 8.50 - 8.63 (m, 1 H), 8.18 (d, J=8.8 Hz, 1 H), 7.89 (d, J=9.1
Hz, 1 H), 7.48 (s, 1 H), 7.17 (dd, J=13.3, 5.8 Hz, 1 H), 5.02 (dd, J=13.3, 2.0 Hz, 1 H), 4.81
(dd, J=5.8, 2.0 Hz, 1 H), 1.37 (s, 9 H); MS (m/z) 441.0 (M+H+). Example 65
[d]thiazol-5-ylamino)-7-methoxy-N,N-dimethylquinazoline-6-sulfonamide
Figure imgf000100_0001
To a vial was added DMAP (3.75 mg, 0.03 mmol) followed by a suspension of 4-
(benzo[d]thiazol-5-ylamino)-7-methoxyquinazoline-6-sulfonyl chloride (125 mg, 0.31 mmol) in THF (2 mL), then TEA (0.17 mL, 1.23 mmol), and finally dimethylamine (2.0 M in THF, 0.30 mL). The reaction was stirred at rt overnight. It was then concentrated and the crude material was dissolved in 1 : 1 DMSO:MeOH and purified by RP HPLC (10 -> 50 % MeCN in water with 0.1 % TFA) on a 5 μΜ C 18 OBD Sunfire 30 x 100 mm. Desired fractions were combined, concentrated, and the residue was redissolved in MeOH and treated with MP-carbonate resin. The solution was pipetted off the resin and concentrated to afford the title compound (19 mg, 14 %). 1H NMR (DMSO-d6) d 11.05 (br. s., 1H), 9.45 (s, 1H), 9.18 (s, 1H), 8.76 (s, 1H), 8.55 (d, J = 1.5 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.85 (dd, J = 8.7, 1.9 Hz, 1H), 7.41 (s, 1H), 4.08 (s, 3H), 2.83 (s, 6H); MS (m/z) 416.1 (M+H+).
The following compound was prepared using procedures analogous to those described above using the appropriate amine.
Figure imgf000100_0002
Ή NMR (DMSO-d6) δ 10.97
(br. s., 1H), 9.44 (s, 1H), 9.19
(s, 1H), 8.74 (s, 1H), 8.57 (s,
1H), 8.20 (d, J = 8.8 Hz, 1H),
as in Ex.
442 7.86 (d, J = 8.6 Hz, 1H), 7.40
65
1 (s, 1H), 4.09 (s, 3H), 3.33 (t, J
= 6.4 Hz, 4H), 1.73 - 1.86 (m,
Ai-(7-methoxy-6-(pyrrolidin- 1 - 4H)
ylsulf onyl)quinazolin-4- yl)benzo[i/]thiazol-5-amine
:H NMR (DMSO-d6) δ 10.73
(br. s., 1H), 9.43 (s, 1H), 9.14
(s, 1H), 8.70 (s, 1H), 8.58 (s,
1H), 8.19 (d, J = 8.6 Hz, 1H), as in Ex.
458
1 7.87 (d, J = 8.6 Hz, 1H), 7.40 65 jV-(7-methoxy-6- (s, 1H), 4.07 (s, 3H), 3.58 - (morpholinosulfonyl)quinazolin-4- 3.67 (m, 4H), 3.18 - 3.24 (m,
yl)benzo[c/]thiazol-5-amine 4H)
:H NMR (DMSO-d6) 5 1 1.34
HN^ N (br. s., 1H), 9.47 (s, 1H), 9.20
(s, 1H), 8.83 (s, 1H), 8.52 (d, J
= 2.0 Hz, 1H), 8.24 (d, J = 8.5
as in Ex.
432 Hz, 1H), 7.83 (dd, J = 8.5, 2.0
65
4-(benzo[i/]thiazol-5-ylamino)-iV-(2- Hz, 1H), 7.52 (t, J = 5.8 Hz,
hydroxyethyl)-7-methoxyquinazoline- 1H), 7.41 (s, 1H), 4.09 (s, 3H),
6-sulfonamide 3.38 (t, J = 6.4 Hz, 2H), 2.87 - 2.97 (m, 2H) Τ$> :H NMR (DMSO-d6) 5 1 1.52
(br. s., 1H), 9.48 (s, 1H), 9.24
OLV (s, 1H), 8.87 (s, 1H), 8.51 (s,
1H), 8.26 (d, J = 8.8 Hz, 1H),
7.87 (d, J = 7.8 Hz, 1H), 7.82 as in Ex.
472
(dd, J = 8.7, 1.4 Hz, 1H), 7.41 65
4-(benzo ?]thiazol-5-ylamino)-7- (s, 1H), 4.12 (s, 3H), 3.74 (d, J methoxy-jV-(tetrahydro-2//-pyran- = 1 1.5 Hz, 2H), 3.27 - 3.34
4-yl)quinazoline-6-sulf onamide (m, 1H), 3.14 - 3.28 (m, 2H),
1.40 - 1.60 (m, 4H)
:H NMR (DMSO-d6) 5 10.84
(br. s., 1H), 9.44 (s, 1H), 9.14
(s, 1H), 8.72 (s, 1H), 8.59 (s,
1H), 8.19 (d, J = 8.5 Hz, 1H), as in Ex.
460
1 7.87 (d, J = 8.5 Hz, 1H), 7.40 65
4-(benzo[ii]thiazol-5-ylamino)-7V-(2- (s, 1H), 7.13 (t, J = 6.1 Hz,
hydroxy-2-methylpropyl)-7- 1H), 4.08 (s, 3H), 2.72 (d, J = methoxyquinazoline-6-sulf onamide 6.0 Hz, 2H), 1.07 (s, 6H)
Figure imgf000102_0001
Figure imgf000103_0001
Pharmaceutical Compositions
Example A
Tablets are prepared using conventional methods and are formulated as follows:
Ingredient Amount per tablet
Compound 5mg
Microcrystalline cellulose lOOmg
Lactose lOOmg Sodium starch glycollate 30mg
Magnesium stearate 2mg
Total 237mg
Example B
Capsules are prepared using conventional methods and are formulated as follows: Ingredient Amount per tablet
Compound 15mg
Dried starch 178mg
Magnesium stearate 2mg
Total 195mg
Biological Assay:
A fluorescent polarization based binding assay was developed to quantitate interaction of novel test compounds at the ATP binding pocket of RIPK2, by competition with a fluorescently labeled ATP competitive ligand. Full length FLAG His tagged RIPK2 was purified from a Baculovirus expression system and was used at a final assay concentration of twice the KDapparent. A fluorescent labeled ligand (5-({[2-({[3-({4-[(5- hydroxy-2-methylphenyl)amino]-2-pyrimidinyl}amino)phenyl]carbonyl}amino)ethyl] amino} carbonyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid, prepared as described in WO2011/120025) was used at a final assay concentration of 5nM. Both the enzyme and ligand were prepared in solutions in 50mM HEPES pH7.5, 150mM NaCl, lOmM MgCl2, ImM DTT, and lmM CHAPS. Test compounds were prepared in 100% DMSO and lOOnL was dispensed to individual wells of a multiwell plate. Next, 5ul RIPK2 was added to the test compounds at twice the final assay concentration, and incubated at rt for 10 min. Following the incubation, 5ul of the fluorescent labeled ligand solution, was added to each reaction, at twice the final assay concentration, and incubated at rt for at least 10 min. Finally, samples were read on an instrument capable of measuring fluorescent polarization. Test compound inhibition was expressed as percent (%) inhibition of internal assay controls. For concentration/dose response experiments, normalized data were fit and pICsoS determined using conventional techniques. The pICsoS are averaged to determine a mean value, for a minimum of 2 experiments.
As determined using the above method, the compounds of Examples 1-80 exhibited a pIC5o between approximately 5.0 and 9.0. For instance, the compounds of Examples 4 and 16 inhibited RIP2 kinase in the above method with a mean pIC5o of approximately 7.5 and 8.5, respectively. The compounds of Examples 4, 6, 16, 21 , and 23 inhibited RIP2 kinase in the above method with a mean pICso in the range of
approximately 7.0-9.0.
FLAG His tagged RIPK2 Preparation:
Full-length human RIPK2 (receptor-interacting serine -threonine kinase 2) cDNA was purchased from Invitrogen (Carlsbad, California, USA, Clone ID:IOH6368, RIPK2- pENTR 221). Gateway® LR cloning was used to site-specifically recombine RIPK2 downstream to an N-terminal FLAG-6His contained within the destination vector pDEST8- FLAG-His6 according to the protocol described by Invitrogen. Transfection into
Spodoptera frugiperda(Sf9) insect cells was performed using Cellfectin® (Invitrogen), according to the manufacturer's protocol.
Sf9 cells were grown in Excell 420 (SAFC Biosciences, Lenexa, Kansas, US;
Andover, Hampshire UK) growth media at 27°C, 80 rpm in shake flask until of a sufficient volume to inoculate a bioreactor. The cells were grown in a 50 litre working volume bioreactor (Applikon, Foster City, California, US; Schiedam, Netherlands) at 27°C, 30% dissolved oxygen and an agitation rate of 60-140 rpm until the required volume was achieved with a cell concentration of approximately 3.7xe6 cells/mL. The insect cells were infected with Baculovirus at a multiplicity of infection (MOI) of 12.7. The cultivation was continued for a 43 hour expression phase. The infected cells were removed from the growth media by centrifugation at 2500 g using a Viafuge (Carr) continuous centrifuge at a flow rate of 80 litres/hour. The cell pellet was immediately frozen and subsequently supplied for purification.
Purification Procedure I: 9.83 x 1010 Insect cells were re-suspended in 1.4 L lysis buffer (50mM Tris (pH 8.0), 150mM NaCl, 0.5mM NaF, 0.1% Triton X-100, lmL/litre Protease Inhibitor Cocktail Set III (available from EMD Group; CalBiochem/Merck Biosciences, Gibbstown, New Jersey, US; Damstadt, Germany) and processed by dounce homogenization on ice. The suspension was then clarified by centrifugation at 47,900g for 2 h, at 4°C. The lysate was decanted from the insoluble pellet and loaded at a linear flow rate of 16 cm/h onto a 55 mL FLAG-M2 affinity column (2.6 x 10.4 cm) that had been pre- equilibrated with 10 column volumes buffer A (50mM Tris (pH 8.0), 150mM NaCl,
0.5mM NaF, lmL/litre Protease Inhibitor Cocktail Set III). The column was then washed with 15 column volumes buffer A, and eluted with 6 column volumes buffer B (buffer A + 150μg/mL 3X FLAG peptide) at a linear flow rate of 57 cm/h. Fractions identified by SDS-PAGE as containing protein of interest were dialyzed to remove the 3X FLAG peptide from the preparation against 5 L of Buffer A (not containing the Protease Inhibitor Cocktail) overnight, using 10 kDa MWCO SnakeSkin Pleated Dialysis Tubing. The purification process yielded 11.3 mg of total protein, with the RIPK2 present at 40% purity by gel densitometry scanning, and identity confirmed by peptide mass fingerprinting. The main contaminating proteins in the preparation were identified as lower molecular weight degraded species of RIPK2.
Purification Procedure II: lOOg cells (10 liter scale fermentation) were frozen, thawed, and re-suspended in 1L lysis buffer (50mM Tris HCL pH7.5, 250 mM NaCl, O. lmM TCEP, 3ml Protease inhibitor cocktail) and lysed by high pressure homogenization at 10,000 psi once (Avestin). The suspension was then clarified by centrifugation at 35,000g for 45 minutes at 4°C. The supernatant was collected by centrifugation and incubated with 5 ml anti-FLAG-M2 resin which was pre-equilibrated with buffer A (50mM Tris HCL pH7.5, 250 mM NaCl, O. lmM TCEP). After protein binding at 4 C degree for 1 hour, the resin was packed into two 25ml disposable columns. Each column was washed with 25ml buffer A and eluted with 10ml (buffer A + 200ug/ml Flag peptide). The elution pool was concentrated to 1ml and applied to a superdex 200 (16/60) sizing column.
Fractions containing full length RIPK2 were collected according to SDS-PAGE analysis results. The purification process yielded 1.36mg/L 80% pure RIPK2 protein and identity was confirmed by peptide mass fingerprinting. Biological in vivo Assay
The efficacy of RIP2 inhibitors may also be evaluated in vivo in rodents.
Intraperitoneal (i.p.) or intravenous (z'.v.) administration of L18-MDP in mice has been shown to induce an inflammatory response through activation of the NOD2 signaling pathway (Rosenweig, H. L., et al. 2008. Journal of Leukocyte Biology 84:529-536). The level of the inflammatory response in the L18-MDP treated mice/rats is monitored using conventional techniques by measuring increases in cytokine levels (IL8, TNFa, IL6 and IL-Ιβ) in serum and/or peritoneal lavage fluid and by measuring neutrophil influx into the peritoneal space (when L18-MDP is dosed i.p.). Inhibition of the L18-MDP induced inflammatory response in treated rodents may be shown by orally pre-dosing with selected compounds of this invention, then measuring and comparing cytokine levels (IL8, TNFa, IL6 and IL-1 β) in serum and/or peritoneal lavage fluid and neutrophil influx into the peritoneal space (when L18-MDP is dosed i.p.) using conventional techniques.
For example, rats were orally pre-dosed with a compound of Example 4, 6, 16, or 21, at a dose of 2 mg/kg or 10 mg/kg (8 rats) and with prednisolone (8 rats, used as a positive control), followed by dosing with L18-MDP (50 μg/rat) 0.25 h/min after pre- dosing. Combined cytokine levels (IL8, TNFa, IL6 and IL-Ιβ) in whole blood samples taken from the rats in this study were measured using an antibody based detection (Meso- Scale Discovery platform). The combined cytokine response was calculated as the averaged response for the 4 cytokines measured relative to the response observed in the vehicle-treated mice, and are depicted in the figures as the mean ± standard error of the mean (n=8 rats /group).
References:
WO2011/011522, WO2009080200, WO2008/33747, WO2008/33749,
US6,046,206, WO96/09294, CA2086968, WO93/07124, EP1199070, CAS Registry No. 1347460-85-8, J. Med. Chem. (2010), 53(3) 2000-2009.

Claims

What is claimed is:
1. A compound according to Formula (I):
Figure imgf000108_0001
R1 is H, -S02(Ci-C4)alkyl, -CO(Ci-C4)alkyl, or (Ci-C4)alkyl;
R2 is - SRa, -SORa, -S02Ra, -S02NH2, or -S02NRbRc,
wherein Ra is (Ci-C6)alkyl, halo(Ci-Ce)alkyl, (C3-Cy)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:
said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of cyano, hydroxyl, (Ci-C6)alkoxy,
(Ci-C6)alkoxy(C2-C6)alkoxy, -C02H, -C02(Ci-C4)alkyl, -S02(Ci-C4)alkyl,
(C3-C7)cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and (phenyl)(Ci-C4 alkyl)amino-, wherein said
(C3-C7)cycloalkyl, phenyl, (phenyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said (C3-C7)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1 -3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, -CF3, hydroxyl, amino,
((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl,
phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy;
Rb is (Ci-Ce)alkyl or 4-7 membered heterocycloalkyl, wherein: said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from the group consisting of hydroxyl, (Ci-C6)alkoxy,
(Ci-C6)alkoxy(C2-C6)alkoxy, -C02H, -C02(Ci-C4)alkyl, (C1-C4 alkyl)amino-,
(C1-C4 alkyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, and 4-7 membered
heterocycloalkyl, wherein said 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of halogen, (Ci-C4)alkyl, hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of hydroxyl, amino, (Ci-C4)alkyl, (Ci-C4)alkoxycarbonyl-, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
Rc is H, (Ci-C4)alkoxy or (Ci-C6)alkyl;
or Rb and Rc taken together with the nitrogen atom to which they are attached form a 3-7 membered heterocycloalkyl group, optionally containing one or two additional ring heteroatoms each independently selected from nitrogen and oxygen, wherein said 3-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from the group consisting of (Ci-C4)alkyl, hydroxy, -C02H and -CO(Ci-C4)alkyl;
R3 is H, halogen, hydroxy, (Ci-C4)alkyl-,(C2-C4)alkenyl-, halo(Ci-C4)alkyl-, hydroxy(C2-C4)alkenyl-, (Ci-C4)alkoxy-, (C2-C4)alkenyloxy-, halo(Ci-C4)alkoxy-,
(Ci-C4)alkoxy(Ci-C6)alkyl-, halo(Ci-C4)alkoxy(Ci-C6)alkyl-,
(Ci-C4)alkoxy(C2-C6)alkoxy-, halo(Ci-C4)alkoxy(C2-C6)alkoxy-, hydroxy(Ci-Ce)alkyl-, hydroxy(C2-C6)alkoxy-, hydroxy(C3-C4)alkenyl-, cyano(C i-C4)alkyl-,
cyano(C2-C6)alkoxy-, (Ci-C4)alkyl-thio-(C2-C4)alkoxy, (Ci-C4)alkyl- sulfonyl-(C2-C4)alkoxy-, carboxy-(Ci-Ce)alkoxy-, carboxy-(C2-C4)alkenyl-oxy-,
(Ci-C4)alkoxycarbonyl(Ci-C6)alkoxy-, (Ci-C4)alkoxycarbonyl(C2-C4)alkenyl-oxy-, carboxy(C2-C4)alkenyl-, (Ci-C4)alkoxycarbonyl(C2-C4)alkenyl-,
aminocarbonyl(Ci-C6)alkoxy-, aminocarbonyl(C2-C4)alkenyl-oxy-,
(C3-C6)cycloalkyl(Ci-C4)alkoxy-, (C3-Ce)cycloalkoxy-, 4-6 membered- heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered-heterocycloalkyl-oxy-,
wherein the halo(Ci-C4)alkyl-, halo(Ci-C4)alkoxy-,
halo(Ci-C4)alkoxy(Ci-C6)alkyl-, or halo(Ci-C4)alkoxy(C2-C6)alkoxy- groups contain 2 or 3 halo atoms, wherein the (C3-C6)cycloalkyl moiety of the (C3-C6)cycloalkyl(Ci-C4)alkoxy- or (C3-C6)cycloalkoxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (Ci-Ce)alkoxy and (Ci-C4)alkoxy(C2-Ce)alkoxy, and
wherein the 4-6 membered heterocycloalkyl moiety of the 4-6 membered heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered-heterocycloalkyl-oxy- is optionally substituted by a group selected from the group consisting of cyano, halo, hydroxyl, (Ci-C6)alkoxy and (Ci-C4)alkoxy(C2-C6)alkoxy;
Z is phenyl or aryl(Ci-C4)alkyl-, wherein in the phenyl group or the aryl moiety of the aryl(Ci-C4)alkyl- group is substituted by R4, R5, R6 and R7, wherein:
R4 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
each of R5, R6 and R7is independently selected from the group consisting of H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and (Ci-C4)alkoxy; or
Z is phenyl or pyridyl, substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5 -membered ring containing 1 , 2 or 3 heteroatoms each independently selected from N, O and S, which 5 -membered ring is substituted by R11; wherein one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or (Ci-C4)alkoxy; or
Figure imgf000110_0001
Z is pyrazolyl, having the formula:
R12 is H, methyl or hydroxymethyl; R is methyl, trifluoromethyl or hydroxymethyl;
R14 is H, OH, or (Ci-C3)alkyl; or
R12 and R13, taken together with the atoms to which they are attached, form a 6-membered ring substituted by R15 and R16, wherein the 6-membered ring optionally contains 1 nitrogen atom;
wherein R15 and R16 are each independently selected from the group consisting of H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy,
phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy;
provided that the compound is not:
ethyl 5-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl] thio}pentanoate,
ethyl 4-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio} butanoate,
ethyl 7-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl]thio} heptanoate,
N-(3 -chloro-4-fluorophenyl)-7-methoxy-6- [(trifluoromethyl)sulfonyl] -4- quinazolinamine,
ethyl 7-{[4-[(3-chloro-4-fluorophenyl)amino]-7-(methoxy)-6-quinazolinyl] sulfonyl} heptanoate,
N-[(3,4-difluorophenyl)methyl]-6-[(methyl)sulfonyl]-4-quinazolinamine,
3 -methoxy-5 - [[6- [(methylthio)] -4-quinazolinyl]amino]-phenol,
3 -methoxy-5 - [[6- [(methylsulfinyl)]-4-quinazolinyl] amino]-phenol,
N- [(3 ,4-dichlorophenyl)methyl] -6-(methylthio)-4-quinazolinamine,
N-[(3-fluoro-4-methoxyphenyl)methyl]-6-(methylthio)-4-quinazolinamine,
6-(methylthio)-N-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,
6-(methylsulfonyl)-N-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,
6-(methylsulfinyl)-N-[4-(phenylmethoxy)phenyl]-4-quinazolinamine,
6-(methylthio)-N-(4-(phenoxyphenyl)-4-quinazolinamine,
N-(3-(methylphenyl)-6-(methylthio)-4-quinazolinamine, or a salt thereof.
2. The compound or salt according to claim 1 , wherein:
R1 is H, -S02(Ci-C4)alkyl, -CO(C C4)alkyl, or (Ci-C4)alkyl;
R2 is - SRa, -SORa, or -S02Ra, wherein Ra is (Ci-C6)alkyl, halo(Ci-C6)alkyl, (C3-Cy)cycloalkyl, 4-7 membered heterocycloalkyl, aryl, or heteroaryl, wherein:
said (Ci-C6)alkyl is optionally substituted by one or two groups each independently selected from cyano, hydroxyl, (Ci-C6)alkoxy, (Ci-C6)alkoxy(C2-C6)alkoxy, -C02H,
-C02(Ci-C4)alkyl, -S02(Ci-C4)alkyl, (C3-Cy)cycloalkyl, phenyl, 5-6 membered heteroaryl, 9-10 membered heteroaryl, 4-7 membered heterocycloalkyl and
(phenyl)(Ci-C4 alkyl)amino-, wherein said (C3-Cy)cycloalkyl, phenyl,
(phenyl)(Ci-C4 alkyl)amino-, 5-6 membered heteroaryl, 9-10 membered heteroaryl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-,
hydroxy(Ci-C4)alkyl and (Ci-C4)alkoxy,
said (C3-C7)cycloalkyl or 4-7 membered heterocycloalkyl is optionally substituted by 1-3 groups each independently selected from halogen, -CF3, hydroxyl, amino,
((Ci-C4)alkyl)amino-, ((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl,
phenyl(Ci-C4)alkyl-, hydroxy(Ci-C4)alkyl-, oxo and (Ci-C4)alkoxy, and
said aryl or heteroaryl is optionally substituted by 1-3 groups each independently selected from halogen, -CF3, hydroxyl, amino, ((Ci-C4)alkyl)amino-,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino-, (Ci-C4)alkyl, phenyl(Ci-C4)alkyl-,
hydroxy(Ci-C4)alkyl- and (Ci-C4)alkoxy;
R3 is H, halogen, hydroxy, (Ci-C4)alkyl-,(C2-C4)alkenyl-, halo(Ci-C4)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C4)alkoxy-, (Ci-C4)alkoxy(Ci-C6)alkyl-,
halo(Ci-C4)alkoxy(Ci-C6)alkyl-, (Ci-C4)alkoxy(C2-C6)alkoxy-,
halo(Ci-C4)alkoxy(C2-C6)alkoxy-, hydroxy(Ci-Ce)alkyl-, hydroxy(C2-Ce)alkoxy-, cyano(Ci-C4)alkyl-, cyano(C2-C6)alkoxy-, carboxy-(Ci-C6)alkoxy-,
(C i -C4)alkoxycarbonyl(C i -C6)alkoxy-, (C3-C6)cycloalkyl(C i -C4)alkoxy-,
(C3-Ce)cycloalkoxy-, 4-6 membered-heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered- heterocycloalkoxy-, wherein the halo(Ci-C4)alkyl-, halo(Ci-C4)alkoxy-,
halo(Ci-C4)alkoxy(Ci-Ce)alkyl-, or halo(Ci-C4)alkoxy(C2-C6)alkoxy- groups contain 2 or 3 halo atoms; and
wherein the (C3-C6)cycloalkyl moiety of the (C3-C6)cycloalkyl(Ci-C4)alkoxy- or (C3-Ce)cycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (Ci-C6)alkoxy and (Ci-C4)alkoxy(C2-C6)alkoxy;
wherein the 4-6 membered-heterocycloalkyl moiety of the 4-6 membered- heterocycloalkyl(Ci-C4)alkoxy-, or 4-6 membered-heterocycloalkoxy-, is optionally substituted by a group selected from cyano, halo, hydroxyl, (Ci-C6)alkoxy and
(Ci-C4)alkoxy(C2-C6)alkoxy;
Z is phenyl or aryl(Ci-C4)alkyl-, substituted by R4, R5, R6 and R7, wherein:
R4 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy- is optionally substituted by 1-3 substituents each independently selected from halogen, -CF3, (Ci-C4)alkyl and
(Ci-C4)alkoxy; and
each of R5, R6 and R7is independently selected from H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl and (Ci-C4)alkoxy; or
Z is phenyl or pyridyl substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent atoms and taken together with the atoms to which they are attached form a 5-membered heterocyclic group containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered heterocyclic group is substituted by R11;
wherein one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl or (Ci-C4)alkoxy; or
- I l l - Z is pyrazolyl, having the formula:
Figure imgf000114_0001
wherein:
R12 is H, methyl or hydroxymethyl;
R13 is methyl, trifluoromethyl or hydroxymethyl;
R14 is H, OH, or (Ci-C3)alkyl; or
R12 and R13, taken together with the atoms to which they are attached, form a 6 membered carbocyclic ring or heterocyclic ring substituted by R15 and R16, wherein the heterocyclic ring contains 1 nitrogen atom;
wherein R15 and R16 are each independently selected from H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy.
3. The compound or salt according to claim 1 or claim 2, wherein R1 is H.
4. The compound or salt according to any one of claims 1-2, wherein R2 is or -S02Ra.
5. The compound or salt according to any one of claims 1-4, wherein Ra is an optionally substituted (Ci-C6)alkyl or 5-6-membered heterocycloalkyl group, wherein: said (Ci-C6)alkyl is optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, (Ci-C2)alkoxy(C2-C3)alkoxy-, amino,
(Ci-C3 alkyl)amino-, (Ci-C3 alkyl)(Ci-C2 alkyl)amino-, 5-6-membered heterocycloalkyl (optionally substituted by (Ci-C4)alkyl), and C3-C6cycloalkyl (optionally substituted by (Ci-C4)alkyl or hydroxy(Ci-C4)alkyl), and
said 5-6 membered heterocycloalkyl is optionally substituted by 1 or 2 groups each independently selected from the group consisting of halogen, (Ci-C4)alkyl, and hydroxy(C i -C4)alkyl-;
wherein any of said 5-6 membered heterocycloalkyl contains 1 heteroatom selected from N, O and S.
6. The compound or salt according to any one of claims 1-4, wherein Ra is a (Ci-C6)alkyl group optionally substituted by a substituent selected from the group consisting of hydroxyl, (Ci-C2)alkoxy, and (Ci-C2)alkoxy(C2-C3)alkoxy- or Ra is a
5-6-membered heterocycloalkyl group optionally substituted by 1 or 2 independently selected (Ci-C4)alkyl groups.
7. The compound or salt according to any one of claims 1-4, wherein Ra is an unsubstituted (Ci-C5)alkyl.
8. The compound or salt according to any one of claims 1-4, wherein Ra is -CH3, -CH(CH3)2, or -C(CH3)3.
9. The compound or salt according to any one of claims 1-4, wherein Ra is
-CH2CH2OH, -C(CH3)2CH2CH2OH, or tetrahydro-2H-pyran-4-yl.
10. The compound or salt according to claim 1 or claim 3, wherein Rb is a
(Ci-C4)alkyl substituted by hydroxyl, (Ci-C2)alkoxy, (Ci-C3 alkyl)amino-,
(Ci-C3 alkyl)(Ci-C2 alkyl)amino-, a 4-6-membered heterocycloalkyl, optionally substituted by (Ci-C4)alkyl, or a 5-6-membered heteroaryl, optionally substituted by (Ci-C4)alkyl.
11. The compound or salt according to claim 1 or claim 3, wherein Rb is -CH3, -CH(CH3)2, -CH2CH2OH, -CH2CH2OCH3, -CH2C(CH3)2OH, -CH2CH(CH3)OH,
-CH2CH2N(CH3)2, oxetan-3-yl, tetrahydro-2H-pyran-4-yl, -CH2-tetrahydro-2H-pyran-4-yl, or -CH2CH2-lH-tetrazol-5-yl.
12. The compound or salt according to any one of claims 1, 3, 10 or 11, wherein Rc is Η or CH3.
13. The compound or salt according to claim 1 or claim 3, wherein Rb and Rc taken together with the nitrogen atom to which they are attached form a 5-6-membered heterocycloalkyl, optionally containing 1 additional heteroatom selected from N and O, and optionally substituted by a hydroxyl, (Ci-C4)alkyl, carboxy or (Ci-C4)alkylcarbonyl- group.
14. The compound or salt according to claim 1 or claim 3, wherein Rb and Rc taken together with the nitrogen atom to which they are attached form a morpholin-4-yl, 4-methylcarbonyl-piperazin-l-yl, pyrrolidin-l-yl, 3-hydroxy-pyrrolidin-l-yl, or
2-(carboxy)- 1 -pyrrolidin- 1 -yl group .
15. The compound or salt according to any one of claims 1-14, wherein R3 is H, halogen, hydroxy, (Ci-C4)alkyl-, (C2-C4)alkenyl-, halo(Ci-C4)alkyl-, (Ci-C4)alkoxy-, halo(C i -C4)alkoxy-, (C3-C6)cycloalkyl(C 1 -C4)alkoxy-, 5 -6-memebered-heterocycloalkyl- oxy-, (Ci-C4)alkoxy(Ci-C6)alkyl-, (Ci-C4)alkoxy(C2-C6)alkoxy-, carboxy-(Ci-C6)alkoxy-, (Ci-C4)alkoxycarbonyl(Ci-C6)alkoxy-, hydroxy(Ci-Ce)alkyl-, or hydroxy(C2-C6)alkoxy-.
16. The compound or salt according to any one of claims 1-14, wherein R3 is H.
17. The compound or salt according to any one of claims 1-14, wherein R3 is halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-,
hydroxy(C2-C3)alkenyl-, (Ci-C4)alkoxy-, (C2-C3)alkenyl-oxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered-heterocycloalkyl-oxy-,
(Ci-C3)alkoxy(Ci-C4)alkyl-, (Ci-C3)alkoxy(C2-C4)alkoxy-, (Ci-C3)alkyl-thio- (C2-C4)alkoxy-, (Ci-C3)alkyl-sulfonyl-(C2-C4)alkoxy-, carboxy-(Ci-C4)alkoxy-, carboxy-(C2-C4)alkenyl-oxy-, (Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-,
(Ci-C3)alkoxycarbonyl(C2-C4)alkenyl-oxy-, aminocarbonyl(Ci-C4)alkoxy-,
aminocarbonyl(C2-C4)alkenyl-oxy-, hydroxy(C2-C4)alkoxy-, or hydroxy(C2-C4)alkenyl- oxy-.
18. The compound or salt according to any one of claims 1-14, wherein R3 is halogen, hydroxy, (Ci-C3)alkyl-, (C2-C3)alkenyl-, halo(Ci-C2)alkyl-, (Ci-C4)alkoxy-, halo(Ci-C3)alkoxy-, (C5-C6)cycloalkyl(Ci-C3)alkoxy-, 5-6-memebered-heterocycloalkyl- oxy-, (Ci-C3)alkoxy(Ci-C4)alkyl-, (Ci-C3)alkoxy(C2-C4)alkoxy-, carboxy-(Ci-C4)alkoxy-, (Ci-C3)alkoxycarbonyl(Ci-C4)alkoxy-, or hydroxy(C2-C4)alkoxy-.
19. The compound or salt according to any one of claims 1-14, wherein R3 is chloro, -CH2CH3, -CH=CH2, -CH=CHCH2OH, -OCH=CH2, -OCH=CH-C02H,
-OCH=CH-C02CH3, -OCH=CH-CONH2, -OH, -OCH3, -OCF2H, -OCH(CH3)2,
-OCH2CH3, -OCH2CF3, -OCH2CH2CH3, -OCH2CH2CI, -OCH2CH2Br, -OCH2CH2SCH3, -OCH2CH2SO2CH3, -OCH2CH2S02CH(CH3)2, -OCH2CH2OH, -OCH2CH2CH2OH, -OCH2CH2OCH3, -OC(CH3)2CH2OH, -OCH(CH3)CH2OH, -OCH(CH3)C02CH3,
-OCH2CH(CH3)OH, -OC(CH3)2C02CH2CH3, -OCH2C02H, -OCH2CONH2, -OCH2- cyclohexyl, or -0-tetrahydro-2H-pyran-4-yl.
20. The compound or salt according to any one of claims 1-19, wherein Z is phenyl, substituted by 1 or 2 substituents each independently selected from the group consisting of hydroxyl, halogen, hydroxy(Ci-C4)alkyl, (Ci-C4)alkyl, and (Ci-C4)alkoxy.
21. The compound or salt according to any one of claims 1-19, wherein Z is
2- methyl-5 -hydroxy-phenyl, 2-fluoro-4-chloro-phenyl, 3-methoxy-4-chloro-phenyl, or
3- hydroxy-4-chloro-phenyl.
22. The compound or salt according to any one of claims 1-19, wherein Z is phenyl or pyridyl substituted by R8, R9 and R10, wherein:
R8 and R9 are located on adjacent carbon atoms and taken together with the atoms to which they are attached form a 5-membered ring containing 1, 2 or 3 heteroatoms each independently selected from N, O and S, which 5-membered ring is substituted by R11; wherein one of R10 or R11 is H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy, phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, or aminocarbonyl, where the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy; and
the other of R10 or R11 is H, hydroxyl, halogen, -CF3, hydroxy(Ci-C4)alkyl,
(Ci-C4)alkyl or (Ci-C4)alkoxy;
Figure imgf000118_0001
or Z is pyrazolyl, having the formula: wherein:
R12 is H, methyl or hydroxymethyl;
R13 is methyl, trifluoromethyl or hydroxymethyl;
R14 is H, OH, or (Ci-C3)alkyl;
or R12 and R13, taken together with the atoms to which they are attached, form a
6-membered ring substituted by R15 and R16, wherein the 6-membered ring contains 1 nitrogen atom;
wherein R15 and R16 are each independently selected from the group consisting of H, halogen, cyano, (Ci-C4)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, phenoxy,
phenyl(Ci-C4)alkoxy, hydroxyl, hydroxy(Ci-C4)alkyl-, and aminocarbonyl, wherein the phenyl moiety of said phenoxy or phenyl(Ci-C4)alkoxy is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, -CF3, (Ci-C4)alkyl and (Ci-C4)alkoxy.
23. The compound or salt according to any one of claims 1-19, wherein Z is benzothiazolyl, optionally substituted by 1-3 substituents independently selected from the group consisting of halogen, (Ci-C4)alkyl, halo(Ci-C4)alkyl or (Ci-C4)alkoxy.
24. The compound or salt according to any one of claims 1-19, wherein Z is benzo[<i]thiazol-5-yl.
25 The compound or salt according to any one of claims 1-19, wherein Z is pyrazolyl, R12 is H or methyl, R13 is methyl or trifluoromethyl, and R14 is H or methyl.
26. The compound or salt according to any one of claims 1-19, wherein Z is pyrazolyl, R12 and R13 are each methyl, and R14 is H.
27. The compound or salt according to any one of claims 1-19, wherein Z is an optionally substituted indazolyl or pyrazolo[3,4-£]pyridinyl, each optionally substituted by hydroxyl, chloro, fluoro, -CF3, cyano, hydroxymethyl-, methyl, methoxy or aminocarbonyl.
28. The compound or salt according to any one of claims 1-19, wherein Z is 5-fluoro-lH-indazol-3-yl, lH-indazol-6-yl or 3-methyl-lH-indazol-6-yl.
29. The compound or salt according to any one of claims 1-28, wherein the salt is a pharmaceutically acceptable salt of said compound.
30. A compound of any one of Examples 1-80, or a pharmaceutically acceptable salt thereof.
31. A compound which is :
N- 1 ,3-benzothiazol-5-yl-6-[(l , 1 -dimethylethyl)sulfonyl]-4-quinazolinamine, N- 1 ,3-benzothiazol-5-yl-6-[(l -methylethyl)sulfonyl]-4-quinazolinamine,
N-(6-(tert-butylsulfonyl)-7-methoxyquinazolin-4-yl)benzo[(i]thiazol-5 -amine, or 2-((4-(benzo[<i]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7- yl)oxy)ethanol,
or a pharmaceutically acceptable salt, thereof.
32. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 29-31 , and one or more
pharmaceutically acceptable excipients.
33. A method of treating a disease mediated by inhibition of RIP2 kinase comprising administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to any one of claims 29-31 to a human in need thereof.
34. A compound or pharmaceutically acceptable salt thereof according to any one of claims 29-31 for use in the treatment of a disease mediated by inhibition of RIP2 kinase.
35. Use of the compound, or pharmaceutically acceptable salt thereof, according to any of claims 29-31 in the manufacture of a medicament for the treatment of a disease mediated by inhibition of RIP2 kinase.
36. The method, compound or use according to claims 33-35, wherein the disease mediated by inhibition of RIP2 kinase is selected from uveitis, interleukin-1 converting enzyme associated fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, an inflammatory bowel disorder, ulcerative colitis, Crohn's disease, early-onset and extra-intestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis, asthma, graft versus host disease, systemic lupus erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome/early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease.
PCT/US2012/051247 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors WO2013025958A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP12824263.3A EP2744501B1 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
MX2014001879A MX2014001879A (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors.
ES12824263.3T ES2615749T3 (en) 2011-08-18 2012-08-17 Aminoquinazolines as kinase inhibitors
CA2845630A CA2845630C (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
SG2014009526A SG2014009526A (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
CN201280050811.1A CN103874495B (en) 2011-08-18 2012-08-17 As the amido quinazoline of inhibitors of kinases
BR112014003693A BR112014003693A2 (en) 2011-08-18 2012-08-17 amino quinazolines as kinase inhibitors
NZ621314A NZ621314B2 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
AU2012296411A AU2012296411B2 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
EA201490474A EA025436B1 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
US14/239,193 US9604938B2 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
KR1020147006731A KR20140054246A (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
JP2014526237A JP6090801B2 (en) 2011-08-18 2012-08-17 Aminoquinazolines as kinase inhibitors
IL230902A IL230902A0 (en) 2011-08-18 2014-02-10 Amino quinazolines as kinase inhibitors
MA36820A MA35434B1 (en) 2011-08-18 2014-03-12 Amino-quinazolines as kinase inhibitors
US15/431,942 US9994529B2 (en) 2011-08-18 2017-02-14 Amino quinazolines as kinase inhibitors
US15/978,377 US20180258056A1 (en) 2011-08-18 2018-05-14 Amino quinazolines as kinase inhibitors
US16/286,920 US10717711B2 (en) 2011-08-18 2019-02-27 Amino quinazolines as kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524925P 2011-08-18 2011-08-18
US61/524,925 2011-08-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/239,193 A-371-Of-International US9604938B2 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors
US15/431,942 Continuation US9994529B2 (en) 2011-08-18 2017-02-14 Amino quinazolines as kinase inhibitors

Publications (1)

Publication Number Publication Date
WO2013025958A1 true WO2013025958A1 (en) 2013-02-21

Family

ID=47715493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/051247 WO2013025958A1 (en) 2011-08-18 2012-08-17 Amino quinazolines as kinase inhibitors

Country Status (21)

Country Link
US (4) US9604938B2 (en)
EP (1) EP2744501B1 (en)
JP (1) JP6090801B2 (en)
KR (1) KR20140054246A (en)
CN (1) CN103874495B (en)
AU (1) AU2012296411B2 (en)
BR (1) BR112014003693A2 (en)
CA (1) CA2845630C (en)
CL (1) CL2014000398A1 (en)
CO (1) CO6880068A2 (en)
CR (1) CR20140079A (en)
DO (1) DOP2014000033A (en)
EA (1) EA025436B1 (en)
ES (1) ES2615749T3 (en)
IL (1) IL230902A0 (en)
MA (1) MA35434B1 (en)
MX (1) MX2014001879A (en)
PE (1) PE20141408A1 (en)
SG (1) SG2014009526A (en)
TW (1) TWI547494B (en)
WO (1) WO2013025958A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043446A1 (en) 2012-09-13 2014-03-20 Glaxosmithkline Llc Prodrugs of amino quinazoline kinase inhibitor
WO2014043437A1 (en) 2012-09-13 2014-03-20 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
JP2014515730A (en) * 2011-03-04 2014-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Aminoquinolines as kinase inhibitors
WO2014128622A1 (en) 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
WO2014140299A1 (en) * 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
WO2016042087A1 (en) * 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic rip2 kinase inhibitors
WO2016172134A2 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2017046036A1 (en) 2015-09-14 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Compounds for the modulation of rip2 kinase activity
US9604938B2 (en) 2011-08-18 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
WO2018130443A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2018130437A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2020043122A1 (en) * 2018-08-28 2020-03-05 南京明德新药研发有限公司 Quinazoline derivatives as rip2 kinase inhibitor
WO2020094613A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Nod2 inhibitors for the treatment of hereditary periodic fevers
WO2022002818A1 (en) 2020-07-02 2022-01-06 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2024059169A1 (en) * 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI730959B (en) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 Heterocyclic amides as kinase inhibitors
JP7124266B2 (en) 2020-05-28 2022-08-24 幸水 深谷 Citrus fruit manufacturing method and citrus fruit

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007124A1 (en) 1991-09-30 1993-04-15 Eisai Co., Ltd. Nitrogenous heterocyclic compound
CA2086968A1 (en) 1992-01-20 1993-07-21 Andrew John Barker Quinazoline derivatives
WO1996009294A1 (en) 1994-09-19 1996-03-28 The Wellcome Foundation Limited Substituted heteroaromatic compounds and their use in medicine
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
EP1199070A2 (en) 2000-10-20 2002-04-24 Pfizer Limited Use of PDE V inhibitors for improved fecundity in mammals
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
WO2008033749A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
WO2009080200A1 (en) 2007-12-20 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximide-substituted quinoline and quinazoline derivatives as kinase inhibitors
WO2011011522A2 (en) 2009-07-21 2011-01-27 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916135A (en) 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP2994165B2 (en) * 1992-06-26 1999-12-27 ゼネカ・リミテッド Quinazoline derivative, method for producing the same, and pharmaceutical preparation containing the quinazoline derivative for obtaining anticancer activity
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PT912559E (en) 1996-07-13 2003-03-31 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE
WO1998005647A1 (en) 1996-08-01 1998-02-12 Dow Agrosciences Llc Quinolinium derivatives having fungicidal activity
NZ334125A (en) 1996-09-25 2000-10-27 Zeneca Ltd Quinoline derivatives inhibiting the effect of growth factors such as VEGF
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
RS49779B (en) * 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
WO2001055116A2 (en) 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
JP2004505964A (en) 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ Quinoline derivatives having VEGF inhibitory activity
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
PE20020958A1 (en) 2001-03-23 2002-11-14 Bayer Corp RHO-KINASE INHIBITORS
HN2002000067A (en) 2001-03-23 2003-10-24 Bayer Healthcare Llc INHIBITORS OF THE RHO - QUINASA.
SE0101675D0 (en) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
CN100491372C (en) 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 Substituted quinazoline derivatives as inhibitors of aurora kinases
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2004030672A1 (en) * 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20040122161A1 (en) 2002-12-21 2004-06-24 Paul Charles W. Hot melt adhesive based on acrylic block copolymers
RU2357971C2 (en) 2002-12-24 2009-06-10 Астразенека Аб Phosphonoxyquinazoline derivatives and their pharmaceutical application
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
JP2007501854A (en) 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク Quinazolines and pyrido [3,4-D] pyrimidines as receptor tyrosine kinase inhibitors
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
CA2538884C (en) 2003-09-16 2010-09-21 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
EP1673085B1 (en) 2003-09-26 2011-11-09 Exelixis, Inc. C-met modulators and methods of use
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
EP1699780A1 (en) 2003-12-23 2006-09-13 Pfizer, Inc. Novel quinoline derivatives
CN1934100A (en) 2004-03-23 2007-03-21 万有制药株式会社 Substituted quinazoline or pyridopyrimidine derivative
WO2005115145A2 (en) 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
EP1781293A1 (en) 2004-06-04 2007-05-09 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
FR2873695A1 (en) 2004-07-30 2006-02-03 Palumed Sa HYBRID MOLECULES QA OR Q IS AMINOQUINOLINE AND A IS AN ANTIBIOTIC OR A RESISTANCE INHIBITOR), THEIR SYNTHESIS AND USES THEREOF AS ANTIBACTERIAL AGENT
WO2006066955A1 (en) 2004-12-22 2006-06-29 Bayer Schering Pharma Aktiengesellschaft Quinoline derivative, use and production thereof, and drug containing the same
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-met modulators and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
ITMI20052008A1 (en) 2005-10-21 2007-04-22 Ctg Pharma S R L NEW ANTIMALARIC DERIVATIVES OF 4-AMINOCHINOLINA
FR2902100A1 (en) 2006-06-13 2007-12-14 Sanofi Aventis Sa DUAL MOLECULES COMPRISING A PEROXYDIC DERIVATIVE, THEIR SYNTHESIS AND THEIR THERAPEUTIC APPLICATIONS
US7511063B2 (en) 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
JP2008063278A (en) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd Method for producing 1-pyridin-4-yl-indole
US7977347B2 (en) 2006-09-11 2011-07-12 Curis, Inc. Quinazoline based EGFR inhibitors
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
WO2008119771A2 (en) 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
CN101663293B (en) 2007-04-23 2013-07-31 塞诺菲-安万特股份有限公司 Quinoline-carboxamide derivatives as p2y12 antagonists
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2008150957A2 (en) 2007-06-01 2008-12-11 Wyeth Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
CN101362719B (en) 2007-08-06 2012-04-18 北京师范大学 Chinolines derivates and composition containing thereof
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US9028693B2 (en) 2007-12-07 2015-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apparatus for countercurrent chromatography
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
WO2009111691A2 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and egfr antagonists
CA2739302A1 (en) * 2008-10-17 2010-04-22 Brendan C. Bender Treatment method
DE102008062566A1 (en) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Amino acid ester prodrugs and their use
WO2011112588A2 (en) 2010-03-08 2011-09-15 Case Western Reserve University Compositions and methods for treating inflammatory disorders
WO2011120026A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Pyrazolyl-pyrimidines as kinase inhibitors
WO2011123609A1 (en) 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
WO2011140442A1 (en) 2010-05-07 2011-11-10 Glaxo Group Limited Amino-quinolines as kinase inhibitors
UY33549A (en) 2010-08-10 2012-01-31 Glaxo Group Ltd QUINOLIL AMINAS AS INHIBITING AGENTS OF KINASES
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
EP2680886B1 (en) 2011-02-28 2016-08-10 Calitor Sciences, LLC Substituted quinoline compounds
ES2609578T3 (en) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
TWI547494B (en) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
AR092529A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT
TW201425307A (en) 2012-09-13 2014-07-01 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
TWI630203B (en) 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 Quinazolines as kinase inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007124A1 (en) 1991-09-30 1993-04-15 Eisai Co., Ltd. Nitrogenous heterocyclic compound
CA2086968A1 (en) 1992-01-20 1993-07-21 Andrew John Barker Quinazoline derivatives
WO1996009294A1 (en) 1994-09-19 1996-03-28 The Wellcome Foundation Limited Substituted heteroaromatic compounds and their use in medicine
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
EP1199070A2 (en) 2000-10-20 2002-04-24 Pfizer Limited Use of PDE V inhibitors for improved fecundity in mammals
WO2008033749A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
WO2009080200A1 (en) 2007-12-20 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximide-substituted quinoline and quinazoline derivatives as kinase inhibitors
WO2011011522A2 (en) 2009-07-21 2011-01-27 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
AM. J. HUM. GENET., vol. 70, 2002, pages 845 - 857
AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 142, 2006, pages 1089 - 1092
ARTHRITIS & RHEUMATISM, vol. 54, 2006, pages 3337 - 3344
ARTHRITIS & RHEUMATISM, vol. 60, 2009, pages 1797 - 1803
BERGE; BIGHLEY; MONKHOUSE, J.PHARM.SCI, vol. 66, 1977, pages 1 - 19
BIOCHEM J404, 2007, pages 179 - 190
BLOOD, vol. 105, 2005, pages 1195 - 1197
BRITISH MEDICAL BULLETIN, vol. 87, 2008, pages 17 - 30
CELLULAR SIGNALLING, vol. 18, 2006, pages 2223 - 2229
CURRENT BIOLOGY, vol. 8, 1998, pages 885 - 889
CURRENT RHEUMATOLOGY REPORTS, vol. 7, 2005, pages 427 - 433
DIAGNOSTIC PATHOLOGY, vol. 4, 2009, pages 23
EMBO JOURNAL, vol. 27, 2008, pages 373 - 383
EMBO REPORTS, vol. 2, 2001, pages 736 - 742
EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 12, 2004, pages 206 - 212
EUROPEAN JOURNAL OF HUMAN GENETICS, vol. 13, 2005, pages 742 - 747
EXPERIMENTAL DERMATOLOGY, vol. 17, 2008, pages 1057 - 1058
HUM. MOL. GENET, vol. 14, 2005, pages 1245 - 1250
HUM. MOL. GENET., vol. 14, 2005, pages 935 - 941
INFLAMMATORY BOWEL DISEASES, vol. 14, 2008, pages 295 - 302
INFLAMMATORY BOWEL DISEASES, vol. 15, 2009, pages 1145 - 1154
J. BIOL. CHEM., vol. 273, 1998, pages 12296 - 12300
J. BIOL. CHEM., vol. 273, 1998, pages 16968 - 16975
J. BIOL. CHEM., vol. 275, 2000, pages 27823 - 27831
J. BIOL. CHEM., vol. 284, 2009, pages 19183 - 19188
J. MED. CHEM., vol. 53, no. 3, 2010, pages 2000 - 2009
JLMMUNOL, vol. 178, 2007, pages 2380 - 2386
JOURNAL OF CLINICAL IMMUNOLOGY, vol. 29, 2009, pages 78 - 89
JOURNAL OF RHEUMATOLOGY, vol. 32, 2005, pages 373 - 375
MANON ET AL., J. MOL. BIOL., vol. 365, 2007, pages 160 - 174
MANON ET AL.: "Solution Structure of NOD1 CARD and Mutational Analysis of its Interaction with the CARD of Downstream Kinase RICK", JOURNAL OF MOLECULAR BIOLOGY, vol. 365, no. 1, 2007, pages 160 - 174, XP005728215 *
MICROBES AND INFECTION, vol. 11, 2009, pages 912 - 918
MUCOSAL IMMUNOLOGY, vol. 1, no. 1, 2008
NATURE GENETICS, vol. 29, 2001, pages 19 - 20
NATURE REVIEWS IMMUNOLOGY, vol. 6, 2006, pages 9 - 20
RHEUMATOLOGY, vol. 49, 2010, pages 194 - 196
ROSENWEIG, H. L. ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, vol. 84, 2008, pages 529 - 536
SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, vol. 23, 2006, pages 23 - 29
See also references of EP2744501A4

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515730A (en) * 2011-03-04 2014-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Aminoquinolines as kinase inhibitors
US10220030B2 (en) 2011-03-04 2019-03-05 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US9994529B2 (en) 2011-08-18 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
US9604938B2 (en) 2011-08-18 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
US10717711B2 (en) 2011-08-18 2020-07-21 Glaxosmithkline Intellectual Property Development Limited Amino quinazolines as kinase inhibitors
US9216965B2 (en) 2012-09-13 2015-12-22 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
JP2015529681A (en) * 2012-09-13 2015-10-08 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Prodrugs of aminoquinazoline kinase inhibitors
EP2895174A1 (en) * 2012-09-13 2015-07-22 GlaxoSmithKline Intellectual Property Development Limited Prodrugs of amino quinazoline kinase inhibitor
EP3323819A1 (en) 2012-09-13 2018-05-23 GlaxoSmithKline Intellectual Property Development Limited Prodrugs of amino quinazoline kinase inhibitor
EP2895167A4 (en) * 2012-09-13 2016-03-16 Glaxosmithkline Ip Dev Ltd Amino-quinolines as kinase inhibitors
WO2014043446A1 (en) 2012-09-13 2014-03-20 Glaxosmithkline Llc Prodrugs of amino quinazoline kinase inhibitor
EP2895174A4 (en) * 2012-09-13 2016-03-30 Glaxosmithkline Ip Dev Ltd Prodrugs of amino quinazoline kinase inhibitor
US9695161B2 (en) 2012-09-13 2017-07-04 Glaxosmithkline Intellectual Property Development Limited Prodrugs of amino quinazoline kinase inhibitor
US9586953B2 (en) 2012-09-13 2017-03-07 Glaxosmithkline Intellectual Property Development Limited Prodrugs of amino quinazoline kinase inhibitor
WO2014043437A1 (en) 2012-09-13 2014-03-20 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
CN105143208B (en) * 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 It is used as the quinazoline of kinase inhibitor
US9650364B2 (en) 2013-02-21 2017-05-16 GlaxoSmithKline Intellectual Property Development Limted Quinazolines as kinase inhibitors
WO2014128622A1 (en) 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
CN105143208A (en) * 2013-02-21 2015-12-09 葛兰素史密斯克莱知识产权发展有限公司 Quinazolines as kinase inhibitors
WO2014140299A1 (en) * 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
CN105228625A (en) * 2013-03-15 2016-01-06 昂科迪塞恩股份有限公司 Macro ring RIP2 inhibitors of kinases
WO2016042087A1 (en) * 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic rip2 kinase inhibitors
JP2017528481A (en) * 2014-09-17 2017-09-28 オンコデザイン エス．ア． Macrocyclic RIP2 kinase inhibitor
US10676486B2 (en) 2014-09-17 2020-06-09 Oncodesign S.A. Macrocyclic RIP2 kinase inhibitors
EA032872B1 (en) * 2014-09-17 2019-07-31 Онкодизайн С.А. Macrocyclic rip2 kinase inhibitors
WO2016172134A2 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2017046036A1 (en) 2015-09-14 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Compounds for the modulation of rip2 kinase activity
CN109311867A (en) * 2016-04-20 2019-02-05 葛兰素史克知识产权开发有限公司 Conjugate comprising RIPK2 inhibitor
AU2017253560B2 (en) * 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
US20190119271A1 (en) * 2016-04-20 2019-04-25 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
WO2018130437A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2018130443A1 (en) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2020043122A1 (en) * 2018-08-28 2020-03-05 南京明德新药研发有限公司 Quinazoline derivatives as rip2 kinase inhibitor
CN112638905A (en) * 2018-08-28 2021-04-09 南京明德新药研发有限公司 Quinazoline derivatives as RIP2 kinase inhibitors
WO2020094613A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Nod2 inhibitors for the treatment of hereditary periodic fevers
WO2022002818A1 (en) 2020-07-02 2022-01-06 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
WO2024059169A1 (en) * 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors

Also Published As

Publication number Publication date
KR20140054246A (en) 2014-05-08
CR20140079A (en) 2014-06-25
MA35434B1 (en) 2014-09-01
BR112014003693A2 (en) 2017-03-07
CL2014000398A1 (en) 2014-08-01
CA2845630C (en) 2019-05-21
CO6880068A2 (en) 2014-02-28
PE20141408A1 (en) 2014-10-29
EP2744501A4 (en) 2015-03-18
NZ621314A (en) 2016-02-26
MX2014001879A (en) 2014-05-30
IL230902A0 (en) 2014-03-31
US9994529B2 (en) 2018-06-12
TWI547494B (en) 2016-09-01
CA2845630A1 (en) 2013-02-21
AU2012296411B2 (en) 2017-02-16
EA025436B1 (en) 2016-12-30
ES2615749T3 (en) 2017-06-08
US20190194145A1 (en) 2019-06-27
TW201321377A (en) 2013-06-01
US20170152233A1 (en) 2017-06-01
CN103874495B (en) 2016-04-20
CN103874495A (en) 2014-06-18
DOP2014000033A (en) 2014-06-01
SG2014009526A (en) 2014-05-29
JP2014525937A (en) 2014-10-02
EP2744501A1 (en) 2014-06-25
EA201490474A1 (en) 2014-11-28
US9604938B2 (en) 2017-03-28
US10717711B2 (en) 2020-07-21
US20180258056A1 (en) 2018-09-13
US20140206688A1 (en) 2014-07-24
AU2012296411A1 (en) 2014-03-06
JP6090801B2 (en) 2017-03-08
EP2744501B1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
US10717711B2 (en) Amino quinazolines as kinase inhibitors
US10220030B2 (en) Amino-quinolines as kinase inhibitors
EP2603218B1 (en) Quinolyl amines as kinase inhibitors
AU2013315387B2 (en) Amino-quinolines as kinase inhibitors
PH12015500363B1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ621314B2 (en) Amino quinazolines as kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280050811.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12824263

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 230902

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14032108

Country of ref document: CO

Ref document number: 000212-2014

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2014526237

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2845630

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14239193

Country of ref document: US

Ref document number: MX/A/2014/001879

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014000398

Country of ref document: CL

Ref document number: CR2014-000079

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2012296411

Country of ref document: AU

Date of ref document: 20120817

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012824263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012824263

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147006731

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201490474

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014003693

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014003693

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140217